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  Leishmaniasis is one of several tropical diseases classified as a “neglected tropical 
disease”.  Its global prevalence is 12 million people with an estimated at-risk population 
of 350 million people.1  Current treatments include antimonials, amphotericin B, 
pentamidine, and miltefosine.  Access to these medications is often limited in the 
impoverished nations that Leishmaniasis predominantly affects.  Drug resistance and 
toxicity are also significant drawbacks to the current treatments.3  Therefore, there is an 
immediate need for the research and development of novel therapeutic molecules and 
strategies to combat Leishmaniasis. 
 
  In 2007, Senn and coworkers reported the isolation of four polyacetylene compounds 
from the Tanzanian medicinal plant Cussonia zimmermannii.124   Three of the four 
compounds displayed activity against Trypanosoma brucei rhodesiense, Trypanosoma 
cruzi, Plasmodium falciparum, and Leishmania donovani.  Of these four compounds, 
Compound 1 had the lowest IC50 (0.32uM) and the highest selectivity index (37; IC50 for 
rat skeletal myoblasts/IC50 for L. donovani) when screened against Leishmania donovani 
in infected macrophages.124   
 
 
  We herein report the total synthesis and in vitro antileishmanial activity of the four 
diastereomers of 1 as well as thirty-four analogues of 1.  In vitro antileishmanial testing 
yielded numerous compounds that possessed increased antileishmanial activity as 
compared to the natural product including one compound that displayed over a 100-fold 
increase in activity.  We also report the results of three of our compounds that were 
evaluated in an in vivo mouse model of Leishmaniasis. 
 
  As there are numerous reported examples of antileishmanial compounds that also 
possess significant anticancer activity, twenty-four of our compounds were submitted to 
the National Cancer Institute (NCI) to evaluate their anticancer activity.  Several of our 
compounds possessed potent anticancer activity in the NCI60 one-dose screen and are 
currently being evaluated in advanced staging of testing at the NCI.   
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1.1  Introduction to protozoal disease and epidemiology 
Protozoal infections are endemic in many parts of the world leading to hundreds 
of thousands of deaths each year.  According to the World Health Organization (WHO), 
malaria alone caused an estimated 655,000 deaths in 2010. 1 In addition to the high 
mortality rates, protozoal infections lead to significant decreases in quality of life for 
millions of others.  Protozoal infections are most common in impoverished nations and 
for this reason, there has been less money invested in discovering new treatments to 
combat protozoal diseases.  Due to this lack of research, many protozoal diseases such as 
Leishmaniasis and trypanosomiasis are often classified under the category of “neglected 
diseases”.  The main focus of our research was to develop novel antileishmanial agents in 
an attempt to add to the chemotherapeutic arsenal to help combat the morbidity and 
mortality associated with Leishmaniasis. 
According to WHO, Leishmaniasis causes approximately 60,000 deaths per year.2  
The overall prevalence of Leishmaniasis is estimated at 12 million people with an annual 
incidence of 2 million.3  Leishmaniasis is endemic in 88 countries with a worldwide 
distribution as shown in Figure 1.1.4  In these endemic countries, an estimated 350 
million people are at risk of contracting Leishmaniasis.  There are four main clinical 
forms of the disease: 1) visceral Leishmaniasis (VL, also known as kala-azar), 2) 
localized cutaneous Leishmaniasis (LCL), 3) mucocutaneous Leishmaniasis (MCL), and 
4) diffuse cutaneous Leishmaniasis (DCL).  VL and LCL are the most common forms.  
Nearly all of the deaths due to Leishmaniasis are caused by VL which is typically fatal if 
left untreated.  VL is characterized by an insidious onset and is particularly lethal to 
children and immuno-compromised individuals such as those with HIV.5  Although not 
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usually lethal, the cutaneous forms are characterized by large skin ulcers which can lead 
to permanent disfigurement due to scarring of infected areas of the body.3 
 
Figure 1.1:  Distribution map showing Leishmaniasis endemicity4 (Image reprinted with permission). 
1.2  Leishmania biology and transmission 
There are 21 species of the genus Leishmania 
that can cause Leishmaniasis.3  The genus Leishmania 
falls under the class of Kinetoplastida (single-cell 
flagellate protozoa) and the order of Trypanosomatida 
(single flagellum Kinetoplastids).  Members of the 
Kinetoplastida class are characterized by a single large 
mitochondrian within which resides a dark staining mass of DNA called a kinetoplast 
(Figure 1.2).6 Members of the genus Leishmania are obligate intramacrophage protozoa 
and can infect a variety of hosts including humans, rodents, and dogs.7  The vector for 
transmission of Leishmania from host to host is typically the sandfly of which there are at 
least 30 species capable of serving as the vector.  Although rare, transmission can also 
Figure 1.2:  Promastigotes of Leishmania donovani.  
Arrow points to kinetoplast.123  (Image reprinted 
with permission). 
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occur from the sharing of dirty needles and blood transfusions.8  Both the sandfly and the 
host (e.g. human) are essential to the life cycle of Leishmania (Figure 1.3).9   
 
Figure 1.3:  Life cycle of Leishmania9 (Image reprinted with permission). 
As is shown in Figure 1.3, the disease is transmitted to humans when an infected sandfly 
takes a blood meal from a human and injects the promastigote form of the protozoa into 
the skin.  Once in the human, the promastigotes 
are taken up by macrophages and then morph into 
the amastigote form (Figure 1.4).  Rapid 
multiplication of the amastigotes leads to cell 
lysis causing the release of the amastigotes into 
the blood stream.  When another sandfly takes a 
blood meal from an infected human (or other 
host), it can ingest the amastigote infected macrophages.  The amastigotes can morph into 
Figure 1.4:  Macrophage infected with amastigotes 
from Leishmania donovani.123 (Image reprinted 
with permission). 
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promastigotes and multiply in the gut.  These promastigotes migrate to the proboscis and 
are then ready to be injected into another human completing the life cycle. 
 Once a human is infected, there are a myriad of pathological processes that 
determine which of the four main forms (VL, LCL, MCL, or DCL) of Leishmaniasis 
evolves.  A full discussion of these pathological processes is beyond the scope of this 
dissertation.  However, it is worth noting that the specific species of Leishmania involved 
in the infection plays a significant role is the resulting disease form.  For example, VL is 
typically caused by L. dovovani, L. infantum, or L. tropica in the Old World and 
L.donovani chagasi in the New World (Table 1.1).10  As evidence that more than just the 
species is involved in determining disease progression, some species can cause more than 
one form of the disease.  For example, L. donovani chagasi can lead to both VL and 
LCL. 
 
Figure 1.5:  Clinical forms of Leishmaniasis, associated parasites, and geographic 
location.10 
Form of Disease New World Parasite* Old World Parasite* Geography
VL L. donovani chagasi L. donovani
L. infantum
L. tropica
LCL L. b. braziliensis L. major
L. b. guyanensis L. tropica
L. b. panamensis L. aethiopica
L. m. mexicana L. infantum
L. m. amazonensis
L. donovani chagasi
MCL L. b. braziliensis N/A
L. b. panamensis
DCL L. m. amazonensis L. aethiopica
L. mexicana
L. m. pifanoi
China, India, Bangladesh, Asia, 
Sudan, Africa, East Russia, 
Mediterranean, South America
North Africa, India, Middle East, 
China, South Russia, Pakistan, 
Mediterranean, Central and South 
America, Texas, Caribbean
Brazil, Venezuela, Peru, Ecuador, 
Colombia
Venezuela, Bolivia, Mexico, 
Dominican Republic, Brazil, 
Ethiopia
*Old World parasites typically have a species name, whereas New World organisms are divided into species 
and subspecies complexes.
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1.3  Leishmania treatment 
Despite the devastating effects that Leishmania inflicts worldwide, treatment 
options remain relatively limited and expensive.  Seven treatment options will be 
discussed below; three primary drugs (pentavalent antimonials, amphotericin B, and 
pentamidine) that are approved worldwide and four other promising drugs (Miltefosine, 
Paromomycin, Sitamaquine, and Imiquimod) that are approved only in certain countries 
or are in various phases of clinical trials.   
Pentavalent antimonials (such as sodium stibogluconate) are the main first-line 
treatment option for most forms of Leishmaniasis worldwide.  Their first reported use for 
treatment of VL dates all the way back to 1937 in 
China and India.11  The fact that pentavalent 
antimonials remain the primary first-line treatment 
option despite being discovered over 70 years ago 
shows the paucity of advancement in antileishmanial therapeutics.  Pentavalent 
antimonials are hampered by toxicity, dosing regimen, cost, and resistance.  Side-effects 
include cardiotoxicity, arthralgias, and pancreatitis.  Furthermore, patients with both 
Leishmaniasis and HIV-infection are particularly prone to chemical pancreatitis.  
Pentavalent antimonials are only administered IV and typically require inpatient hospital 
treatment for 20-40 days.11  This leads to high cost and often an inability for patients to 
maintain their employment, family responsibilities, and other obligations during this 
time.  Resistance to antimonials is increasing worldwide and is especially prevalent in 
regions of India where up to 65% of new patients do not respond to antimonial 
treatment.12  This antimonial resistance has been confirmed by in vitro analysis of 
Leishmania strains cultured from these patients.13 
Sodium stibogluconate (Pentostam)
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If antimonial treatment is unsuccessful, the main second-line treatment is 
Amphotericin B (Fungizone).11  Amphotericin B treatment is hampered by many of the 
same problems that antimonials have.  It is 
expensive, requires 3-week inpatient stay for 
IV administration, and has a myriad of side 
effects including numerous acute phase 
reactions such as vomiting, blood pressure 
abnormalities, and rigors in addition to chronic effects such as nephrotoxicity and 
electrolyte imbalances.14  A relatively new liposomal formulation of Amphotericin B 
(AmBisome) has been shown to be less toxic than the standard formulation.  However, 
AmBisome is over ten times more expensive than the antimonials and the standard 
Amphotericin B formulation and costs $1000-$2500 to treat one patient.  This high cost 
is often an insurmountable hurdle for impoverished patients to overcome without 
charitable assistance.  Thus far, there is limited evidence of resistance of Leishmania 
species to Amphotericin B.15  However, AmBisome has a significantly longer half-life as 
compared to the standard formulation which increases the likelihood of the development 
of resistant strains.16 
 In addition to Amphotericin B, Pentamidine is also used as a second-line 
treatment if antimonials are unsuccessful.  
Pentamidine has been utilized as an anti-
Leishmania agent for over 40 years but is 
not widely used today.16  Apparent pentamidine resistant strains have evolved in India 
although this has not been confirmed by in vitro studies.  However, resistance is likely as 
Amphotericin B (Fungizone)
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cure rates resulting from pentamidine use in India were greater than 95% in 1980 and less 
than 70% ten years later.17,18  Pentamidine is also plague by the necessity of IV or IM 
administration and significant side effects including hyperglycemia with the development 
of a permanent “diabetes-like syndrome” and fatal cardiac arrhythmias.19 
 In addition to the approved treatments described above, there are numerous anti-
Leishmanial candidates in various stages of clinical trials.  Perhaps the most promising 
candidate is Miltefosine 
(hexadecylphosphocholine) which is currently 
approved for use in India, Colombia, and Germany.20  Miltefosine marks a significant 
advancement in antileishmanial treatment as it is the first oral medication licensed for 
use.  Miltefosine was originally developed as an oral anti-neoplastic agent for the 
treatment of breast cancer and other solid tumors.  However, it fell out of clinical trials 
due to gastro-intestinal (GI) toxicity.21  Miltefosine’s antileishmanial activity was 
serendipitously discovered in 1987.22  In clinical trials as an antileishmanial treatment, 
Miltefosine still caused significant GI disturbances (nausea, vomiting, and diarrhea) in 
most patients.  The GI side-effects typically lasted one day or less and most patients were 
able to complete the therapeutic regimen.  Other common side effects of Miltefosine 
include reversible nephrotoxicity and reversible hepatotoxicity.21  In Phase III clinical 
trials, Miltefosine cured 94% of the 299 enrolled patients with VL.  Only 8 (2.7%) of the 
299 patients had to discontinue Miltefosine treatment due to its side-effects.  A 
significant drawback to Miltefosine is that it was shown to be teratogenic in rats and is 
thus unavailable to pregnant women and extra caution must be taken to avoid becoming 
pregnant during treatment and the two months after treatment completion.  Another 
Miltefosine
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shortcoming of Miltefosine is that some species of Leishmania are not as responsive as 
others.  For example, in Guatemala, the most prevalent strains of Leishmania are L. 
braziliensis and L. mexicana.  In one Guatemalan study, the cure rate of LCL with 
Miltefosine was only 53%.16  As far as resistance is concerned, there is little field 
evidence supporting the existence of Miltefosine resistant strains.  However, Miltefosine 
resistant strains of L. donovani have been grown in the lab and resistance is likely to be 
an issue as Miltefosine has a very long half-life (~150 hours). The long half-life causes 
days of sub-therapeutic drug levels at the completion of treatment which is a fertile 
environment for the evolution of resistant strains.23 
Another antileishmanial drug in the development pipeline is the aminoglycoside 
Paromomycin (also known as aminosidine).  In a Phase III clinical trial completed in 
2004, Paromomycin efficacy was compared to amphotericin B 
for treating VL.  Paromomycin showed an effective cure rate of 
95% (501 total patients) compared to amphotericin B which had 
a cure rate of 99% (165 total patients).  Common side effects 
from Paromomycin were liver enzyme increases, pain at injection 
site (IM), and reversible ototoxicity.  Only 1% of patients in the Paromomycin group 
suffered any level of renal dysfunction as compared to 25% of patients in the 
amphotericin B group.  Only 5 patients (1%) in the Paromomycin group had to 
discontinue treatment before finishing the dosing regimen.  For these 5 patients, it was 
not clear if Paromomycin was actually culpable in causing the side effects that resulted in 
discontinued treatment.24  Paromomycin has had limited use thus far and there is little 
field evidence of Paromomycin resistant strains.  Evidence of resistance is limited to a 
Paromomycin (aminosidine)
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1992 study on Paromomycin use for the treatment of DCL.  Two of the patients in this 
study initially were infected with an L. aethiopica strain which had an average in vitro 
ED50 value of 5.6 ug/mL.  After 60 days of treatment with Paromomycin, these patients 
were still infected with L. aethiopica and in vitro analysis showed a significant decrease 
in sensitivity to Paromomycin as the ED50 values rose to an average of 21.6 ug/mL.
25  
Resistance is a legitimate concern for Paromomycin as there are numerous 
aminoglycoside resistant strains of several bacterial species including strains of E. coli 
and P. aeroginosa.26 
Another antileishmanial drug in clinical trials is Sitamaquine which belongs to the 
8-aminoquinoline family of drugs and is administered orally.  
In a Phase II dose-ranging study, sitamaquine had a cure rate of 
87% (106 total patients) for patients with VL.27  Four different 
doses were tested and sitamaquine had a 100% cure rate (23 
patients) at a dose of 2.0 mg/kg.  Interestingly, when the dose was raised to 2.5 mg/kg, 
the cure rate fell to 80% (25 patients).  Vomiting and dyspepsia were the most common 
side effects with each occurring in 8% of the patients.  Nine patients had to discontinue 
the treatment before completion due to nephrotoxicity.  Likely due to its limited clinical 
use, there are no published reports of Leishmania resistance to Sitamaquine in the field 
though Sitamaquine resistant strains of L. donovani have been produced in the lab.28 
The last drug to be discussed in detail in this section is the immunomodulator 
Imiquimod (Aldara).  Imiquimod is a topical cream which is currently 
licensed for the treatment of several diseases including basal cell 
carcinoma, actinic keratosis, and genital warts.29  By itself, Imiquimod 
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failed in treating cases of LCL in a small study involving ten patients.  Only four patients 
were able to complete the dosing regimen and only one patient showed significant 
improvement.30  A later study involved the use of Imiquimod as a supplemental treatment 
along with the pentavalent antimonial meglumine antimonite.  This study involved twelve 
patients whose LCL infection was unresponsive to treatment by meglumine antimonite 
alone.  When treated with Imiquimod and meglumine antimonite together for 20 days, a 
90% cure rate was achieved.30  Although this study only had 12 patients, it provides hope 
that supplemental Imiquimod could be efficacious in areas where antimonial resistant 
strains are endemic.  
 
1.4  Drug mechanisms and validated targets 
In addition to there being relatively few treatment options for Leishmania, the 
actual mechanisms of action for all of these drugs is still unclear.  As stated by Kouni, 
“The rational design of a drug is usually based on biochemical and physiological 
differences between pathogens and host.”43  The nebulousness of the mechanisms of 
action has made it more difficult to rationally design new antileishmanial compounds.   
 
1.4.1 Proposed antileishmanial mechanism of pentavalent antimonials 
Despite being used for over 70 years to treat Leishmaniasis, the mechanism of 
action for pentavalent antimonials is still largely debated.  Furthermore, there is not even 
consensus on whether the active form of the drug is Sb (V) or Sb(III).  Two main models 
are proposed for their mechanism of action: 1) the prodrug model; and 2) the intrinsic 
activity model (also known as Active Sb(V) model).40 
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1.4.1.1  Prodrug model of pentavalent antimonials 
In the prodrug model, Sb(V) is biologically reduced to Sb(III) which then 
possesses the antileishmanial activity.  Studies have shown that this reduction likely takes 
place in the amastigote life stage of Leishmanial species and not in the promastigote 
form.  This is in congruence with experimental evidence which shows that amastigotes 
are much more susceptible to Sb(V) treatment as compared to promastigotes.32  In 
another study, strains of L. infantum were produced with different levels of Sb(III) 
resistance.   When treated with the Sb(V) compound meglumine, the observed Sb(V) 
resistance levels directly correlated with the Sb(III) resistance levels induced in the 
different strains of L. infantum.33  This supports the idea that the level of Sb(III) is the 
determining factor in the susceptibility of Leishmania species to antimonial therapy.  
Another postulation is that it could be the macrophage itself that reduces Sb(V) to Sb(III).  
However, this is unlikely as macrophages have been shown to be extremely sensitive to 
Sb(III) levels and tolerant to Sb(V) levels.34  In other words, if the macrophage itself was 
responsible for the reducing activity, it would be susceptible to both Sb(III) and Sb(V) 
compounds.  It is possible that macrophages can reduce a certain level of Sb(V) to 
Sb(III), but unlikely that macrophages are responsible for producing the Sb(III) levels 
necessary for antiLeishmanial activity.   
The prodrug model is further supported by a 2009 study which disclosed the 
crystal structure of the enzyme trypanothione reductase (TR) from L. infantum with an 
Sb(III) atom coordinated to the active site of TR.35  TR is essential to the survival of 
protozoal species as it is responsible for maintaining the intracellular reducing 
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environment of protozoa.  More specifically, TR is an FAD-dependent NADPH 
oxidoreductase enzyme that catalyzes the reduction of trypanothione disulfide (TS2) to 
trypanothione (T(SH)2) (Figures 1.6 and 1.7).
36  Trypanothione can then reduce 
potentially damaging species such as peroxides.  If TR function is reduced, protozoal 
species are subjected to increased oxidative stress which can damage DNA, proteins, and 
lipids and lead to cell death.37  Sb(III) is capable of binding to TR in its reduced state and 
preventing TR from delivering a hydride to TS2 thereby inhibiting the production of 
T(SH)2 (Figure 1.8).  Instead of a trypanothione based system, mammalian cells use a 
glutathione based system to maintain their reducing environment.  Thus, mammalian 
cells possess the enzyme glutathione reductase (GR) instead of TR (See Figure 1.9).  This 
makes TR a valuable drug target for anti-protozoal therapeutics. 
 
 
 
 
Figure 1.6:  Reduction of trypanothione disulfide to trypanothione. 
Trypanothione (T(SH)2)Trypanothione disulfide (TS2)
Trypanothione Reductase (TR)
NADPH + H+ NADP+
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Figure 1.7:  Catalytic triad mechanism of reduction of trypanothione disulfide. 
 
Figure 1.8:  Sb (III) atom (green sphere) occupying catalytic site of trypanothione reductase.35 
 
Figure 1.9:  Mammals (host) use a glutathione based system to handle reactive oxygen species (ROS) 
whereas protozoa (parasite) use trypanothione based system.36 
C52 and C57
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Another proposed mechanism of action for Sb(III) is via the displacement of 
Zn(II) from zinc-finger proteins.  The Zn(II) atoms normally coordinate to amino acid 
residues (typically cysteines and histidines) and help stabilize the zinc-finger protein’s 
structure.  Therefore, when Zn(II) atoms are displaced by Sb(III) atoms, the structure of 
the protein is altered which can lead to altered protein function as well.  The zinc-finger 
proteins in Leishmania are implicated in DNA replication, structure, and repair.31  In the 
proposed mechanism of action, the Sb(III) atom coordinates to three cysteine residues 
and one histidine which is referred to as a CX2CX4HX4C (X = any other amino acid) or a 
CCHC domain.  A study on the HEXBP (hexamer-binding protein) zinc-finger protein 
found in L. major showed that it has nine CCHC domains.  HEXBP binds to DNA in the 
region that encodes the gene for GP63 which is a major surface glycoprotein found in 
Leishmania.38,39  Although the exact mechanism is yet unknown, if Sb(III) displaces 
Zn(II) in HEXBP, it could alter the structure and function of HEXBP and inhibit the 
ability of the protozoa to produce GP63. 
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Figure 1.10:  Prodrug model and intrinsic activity model describing the different possible mechanisms of 
action for antimonial treatments .40 (Image reprinted with permission). 
1.4.1.2  Intrinsic activity model of pentavalent antimonials 
The intrinsic activity model (Figure 1.10) proposes that it is Sb(V) itself that is 
responsible for the antileishmanial activity of pentavalent antimonials.  Sb(V) was shown 
to inhibit DNA topoisomerase type I in L. donovani whereas Sb(III) did not show 
inhibition activity.  Furthermore, a level selectivity for L. donovani topoisomerase type I 
was observed as Sb(V) did not inhibit the activity of calf-thymus topoisomerase type I or 
DNA gyrase (a type II topoisomerase) from E. coli.41  Topoisomerases relieve 
supercoiling of DNA during replication and transcription and their function is vital to 
these processes. 
Prodrug model Intrinsic activity model
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There is also evidence that Sb(V) disrupts protozoal purine metabolism and 
transport.  All known protozoal species are unable to produce purines and rely on 
salvaging purine compounds from their host.42  Purines are an essential component to 
many physiological processes including DNA synthesis and energy-requiring reactions in 
both parasite and host.43  Therefore, selective disruption of the parasites’ purine salvage 
pathway is a potential target for antileishmanial drugs.  For a parasite’s salvage pathway 
to be functional, it requires correct recognition of the purine substrate, transport of the 
substrate, and conversion of the substrate into the desired product.  Figure 1.X shows the 
proposed purine salvage biochemical pathways in Leishmania.44   
Sb(V) has been shown to form complexes with many purine based compounds 
including adenosine, adenosine monophosphate (AMP), guanosine 5’-monophosphate 
(5’-GMP), and guanosine 5’-disphospho-D-mannose (5’-GDP-
mannose).45,46  Demicheli showed that the Sb(V) atom in 
meglumine antimoniate will trade its original ligand for 
adenosine or AMP in aqueous solution at acidic pH (pH = 5).  
Interestingly, this transfer did not readily occur at neutral pH (pH 
= 7.2) and also did not occur with deoxyadenosine.45  A later 
study showed that Sb(V) complexation with GMP is also faster at 
acidic pH.48  The preference for transfer at acidic pH is important as Leishmania 
amastigotes reside in the acidic environment of the phagolysosome (pH ~ 5) of 
macrophages.49 It is hypothesized that the antileishmanial activity of Sb(V) could be due 
to the inhibition of the two known nucleoside transport proteins (LdNT1 and LdNT2) of 
L. donovani by the Sb(V)-nucleoside complexes.42,48,50  Another hypothesis is that the 
Figure 1.11:  Proposed meglumine 
antimoniate structure.  Meglumine 
antimoniate has been shown to exist 
in numerous different Sb(V)-ligand 
complexes with the major moiety 
being the structure shown.47 
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Sb(V)-nucleoside complexes are formed in the acidic environment and then transported 
across the protozoal plasma membrane encountering the neutral pH of the cytosol where 
they then interfere with the purine salvage pathway.  This idea is plausible as it was 
shown that once formed, the Sb(V)-nucleoside complexes are slow to dissociate even at 
neutral pH.48 
The activity level of the enzymes shown in Figure 1.12 is not the same in all 
parasites. 
  
 
Figure 1.12:  Proposed purine salvage pathway of Leishmania.44  Heavy blue arrows indicate major flux 
pathways. Minor flux pathways indicated by black arrows. Dashed line indicates unlikely pathway 
under normal physiological conditions in Leishmania.  Abbreviations: APRT, adenine 
phosphoribosyltransferase; HGPRT, hypoxanthine-guanine phosphoribosyltransferase; XPRT, xanthine 
phosphoribosyltransferase; AK, adenosine kinase; AAH, adenine aminohydrolase; GDA, guanine 
deaminase; ADSS, adenylosuccinate synthetase; ASL, adenylosuccinate lyase; AMPDA, AMP deaminase; 
IMPDH, inosine monophosphate dehydrogenase; GMPS, GMP synthase; GMPR, GMP reductase; NH, 
nucleoside hydrolase; ADO, adenosine; ADE, adenine; INO, inosine; HYP, hypoxanthine; GUO, 
guanosine; GUA, guanine; XAO, xanthosine; XAN, xanthine.  (Image reprinted with permission). 
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1.4.2  Proposed antileishmanial mechanism of amphotericin B 
 Amphotericin B (AmB) is believed to exert its antileishmanial (and antifungal) 
activity by binding to ergosterol in the protozoal membrane which leads to disruption of 
membrane integrity and an increase in membrane permeability.51,52  One consequence of 
the increased permeability is that monovalent cations and anions such as K+ and Na+ can 
freely flow across the cell membrane which depolarizes the membrane and can lead to 
cell death.53  Selectivity in membrane disruption is possible as mammalian cells use the 
sterol cholesterol in their cell membranes instead of ergosterol.  It is proposed that the 
selectivity is due to the increased van der Waals interactions between the conjugated 
region of AmB and ergosterol as compared to cholesterol.  This increase in attraction is 
believed to be due to one of the double bonds (on the right side of the ergosterol molecule 
as shown in Figure 1.13) in ergosterol which is absent in cholesterol.  As confirmed by 
conformational studies, this double bond causes this region of ergosterol to be much 
flatter than the corresponding region in cholesterol.  This leads to more favorable 
interaction with the flat polyene region of AmB.52  Both sterols can also bind to AmB via 
the hydroxyl group of the sterol and the carboxylate and ammonium ions of AmB with 
incorporation of a water molecule.  This hydrogen bonding interaction is equally likely 
for both sterols and thus does not lead to any selectivity between the two.52 
 Although the binding of AmB and cholesterol likely leads to side-effects, this 
interaction also has been shown to inhibit the entry of Leishmania promastigotes into 
macrophages.  Pucadyil and coworkers showed that cholesterol is required for entry of 
non-opsonized L. donovani into macrophages.  They used methyl-B-cyclodextrin to 
extract cholesterol from J774A.1 macrophage membranes which resulted in a marked 
decrease in L. donovani virulence.  Virulence was restored when these cells were 
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replenished with cholesterol.54  It is proposed that since AmB binds to cholesterol, it 
reduces the amount of free cholesterol available for Leishmania promastigotes to use as 
attachment points for entry.55 
 
Figure 1.13:  Interactions of cholesterol and ergosterol with Amphotericin B.  Larger arrow indicates the stronger 
interaction between Amphotericin B with ergosterol as compared to cholesterol.  The left side of the Amphotericin 
B molecule also shows where either sterol can bind to Amphotericin B via hydrogen bonds with incorporation of a 
water molecule.52 
1.4.3  Proposed antileishmanial mechanism of pentamidine 
Pentamidine is believed to exert its antileishmanial effects by disruption of 
protozoal mitochondrial structure and function.  Though its exact mechanism is 
unknown, several studies have shown significant morphological changes in the 
kinetoplast and mitochondrial membranes.  One study showed that the normal tightly 
bound DNA of the kinetoplast of L. tropica is broken into “a filamentous network” when 
exposed to pentamidine.  In addition, dilatation of the mitochondria was observed along 
with abnormal or absent cristae formation.  Pentamidine is a lipophilic cationic drug 
which can be concentrated in the mitochondria via electrophoresis due to its inside-
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negative membrane potential.56 Fluorescent analogues of pentamidine have been shown 
to accumulate in protozoal mitochondria and bind to kinetoplast DNA.57  Vercesi and 
coworkers propose that once inside the mitochondria, pentamidine can disrupt the 
mitochondrial membranes resulting in decreased membrane potentials and an uncoupling 
of oxidative phosphorylation.56  
 
1.4.4  Proposed antileishmanial mechanism of Miltefosine 
The antiprotozoal mechanism of Miltefosine is still unknown but there are several 
hypotheses including: 1) flagellar membrane damage, 2) interference with alkyl-lipid 
metabolism and ether-lipid remodeling, and 3) inhibiting phosphatidylcholine synthesis.58 
Some mechanisms appear to be more damaging to promastigotes and others to 
amastigotes.  Interestingly, there is significant evidence that Miltefosine can trigger 
apoptosis (programmed cell death) in Leishmania species which certainly seems to be a 
counter-productive process for unicellular organisms.51,58,59  Moreira observed that, “The 
reason apoptosis is not expected to occur in unicellular organisms is that it may lead to 
the extinction of a species in which this type of death is part of a developmental 
program.”60  Though seemingly counter-intuitive in unicellular organisms, Verma states 
that, “apoptosis could be a useful mechanism to avoid killing of the entire population.”59  
Common features of apoptosis are compared to the features of necrosis (non-programmed 
cell death) in Figure 1.14.61  
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Figure 1.14:  Common features of apoptosis and necrosis.61 
 When studying the effects of Miltefosine on Leishmania donovani promastigotes, 
Paris and coworkers observed characteristics of apoptotic promastigote cell death 
including karyorrhexis (nuclear fragmentation), cell shrinkage, and maintenance of cell 
membrane integrity.  In addition, they observed the translocation of phosphatidylserine 
residues from the inside to the outside of the plasma membrane which is also a common 
apoptotic feature.  When present on the cell surface, phosphatidylserine attracts 
phagocytes which will eventually digest the apoptotic cell remnants.  Paris and coworkers 
also tested the effects of caspase inhibitors on miltefosine treated promastigotes.  In 
mammalian, caspases activate enzymes such as endonucleases which perform the DNA 
digesting aspect of apoptosis.  Paris observed that caspase inhibitors do inhibit DNA 
digestion in promastigotes further supporting the postulation of an apoptotic death.58  
Verma and coworkers studied Miltefosine’s effects on amastigotes as well as 
promastigotes.  They observed karyorrhexis in both extracellular and intra-macrophage L. 
donovani amastigotes which supports the apoptotic hypothesis for this life stage as well.59 
Apoptosis Necrosis
Single cells or small clusters of cells Often contiguous cells
Cell shrinkage and convolution Cell swelling
Pyknosis and karyorrhexis Karyolysis, pyknosis, and karyorrhexis
Intact cell membrane Disrupted cell membrane
Cytoplasm retained in apoptotic bodies Cytoplasm released
No inflammation Inflammation usually present
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Figure 1.15: Proposed mechanisms of action of Miltefosine against Leishmania.71 (Image reprinted with permission) 
In addition to the apoptosis hypothesis, there is evidence of several other drug 
targets for miltefosine.  It is possible that these other 
drug targets also play some role in the complex 
apoptotic pathway.  One such target is interference 
with lipid metabolism and remodeling.  For 
Leishmania donovani promastigotes, 
phosphatidylcholine (PC) is the primary phospholipid 
and makes up approximately 45-52%  of the total cell 
phospholipid content.62,63  Following exposure to 
miltefosine, total cell PC content dropped by 42% and 
was accompanied by a 19% increase in 
phosphatidylethanolamine (PE) content.63  
Rakotomanga and coworkers proposed that this 
decrease in PC content was due to miltefosine 
inhibiting the CTP-phosphocholine-
CTP-phosphocholine-
cytidylyltransferase
Figure 1.16:  General phosphatidylcholine 
synthetic pathway in eukaryotes.64 
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cytidylyltransferase enzyme activity in the synthesis of phosphatidylcholine (See Figure 
1.16).63  Croft postulates that miltefosine prevents CTP-phosphocholine-
cytidylyltransferase from convert from its inactive from in the cytosol to its active form 
in the membrane.66  Inhibition of this same enzyme is also hypothesized to contribute to 
the anti-neoplastic activity of miltefosine.65  Rakotomanga also postulates that the CTP-
PE cytidylyltransferase enzyme could be stimulated by miltefosine along with inhibition 
of PE-N-methyltransferase (PEMT).  Stimulation of CTP-PE cytidylyltransferase could 
obviously lead to increased PE as this enzyme is in the PE synthetic pathway.  Inhibition 
of PEMT would lead to a decrease in PC and an increase in PE as PEMT catalyzes the 
transfer of 3 methyl groups from 3 equivalents of S-adenosyl methionine (SAM) 
converting PE to PC (Figure 1.17).67  Inhibition of PEMT is an intriguing target as 
protozoal cells utilize the PEMT pathway as their primary method of PC synthesis 
whereas mammalian cells primarily use the CDP-choline pathway.68 
 
Figure 1.17:  Conversion of PE to PC by the enzyme Phosphatidylethanolamine-N-methyltransferase (PEMT).  SAM = 
S-adenosyl methionine; SAH = S-adenosyl homocysteine 
 
In addition to changes in PC and PE content, it has also been hypothesized that 
miltefosine interferes with synthesis of glycoinositol phospholipids (GIPLs), 
lipophosphoglycans (LPGs), and glycosylphosphatidylinositol (GPI) anchored proteins. 
PEMT
SAM (3 eq.) SAH (3 eq.)
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These compounds are abundant on Leishmania cell surfaces and play a significant role in 
the virulence of the parasite.70  Figure 1.18 shows the size and abundance of these surface 
lipids in Leishmania promasigotes.72  Mammalian cells do not use GIPLs and LPGs at all 
and use significantly less GPI-anchored proteins.  Therefore, interference with the 
synthesis and functions of these molecules should selectively disrupt protozoal cell 
functions without disturbance of mammalian cell functions.70 
 
Figure 1.18:  Surface Lipids of Leishmania72 
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1.4.5  Proposed antileishmanial mechanism of Paromomycin 
Akin to the aminoglycoside inhibition of bacterial protein synthesis, 
paromomycin’s antileishmanial effect is attributed to selective perturbation of protozoal 
protein synthesis.73,74  Fernandez and coworkers showed that Paromomycin significantly 
interferes with translation of mRNA in in vitro analysis of protein synthesis using 
ribosomes from Leishmania promastigotes.   In the same analysis using mammalian cells, 
there was only minimal perturbation of translation indicating a high degree of selectivity 
for protozoal ribosomes over mammalian ribosomes (Figure 1.19).  With the Leishmania 
ribosomes, they observed a decrease in protein synthesis as well as a less accurate 
translation of mRNA.  They also analyzed binding activity of Paromomycin to ribosomes 
which showed strong binding of Paromomycin to Leishmanial ribosomes and minimal 
binding to mammalian ribosomes.  In addition to the in vitro analysis, in vivo studies also 
showed that Paromomycin significantly inhibits protein synthesis in Leishmania 
promastigotes.  Furthermore, they showed that Paromomycin is vastly superior in 
inhibiting protozoal protein synthesis when compared to streptomycin and neomycin 
which are also aminoglycosides.74 
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Figure 1.19:  Paromomycin effect on protein translation with Leishmania mexicana ribosomes (squares) and 
mammalian (rat liver) ribosomes (triangles).74 
 
1.4.6  Proposed antileishmanial mechanism of sitamaquine 
Based on their studies with L. donovani promastigotes, Carvalho and coworkers 
propose that the orally active sitamaquine exerts in antileishmanial activity via inhibition 
of succinate dehydrogenase (SD, also known as respiratory complex II) which is a key 
enzyme in both the citric acid cycle and the electron transport chain.75,76  Carvalho 
postulates that sitamaquine “induces a fast and significant decrease of intracellular free 
ATP levels, thus leading to a bio-energetic collapse of the parasite”.75  Inhibition of SD 
has been shown to result in increased reaction oxygen species (ROS) causing oxidative 
stress which can lead to apoptosis.77  Whereas sitamaquine interferes with respiratory 
complex II, Tafenoquine (which is also an 8-aminoquinoline analogue) was shown to 
inhibit respiratory complex III which also led to apoptosis in Leishmania promastigotes.78 
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1.5  Preventative strategies for control of Leishmania 
 
1.5.1  Vaccine development 
 The ultimate goal for the treatment of Leishmaniasis is the development of a 
successful vaccine to decrease the incidence and prevalence of Leishmaniasis with an 
accompanied decrease in morbidity and mortality.  Due to the “simple life cycle” of 
Leishmania, Davies and coauthors stated, “Of all the parasitic diseases, Leishmaniasis is 
considered the most likely to succumb to vaccination.”79  Despite the relative success seen 
in mouse model Leishmania vaccination studies, success in human trials has remained 
elusive.80   
 The belief that a Leishmaniasis vaccine is an attainable goal stems from the fact 
that patients who have recovered from LCL are usually immune to new infections.81  To 
date, the only successful vaccination strategy in humans has been through the direct 
inoculation of subjects with virulent L. major.82  This strategy has been termed 
“leishmanization” and has been used for over 60 years.83  In the most primitive form of 
leishmanization, “scratched tissue from active lesions of patients with [LCL] was applied 
to, or sandflies were allowed to bite, the skin of healthy individuals.”81  When it works, 
leishmanization results in a small, self-healing lesion which confers immunity to the 
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individual.  However, some individuals develop severe lesions which in certain cases 
never fully resolve.81  For this reason, leishmanization has been deemed unethical and 
discontinued by most countries worldwide with the exception of its current use in 
Uzbekistan and Iran.83 
 Many vaccination studies have been completed using first-generation vaccines 
composed of either live attenuated parasites or whole-killed parasites.  The live 
attenuated vaccines have had varying degrees of success in conferring immunity to 
Leishmania.  Titus and coworkers deleted the gene encoding for dihydrofolate reductase-
thymidylate synthase (DHFR-TS) from a strain of L. major and evaluated its 
immunogenicity in mice.  This altered strain did not cause Leishmaniasis and the 
inoculated mice were markedly more resistant to disease when challenged with wild-type 
L. major.84  However, when this same DHFR-TS deficient strain was evaluated in a 
primate model using Rhesus monkeys, protective immunity did not result as the 
inoculated monkeys developed LCL when challenged with virulent L. major.85 In both 
the mouse and monkey studies, parasites of the DHFR-TS deficient strain persisted at low 
levels in the animals for up to 2-3 months.  The persistence of parasites in subjects 
without disease has been shown in numerous studies.  In one murine study with L. major 
infected mice, all 23 mice in the study recovered from the experimentally induced LCL 
and yet all 23 had persistent parasites after 12 months.  The most common location of the 
persistent parasites was in lymph node near the original inoculation site.86  There is 
debate as to whether the persistent parasites (subclinical infection) are beneficial or 
detrimental to the host.  In a study done by Uzonna and colleagues, persistent parasites 
were necessary to maintain immunity in mice.87  If parasites were completely cleared 
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from the mice, they lost their resistance to subsequent infection.  Uzonna postulated that 
the persistent parasites provided a continuous low level of antigen presentation to T-
memory cells specific for the parasite which confers immunity.   Furthermore, they 
hypothesized that when the parasites are completely cleared, the specific T-memory cells 
die out leaving the host once again susceptible to Leishmaniasis.  The problem with 
subclinical infections is that the host may become immunocompromised from a different 
disease state (such as AIDS) which can result in parasite proliferation and a condition 
known as reactivation Leishmaniasis.87,88,89  In addition, with a long lasting subclinical 
infection, it is possible that a live attenuated non-disease causing parasite may mutate into 
a disease causing strain.83,90  
 The literature on whole killed parasites for use in vaccination exhibits a similar 
history to the live attenuated parasite vaccine in that success has been seen in animal 
models but it has not translated to success in humans.83  Misra and coworkers used a 
monkey model to evaluate an autoclaved L. major vaccine with alum and Bacillus 
Calmette-Guerin (BCG) as adjuvants.  All four monkeys in the unvaccinated group died 
from VL within 180 days whereas 7 of the 8 monkeys in the vaccinated group survived.91  
Mohebali and colleagues later showed that this same vaccine preparation was efficacious 
for canine VL as well.92  However, when tested in a clinical trial in Iran, the vaccine was 
shown to be safe but vaccine efficacy results were inconclusive.  There are plans to re-
evaluate this vaccine in humans with an “improved study design” in hope of more 
conclusive results.93  Several other first generation vaccines have been shown to have 
acceptable safety profiles but “reproducible evidence of protective efficacy has not 
emerged from clinical trials of first generation Leishmaniasis vaccines”.93  As 
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summarized by Coler and Reed, “the results from several clinical trials using whole 
parasite antigens vary from 0-75% efficacy against [LCL] and little (<6%) or no 
protection against VL.”94 
 Numerous second generation vaccines antileishmanial vaccines have also been 
developed though few have been evaluated in humans.  Second generation vaccines 
utilize subunits of Leishmania which can administered in several different ways including 
being conjugated to bacteria or viruses.83  Numerous studies describe success with second 
generation vaccines in murine and canine models.95-100  A vaccine known as Leish-111f is 
the only second generation antileishmanial vaccine that has advanced to human clinical 
trials.80  Leish-111f is a polyprotein composed of three proteins that were each initially 
assessed individually as potential vaccine candidate antigens.101-103  The three proteins 
linked together are: 1) thiol-specific antioxidant (TSA) from L. major, 2) stress-inducible 
protein 1 (LeSTI1) from L. major, and 3) elongation and initiation factor (LeIF) from L. 
braziliensis.83  When evaluated in BALB/c mice, Leish-111f formulations elicited an 
equal or greater immunogenic response as compared with any of the single proteins used 
alone.104  Despite the success in mice, Leish-111f was unsuccessful in curbing 
Leishmanial infections in a canine Phase III field trial.105  A later canine study evaluated 
a modified version of Leish-111f known as Leish-110f.  There are two slight differences 
between Leish-111f and Leish-110f.  Leish-111f has a tag of six histidine residues at one 
end of the polyprotein whereas Leish-110f does not and the lysine274 residue of Leish-
111f has been change to glutamine in Leish-110f.106  When a Leish-110f formulation was 
evaluated in dogs as a combination therapy with pentavalent antimonials, the group 
receiving Leish-110f and antimonial treatment showed significantly less mortality as 
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compared to the groups receiving only antimonial treatment or no treatment.107  Leish-
111f formulations have been evaluated in humans in Phase I and II clinical trials and 
have been deemed both safe and immunogenic though human vaccine efficacy remains to 
be assessed.108 
 Third generation DNA vaccines are also being evaluated for their potential utility 
as antileishmanial agents.  As stated by Nagill, “DNA vaccines are advantageous as they 
are relatively simple to produce, stable, easy to administer and often very 
immunogenic”.83  DNA vaccines involve direct injection of DNA which encodes for 
specific Leishmanial proteins.  Immunogenic responses can occur to the DNA itself 
and/or to the antigenic protein synthesized from the DNA by the host.109  In what is 
known as the “prime-boost vaccine strategy”, a recombinant virus is injected within days 
or weeks of the DNA vaccine.  The recombinant virus is engineered to express the same 
protein that the DNA in the vaccine encodes for.  Numerous studies have shown 
protective immunogenic responses to antileishmanial DNA vaccines and prime-boost 
DNA vaccines in mice and dogs.83,110-115 To the best of my knowledge, there are no 
publications evaluating antileishmanial DNA vaccine use in humans. 
 Overall, it is evident that progress has been made in vaccine development for 
Leishmaniasis yet it is also evident that an efficacious human vaccine is likely several 
years off and possibly decades away.   
 
1.5.2  Vector and reservoir control 
 The phlebotomine sand fly is the only known vector for Leishmania.  Therefore, 
there has been extensive research on methods to control sand fly populations and 
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prevention of sand fly bites.  Common control and preventative measures include 
spraying houses with insecticide, use of insecticide impregnated bed nets and clothing, 
topical repellents, and insecticide application to animal burrows which are common 
breeding grounds for sand flies.79,116  The efficacy of these methods is often difficult to 
accurately assess.  In a 2003 study in Iraq during Operation Iraqi Freedom, members of 
the United States Theater Army Medical Laboratory unit directed Leishmaniasis control 
measures and attempted to evaluate their efficacy at Tallil Air Base.  Their control and 
preventative measures included insecticide impregnated uniforms and bed nets, spraying 
shelters with pesticides (lambda cyhalothrin, cypermethrin, and cyfluthrin), area spraying 
with pesticides (resmethrin and malathion), and removal of sand fly habitat.  From May 
to October, they captured 19,454 sand flies using light traps in twelve different locations 
(10 traps in pesticide treated areas and 2 traps in untreated control areas).  In the first two 
months, similar amounts of sand flies were trapped in both treated areas and control 
areas.  After the first two months, the treated areas showed significant reductions in the 
number of trapped sand flies indicating some efficacy in the pesticide treatment.  
Removal of habitat measures were not efficacious as “hundreds of sand flies were often 
captured in a single light trap placed in the middle of heavily compacted and completely 
denuded tent cities with no apparent ‘normal’ habitat for hundreds of meters in all 
directions.”  The study authors further pointed out that “although it was encouraging that 
we could reduce the [sand fly] numbers over time, it is unclear whether these gradual 
reductions translated into fewer cases of Leishmaniasis in the soldiers stationed at Tallil 
Air Base.”117  Unfortunately, the majority of vector control studies fail to develop any 
clear conclusions on the efficacy of the control measures in preventing cases of 
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Leishmaniasis.  It is often difficult to control the variables in this type of study which can 
cloud conclusions.  Despite the nebulous results, Claborn states that “vector control 
remains a key component of many anti-Leishmaniasis programs and probably will remain 
so until an effective vaccine becomes available.116 
 In addition to vector control, reservoir control has also received much attention.  
There are many animal reservoirs for Leishmanial species including dogs, sloths, rats, 
and gerbils.117  As dogs are the reservoir that most commonly live in close proximity with 
humans, most reservoir control studies have evaluated methods to decrease dog to human 
parasite transmission via the sand fly vector.  These control methods include treating or 
killing seropositive dogs, spraying dogs with insecticide, and using insecticide-
impregnated dog collars.79,120-122  A dog culling study in a city (Jacobina) in Brazil from 
1989-1993 showed that pediatric cases of VL decreased significantly in the years that 
seropositive dogs were killed.  From 1986-1989, there were an average of 10 cases of VL 
per 1000 children in Jacobina.  This number dropped down to an average of 2 cases per 
1000 children from 1990-1993.  This was paralleled by a drop in the number of 
seropositive dogs which was 36% of dogs tested in 1989 and down to 14% in 1993.  The 
authors of the study point out that it is impossible to say if this drop in pediatric VL is 
directly due to the dog culling as there are many other variables at play.121  For instance, 
these types of studies typically involve an increase in information dissemination 
concerning the dangers of Leishmaniasis which can lead to the population taking more 
personal protective measures such as using bed nets and insecticides which may be the 
actual cause of the decrease in disease incidence.  Although clear conclusions from dog 
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control studies are difficult to achieve, dog control measures are still widely used and 
studied. 
 
1.6  Concluding remarks 
  
As shown in the preceding sections, considerable efforts have been made to 
develop numerous therapeutic strategies to combat Leishmaniasis. However, 
Leishmaniasis continues to plague many regions of the world and still has high rates of 
morbidity and mortality associated with it.  For this reason, it is important that research 
continues in the search for novel therapeutic strategies to combat this disease.  Our efforts 
in the endeavor to develop new pharmacological molecules to treat Leishmaniasis are 
detailed in the following chapter. 
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Chapter 2:  Natural product library synthesis and antileishmanial biological activity 
 
2.1  Antiprotozoal polyacetylene compounds discovered by Senn and colleagues 
 
In 2007, Martin Senn and coworkers reported the isolation of four polyacetylene 
compounds (MS-1 through MS-4) from the Tanzanian 
medicinal plant Cussonia zimmermannii.124 MS-1, MS-2, and 
MS-3 were tested for biological activity against Trypanosoma 
brucei rhodesiense, Trypanosoma cruzi, Plasmodium 
falciparum, and Leishmania donovani.  MS-4 was not tested as 
not enough was isolated for biological activity assays.  Of the 
three compounds assayed, MS-2 had the lowest IC50 (0.32uM) 
and the highest selectivity index (37; IC50 for rat skeletal 
myoblasts/IC50 for L. donovani) when screened against Leishmania donovani in infected 
macrophages.  As our goal was to develop antileishmanial agents, we started with MS-2 
as our lead compound to investigate.  As MS-2 was our first synthetic target, it will from 
here forward be referred to as compound 1. 
 
2.2  First Round of SAR studies – Evaluating Stereochemistry 
Senn and coworkers did not determine the absolute or relative stereochemistry of 
the two stereocenters in 1.  As 1 has two stereocenters, there are four stereoisomers of the 
molecule and our initial SAR goal was to synthesize all four stereoisomers and evaluate 
their biological activity.  Retrosynthetic analysis (Figure 2.1) showed that 1 and its 
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stereoisomers could be synthesized by the Cadiot-Chodkiewicz coupling of the respective 
enantiomers of 2 and 3.125  We set both stereocenters by resolving the respective 
propargylic alcohols via enantioselective esterification using Lipase AK from 
Pseudomonas fluorencens.126  In their 1991 JACS publication, Burgess and Jennings 
described the utility of Pseudomonas sp. Lipase AK in resolving a wide variety of 
alcohol substrates including allyl alcohols, propargyl alcohols, and homopropargylic 
alcohols.  Adapted Figure 2.2 from Burgess and Jennings’ article shows their “simple 
model for predicting which substrates will be resolved effectively via biocatalytic 
acylations mediated by crude lipase from Pseudomonas sp. (Amano AK), and the sense 
of the enantioselection.”126 
 
 
Figure 2.1:  Retrosynthetic analysis for compound 1. 
 
Figure 2.2:  Enantioselective esterification model for Pseudomonas sp. lipase Amano AK.126 
 
Small Large
Acylated slowly
LargeSmall
Acylated rapidly
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Scheme 2.1 
The enantiomers of 1-bromoalkyne 2 were prepared as shown in Scheme 2.1.  ±4 
was obtained by the reaction of lithium trimethylsilylacetylide with acrolein.127 
Enzymatic resolution of ±4 by Lipase AK from Pseudomonas fluorescens yielded (S)-4 
and (R)-5.  Enantiomeric excess was determined by Mosher ester preparation.128,129 The 
ee value for (S)-4 was greater than 99%.  To determine the ee value of (R)-5, it was first 
converted to (R)-4 with LAH and then the Mosher ester was prepared which showed an 
ee value of 97%. (S)-4 was converted to 1-bromoalkyne (S)-6 with NBS and AgNO3.
130 
(S)-6 was subsequently acylated with acetic anhydride in pyridine to obtain (S)-2.  (R)-2 
was obtained by brominating (R)-5 at the acetylenic position with NBS and AgF.131  
The enantiomers of propargyl alcohol 3 were synthesized as outlined in Scheme 
2.2.  ±7 was obtained by the reaction of lithium trimethylsilylacetylide with decanal.127 
Enzymatic resolution of ±7 by Lipase AK from Pseudomonas fluorescens yielded (S)-7 
and (R)-8.126 (S)-3 and (R)-3 were obtained by treating (S)-7 and (R)-8 respectively with 
potassium carbonate in methanol.132  Enantiomeric excess was determined by Mosher 
ester preparation.128,129 The ee value of (S)-7 was 94%.  To determine the ee value of (R)-
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8, it was first converted to (R)-7 with LAH and then the Mosher ester was prepared 
which showed an ee value greater than 99%.  Figure 2.3 shows zoomed in areas of the 
spectra of the Mosher esters obtained from ±7, (S)-7, and (R)-7.  The resonance from the 
methine proton in each compound is shown in the zoomed in area and the integration 
values from the methine proton were used to determine ee values. 
 
Scheme 2.2 
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Figure 2.3:  1H NMR spectra of Mosher esters prepared from racemic 7 and following enzymatic resolution via 
Pseudomonas fluorescens lipase. 
The four diastereomers of 1 were then afforded by the Cadiot-Chodkiewicz 
coupling of (S)-2 and (S)-3, (R)-2 and (R)-3, (R)-2 and (S)-3, and (S)-2 and (R)-3 
respectively.133  The reaction scheme for (3S,8R)-1 is shown below in Scheme 2.3.  The 
other 3 stereoisomers were prepared in an analogous fashion by substituting the 
respective reagent enantiomers for each compound.  Our measured optical rotation (Table 
2.1) of the (3S,8S)-1 stereoisomer was consistent with the optical rotation of the natural 
product reported by Senn and in agreement with the optical rotation and absolute 
stereochemistry assignment reported by Trost and coworkers in their synthesis of the 
natural product.124,134  Our 1H NMR (Table 2.1) and 13C NMR (Table 2.3) data also 
closely matched the data reported by Senn. 
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Scheme 2.3 
 
Table 2.1:  Comparison of optical rotation data recorded in Bolstad lab to that reported by Senn and Trost. 
 
Table 2.2:  Comparison of 1H NMR data. 
Specific 
Rotation (°)
Concentration 
(grams/100 mL)
Temperature 
(°C)
Senn Product -28.0 0.85 20
Trost Product -24.3 1.02 23
(3S,8S )-1 -29.1 0.59 17
(3R,8R )-1 31.7 0.90 18
(3R,8S )-1 44.6 1.19 17
(3S,8R )-1 -46.0 0.67 17
The solvent used for all testing was 0.75% ethanol in chloroform.
The wavelength used for all testing was the sodium D line.
MS-2 1H δH Splitting Integration (3S,8S )-1 
1H δH Splitting Integration
(ppm) (J  in Hz) (# of H atoms) (ppm) (J  in Hz) (# of H atoms)
0.88 t (7.0) 3 0.88 t (6.97) 3
1.22 - 1.31 m 12 1.22 - 1.34 m 12
1.43 br, quint. (7.5) 2 1.44 quint. (7.58) 2
1.70 m 2 1.71 m 2
1.81 br, s 1 1.91 d (4.40) 1
2.11 s 3 2.11 s 3
4.43 br, t (6.5) 1 4.43 m 1
5.35 d (10.0) 1 5.36 dd (1.10, 10.03) 1
5.55 d (16.8) 1 5.55 dd (1.22, 16.63) 1
5.86 m 1
5.91 m 1
5.84 - 5.94 m 2
MS-2 1H NMR Data (Senn publication) (3S,8S )-1 1H NMR Data (Bolstad Lab)
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Table 2.3:  Comparison of 13C NMR data. 
The four diastereomers were analyzed for biological activity against Leishmania 
amazonensis which showed the (3S,8R)-1 stereoisomer had the lowest IC50 of 0.63uM 
while the (3S,8S)-1 stereoisomer had an IC50 of 1.28uM (Table 2.4).  The (3R,8S)-1 and 
(3R,8R)-1 stereoisomers displayed no antileishmanial activity at 10uM indicating the 
stereochemistry plays a significant role in the antileishmanial action of the compounds.  
More specifically, it appeared that the stereochemistry at C-3 was more important than C-
8 since the only active compounds had the (S)-configuration at C-3. 
MS-2 13C NMR Data (3S,8S )-1 13C NMR Data
Senn publication Bolstad Lab
 δC (ppm) δC (ppm)
14.1 14.1
20.9 20.9
22.7 22.7
25.0 25.0
29.2 29.2
29.3 29.3
29.48 29.45
29.51 29.48
31.9 31.9
37.4 37.4
62.9 62.9
64.5 64.4
68.6 68.6
70.8 70.8
74.4 74.3
81.3 81.3
119.8 119.7
131.9 131.9
169.5 169.5
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Table 2.4:  Biological activity of the four diastereomers of compound 1 against L. amazonensis in infected 
macrophages. 
 
2.3  Second Round of SAR studies – Lipophilicity and Hansch Cluster Analysis 
Since the (3S,8R)-1 stereoisomer had the lowest IC50, several analogues (Figure 
1) were synthesized with the same stereochemistry.  Analogue selection was based on 
cluster analysis theory (Table 2.5)135,136 as described by Hansch and coworkers and on the 
simplicity of synthesis. The initial analogues set consisted of compounds 9-16 (Figure 
2.4) which all had the (3S,8R) configuration.  Compounds 9 and 10 were synthesized to 
assess the significance of the length of the lipophilic side chain.  Compounds 11-15 are 
analogues of (3S,8R)-1 with different functional groups at the C-8 position.  Compound 
16 has replaced the C-3 acetate with an alcohol. 
C-8C-3
Compound
IC50 L. amazonensis  in 
infected macrophages [uM]
(3S,8R )-1 0.63
a(3S,8S )-1 1.28
(3R,8R )-1 >10
(3R,8S )-1 >10
astereochemistry of natural product
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Figure 2.4:  Second-round SAR study structures. 
 
Table 2.5:  Substituents shown in bold represent the first substituent we chose to use in our analogues from each 
cluster.   Table adapted from Silverman.136 
Cluster Number Typical Members
1 Me, H, 3,4-(OCH2O), CH2CH2COOH, CH=CH2, Et, CH2OH
2 CH=CHCOOH
3a CN, NO2, CHO, COOH, COMe
3b C + CH, CH2Cl, Cl, NNN, SH, SMe, CH=NOH, CH2CN, OCOMe, SCOMe, COOMe, SCN
4a CONH2, CONHMe, SO2NH2, SO2Me, SOMe
4b NHCHO, NHCOMe, NHCONH2, NHCSNH2, NHSO2Me
5 F, OMe, NH2, NHNH2, OH, NHMe, NHEt, NMe2
6 Br, OCF3, CF3, NCS, I, SF5, SO2F
7 CH2Br, SeMe, NHCO2Et, SO2Ph, OSO2Me
8 NHCOPh, NHSO2Ph, OSO2Ph, COPh, N=NPh, OCOPh, PO2Ph
9 3,4-(CH2)3, 3,4-(CH2)4, Pr, i -Pr, 3,4-(CH)4, NHBu, Ph, CH2Ph, t -Bu, OPh
10 Ferrocenyl, adamantyl 
Hansch Cluster Analysis Table
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Compound 9, 10, and 11 were obtained by the Cadiot-Chodkiewicz coupling of 
(S)-2 with terminal alkynes (R)-17, (R)-18, and (R)-19 respectively.  
Compounds (R)-17 and (R)-18 were prepared in an analogous fashion to 
(R)-3 substituting butyraldehyde and palmitic aldehyde respectively for 
decanal as shown in Scheme 2.2.  (R)-19 was obtained via a Mitsunobu 
reaction of (S)-7 with phthalimide which inverted the stereochemistry followed by 
hydrazinolysis and removal of the TMS group via methanolysis (Scheme 2.4).137,138,139,140 
 
 
Scheme 2.4 
Compounds 12, 13, and 14 were all derived from Compound 11.  12 was obtained 
by mesylation of 11.141 13 was synthesized by the reaction of 11 and benzoic 
anhydride.142 14 was afforded by the reductive amination of 11 with butyraldehyde 
followed by NaBH4.
143 Compound 15 was obtained by the mesylation of (3S,8R)-1.  
Compound 16 was afforded via the Cadiot-Chodkiewicz coupling of (S)-6 to (R)-3. 
 
Table 2.6:  Biological activity of compounds 9-10 and 12-16 against L. donovani  in infected macrophages. 
Compound
IC50 L. donovani  in infected 
macrophages [uM]
(3S,8R )-9 0.197
(3S,8R )-10 0.287
(3S,8R )-12 0.055
(3S,8R )-13 0.035
(3S,8R )-14 0.034
(3S,8R )-15 0.061
(3S,8R )-16 0.013
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Compounds 9-10 and 12-16 were evaluated for antileishmanial activity by in vitro 
screening against Leishmania donovani (Table 2.6).  Antileishmanial results for 
Compound 11 were not obtained due to a laboratory complication during the testing 
assay.  All seven compounds tested showed increased antileishmanial activity as 
compared to the lead compound (3S,8R)-1 though it should be noted that (3S,8R)-1 was 
screened against Leishmania amazonensis while the seven analogues were screened 
against Leishmania donovani.  Compounds 12-16 all showed over an order of magnitude 
increase in antileishmanial activity as compared to (3S,8R)-1.  Compounds 12-15 were 
11-fold to 18-fold more active than (3S,8R)-1 and Compound 16 was 48-fold more active 
than (3S,8R)-1.   
Compounds 9 and 10 had IC50 values of 0.197uM and 0.287uM respectively 
which are both lower than the 0.63uM IC50 of lead compound (3S,8R)-1.  9 and 10 were 
evaluated to assess the effects of altering the length of the lipophilic alkyl chain and 
although their IC50 values were lower than (3S,8R)-1, the values were not low enough to 
warrant more exploration of alkyl chain length at this point in the study.  If more 
analogues with different alkyl chain lengths were evaluated, it would allow us to 
determine the ideal length and one would expect a resultant parabolic curve in the 
potency versus carbon chain length graph such as that described by Silverman (Figure 
2.5).136  Dohme and coworkers reported this effect in their 1926 JACS article describing 
their studies on the antibacterial effects of 4-alkylresorcinols where they determined that 
the n-hexyl side chain had the highest potency (Figure 2.5).144 
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Figure 2.5:  Effect of carbon chain length on biological activity.136,144 
 
  
2.4  Third Round of SAR studies 
2.4.1  Synthesis of Third Round SAR Compounds 
Since Compounds 13, 14, and 16 showed the most antileishmanial activity, eight 
analogues were prepared of these compounds for the next round of testing.  The low IC50 
of Compound 16 showed the positive impact of having a hydroxyl group at the C-3 
position instead of an acetate group.  Compounds 13 and 14 had the lowest IC50 values of 
the C-3 acetate compounds and we thus proposed making analogues of 13 and 14 with a 
hydroxyl group at C-3. Compound 21 was formed in two steps by first reacting (R)-19 
with benzoic anhydride to give (R)-20.  (R)-20 was then coupled to (S)-6 to give 
Compound 21 (Scheme 2.6).    Compound 23 was formed by the reductive amination of 
Alkyl chain atomic  weight
Ph
en
ol
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oe
ff
ic
ie
nt
R Phenol coefficient
n -propyl 5
n -butyl 22
n -pentyl 33
n -hexyl 51
n -heptyl 30
n -octyl 0
n -nonyl 0
n -decyl 0
n -undecyl 0
i -butyl 15.2
i -amyl 23.8
i -hexyl 27
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(R)-19 to give (R)-22 which was then coupled to (S)-6 to afford Compound 23 (Scheme 
2.7).   
 
Scheme 2.6 
 
Scheme 2.7 
    With the presence of the phenyl ring in Compound 13, it was amenable to 
analysis via the Topliss Operational Scheme in an effort to determine how the aromatic 
lipophilicity and electronic parameters affect antileishmanial potency.  According to the 
first step of the Topliss Scheme, our goal was to synthesize the 4-chloro; 3,4-dichloro; 4-
methyl; and 4-methoxy derivatives of Compound 13.22  This synthesis was 
straightforward as all four compounds could easily be synthesized via reaction of 11 with 
the appropriate aromatic acid chloride as shown in Scheme 2.8. 
 
Scheme 2.8 
TEA, CH2Cl2, 0°C
TEA, CH2Cl2, 0°C
TEA, CH2Cl2, 0°C
TEA, CH2Cl2, 0°C
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 Since previous studies146,147,148 involving miltefosine analogues have shown that 
introducing cycloalkanes into the alkyl chain has resulted in an increase in 
antileishmanial potency, we decided to synthesize Compound 28 which is an analogue of 
Compound 13 with a cyclohexane ring in the lipophilic chain.  To synthesize Compound 
28 (Scheme 2.9), we started by converting cyclohexanebutyric acid into its aldehyde (30) 
form via LAH reduction followed by a Swern Oxidation.  The TMS acetylene group was 
then added followed by enzymatic resolution of the resultant alcohol.  The alcohol (S)-31 
was then subjected to a Mitsunobu reaction with phthalimide followed by hydrazinolysis 
and methanolysis to yield (R)-34.  (R)-34 was then coupled with (S)-2 which afforded 
(3S,8R)-35.  Treating (3S,8R)-35 with benzoic anhydride and TEA in CH2Cl2 yielded 
Compound 28. 
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Scheme 2.9 
 The final compound included in our third round of SAR evaluation was 
Compound 36 which is an analogue of 16 in which the C-8 hydroxyl group of 16 is 
replaced by an amino group.  This compound was readily available via the Cadiot-
Chodkiewicz coupling of (S)-6 and (R)-19 (Scheme 2.10). 
 
Scheme 2.10 
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2.4.2  Antileishmanial Activity of Third Round SAR Compounds 
 
Table 2.7:  Biological activity of third round SAR compounds against L. donovani  in infected macrophages. 
 As shown in Table 2.7, antileishmanial activity was significantly increased in 
Compounds 21 and 23 as their IC50 values were 0.005uM and 0.003uM respectively 
which represents 64-fold and 107-fold increases in potency respectively as compared to 
the 0.32uM IC50 value of the natural product as reported by Senn.
1 Thus we were 
successful in increasing potency by combining the most potent functional groups from 
the second round SAR study at the C-3 and C-8 positions.    
 
Table 2.8:  Biological activity of Topliss scheme compounds against L. donovani  in infected macrophages. 
 The Topliss scheme compounds 24-27 all had higher IC50 values (Table 2.8) than 
the parent compound 13.  This indicates that the hydrogen atom in the aromatic 4-
position is superior to our four new analogues with functional groups in the 4-position.  
This could indicate that there is a negative steric interaction caused by substituents in the 
Compound
IC50 L. donovani  in infected 
macrophages [uM]
(3S,8R )-21 0.005
(3S,8R )-23 0.003
(3S,8R )-24 0.112
(3S,8R )-25 0.428
(3S,8R )-26 0.126
(3S,8R )-27 0.165
(3S,8R )-28 0.027
(3S,8R )-36 0.040
Potency Rank Substituent
IC50 L. donovani  in infected 
macrophages [uM]
Compound
1 H 0.035 (3S,8R )-13
2 4-Cl 0.112 (3S,8R )-24
3 4-CH3 0.126 (3S,8R )-26
4 4-OCH3 0.165 (3S,8R )-27
5 3,4-dichloro 0.428 (3S,8R )-25
 53 
4-position.  The negative steric hindrance hypothesis is further supported by the fact that 
the 3,4-dichloro compound is significantly less active than the other compounds which 
could be the result of the increased steric hindrance by having a Cl atom in both the 3-
position and 4-position.  Unfortunately, as shown in Table 2.9 in the far right column, 
when the 4-hydrogen compound has the highest potency, the Topliss scheme does not 
provide detailed conclusions regarding the importance of the different electronic and 
lipophilic parameters of the aromatic ring.  If the 4-hydrogen compound has the highest 
potency, Topliss recommends synthesizing a group of analogues with substituents in the 
3-position.  The 3-position compounds are discussed in Section 2.5. 
 
Table 2.9:  Potency order table for Topliss Scheme.145 
 The cyclohexane derivative 28 had an antileishmanial IC50 value of 0.027uM as 
compared to 0.035uM IC50 of the straight chain compound 13.  This represents a slight 
increase in potency with the introduction of the cyclohexane group yet the increase was 
not marked enough for us to explore more cycloalkane derivatives at this time.  We are 
aware though that the analysis of one cycloalkane compound certainly does not provide 
conclusive evidence concerning the potency of straight chain versus cycloalkane 
derivatives. 
 The C-8 amino compound 36 had an IC50 value of 0.040uM which represent a 
decrease in potency as compared to the 0.013uM IC50 value of the related C-8 alcohol 
compound 13.   Compound 36 is also closely related to compound 23 as compound 36 is 
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a primary amine whereas 23 is a secondary amine with an n-butyl group on the nitrogen 
atom.  Compound 36 had a 13-fold decrease in potency as compared to 23. 
 
2.5  Fourth Round of SAR studies 
2.5.1 Synthesis of fourth round SAR compounds 
 The first set of analogues from our fourth round were prepared in accordance with 
the second level of the Topliss scheme recommendations.  Since the 4-hydrogen analogue 
of 13 had the most potency, the Topliss scheme calls for the following four compounds to 
be prepared: 3-Cl, 3-CH3, 3-CF3, and 3,5-Cl2.  In addition, the scheme says the 3-Br and 
3-NH2 analogues may help provide insight as well.  We started by preparing compounds 
37-40 which are the 3-Br, 3-CH3, 3-CF3, and 3,5-Cl2 analogues.  Unfortunately, we had 
an error in our VWR chemical order and did not receive the acid chloride to prepare the 
3-Cl analogue which can easily be prepared at a later date.  The analogues we did prepare 
were readily available via amide bond formation between 11 and the appropriate aromatic 
acid chloride or carboxylic acid (Scheme 2.11). 
 
Scheme 2.11 
    The second set of analogues from the fourth round consisted of compounds in 
which the phenyl ring in 13 was replaced with a heteroaromatic ring.  In place of the 
TEA, CH2Cl2, 0°C
TEA, CH2Cl2, 0°C
DCC, DMAP
CH2Cl2, 0°C
DCC, DMAP
CH2Cl2, 0°C
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phenyl ring, Compounds 41-44 had a 5-methyl isoxazole ring, a 2-pyridine ring, a 
pyrazine ring, and a 2-furan ring respectively.  Like Compounds 37-40, Compounds 41-
44 were readily available via amide bond formation between 11 and the appropriate 
aromatic acid chloride or carboxylic acid (Scheme 2.12). 
 
 
Scheme 2.12 
 The final set of analogues from the fourth round consisted of three more amides 
and an isocyanate all derived from compound 11 (Scheme 2.13).  Compounds 45 was 
synthesized to assess the impact of a chlorine atom in the 2-position of the phenyl ring.  
Since the first set of Topliss structures discussed above in SAR Round 3 showed that 
there may be a negative steric impact by any substituent in the 4-position of the phenyl 
ring, we decided to synthesize Compound 46 with a fluorine atom in the 4-position as the 
fluorine atom is sterically smaller than the previous substituents.  Compound 47 was 
synthesized to evaluate placing a four carbon ethereal linkage between the phenyl ring 
and the amide group.  Compound 48 has an isocyanate group at the C-8 position.  The 
isocyanate group is in Cluster 6 of the Hansch Cluster table shown above and Compound 
48 was the first compound synthesized from this cluster.   
TEA, CH2Cl2, 0°C
DCC, DMAP
CH2Cl2, 0°C
DCC, DMAP
CH2Cl2, 0°C
DCC, DMAP
CH2Cl2, 0°C
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Scheme 2.13 
 
2.5.2  Antileishmanial activity of fourth round SAR compounds 
 
Table 2.10:  Biological activity of fourth-round SAR compounds against L. donovani  in infected 
macrophages. 
 
 Table 2.10 shows the results of the anti-Leishmania testing done of the fourth-
round SAR compounds.  Analogous to the third round SAR Topliss scheme compounds, 
the four compounds prepared in the fourth round SAR for the Topliss scheme all had 
lower IC50 values than the parent compound 13 (Table 2.11).  Once again, this could 
sat. NaHCO3 (aq.)
CH2Cl2, 0°C
DCC, DMAP
CH2Cl2, 0°C
TEA, CH2Cl2, 0°C
TEA, CH2Cl2, 0°C
Compound
IC50 L. donovani  in infected 
macrophages [uM]
(3S,8R )-37 0.184
(3S,8R )-38 0.120
(3S,8R )-39 0.191
(3S,8R )-40 0.252
(3S,8R )-41 0.077
(3S,8R )-42 0.089
(3S,8R )-43 0.042
(3S,8R )-44 0.050
(3S,8R )-45 0.109
(3S,8R )-46 0.072
(3S,8R )-47 0.529
(3S,8R )-48 21.65
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indicate a negative steric interaction due to the increased bulk of the substituents in the 3-
position.  A difference in activity is observed between the dichloro compounds as the 3,5-
dichloro compound (Compound 40) had an IC50 value of 0.252 uM whereas the 3,4-
dichloro compound (Compound 25) had an IC50 value of 0.428 uM.  In contrast, the 
placement of the methyl group did not impact activity as the 3-CH3 compound 
(Compound 38) had an IC50 value of 0.120 uM whereas the 4-CH3 compound 
(Compound 26) had an IC50 value of 0.126 uM. 
 
Table 2.11:  Biological activity of Topliss scheme compounds against L. donovani  in infected 
macrophages. 
 
 
The substitution of a heteroaromatic ring in place of the phenyl ring in 13 did not 
have a large impact on the antileishmanial activity of the compound as shown in Table 
2.12.  Compound 13 had the lowest IC50 value of the five compounds tested and the IC50 
range of the five compounds was 0.035-0.089uM.  Though the substitution of the phenyl 
ring for heteroaromatic rings did not improve antileishmanial activity, it also did not 
drastically reduce antileishmanial activity as evidenced by the narrow range of IC50 
values for the five compounds.  
Potency Rank Substituent
IC50 L. donovani  in infected 
macrophages [uM]
Compound
1 H 0.035 (3S,8R )-13
2 3-CH3 0.120 (3S,8R )-38
3 3-Br 0.184 (3S,8R )-37
4 3-CF3 0.191 (3S,8R )-39
5 3,5-dichloro 0.252 (3S,8R )-40
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Table 2.12:  Biological activity of heteroaromatic compounds against L. donovani  in infected 
macrophages.  Compound 13 is shown for comparison. 
 
Although Compounds 45 and 46 were not part of the Topliss operational scheme 
at this point, their IC50 values can be meaningfully compared to the Topliss structures 
prepared thus far.  Compounds 45 and 46 both had higher IC50 values than Compound 13 
but Compounds 45 and 46 had lower IC50 values than all of the other eight Topliss 
structures prepared.  Compound 45 had an IC50 value of 0.109 uM whereas Compound 46 
had an IC50 value of 0.072 uM.  The IC50 value of Compound 45 is very similar to the 
IC50 value of 0.112 uM for Compound 24 which has the 4-chloro substituent.  This 
indicates that replacing a hydrogen atom in Compound 13 with a chlorine atom at either 
the meta or para position has a similar negative impact on antileishmanial activity.    The 
para fluorine atom of Compound 46 also caused an increase in IC50 value as compared 
with Compound 13.  However, Compound 46 did retain more antileishmanial activity as 
compared to all of the other Topliss structures prepared.  This supports the hypothesis 
that it could be a negative steric interaction at the para position that is causing the 
decrease in antileishmanial activity rather than the decrease being caused by other 
parameters such as lipophilicity or electronic effects.    
Potency Rank Aromatic Ring
IC50 L. donovani  in infected 
macrophages [uM]
Compound
1 Phenyl 0.035 (3S,8R )-13
2 Pyrazine 0.042 (3S,8R )-43
3 2-furan 0.050 (3S,8R )-44
4 5-methyl isoxazole 0.077 (3S,8R )-41
5 2-pyridine 0.089 (3S,8R )-42
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The ethereal linkage of Compound 47 caused a dramatic reduction in 
antileishmanial activity as Compound 47 had an IC50 value that was 15-fold higher than 
Compound 13.  The introduction of the isothiocyanate group of Compound 48 caused an 
even more dramatic reduction in activity as its IC50 value was over 600-fold higher than 
Compound 13.   
 
2.6  Fifth round of SAR studies 
2.6.1 Synthesis of fifth round SAR compounds 
The fifth and final round of SAR compounds prepared involved the synthesis of 
four compounds with different C-8 substituents and four compounds with different 
groups at the alkene position of the natural product.  The four groups installed at the C-8 
position were the carbamate, the acetamide, the ethylamino, and the methyl ether groups 
of Compounds 49-52 respectively (Scheme 2.14).  The alkene position was changed to a 
cyclopropyl group in Compound 53, a methyl substituted alkene in Compound 54, a 
phenyl group in Compound 55, and a para-ethoxy phenyl group in Compound 56.  The 
synthetic routes to Compounds 49-52 were similar as they all involved the synthesis of 
their respective terminal alkyne right-hand portion of the molecule followed by the 
Cadiot-Chodkiewicz coupling to the previously prepared bromoalkyne S-6.   
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Scheme 2.14 
The synthetic routes to Compounds 53-56 (Scheme 2.15) were also similar as they each 
involved the reaction of TMS-acetylene with the appropriate aldehyde followed by 
enzymatic resolution and bromination 
.
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Scheme 2.15 
Cadiot-Chodkiewicz coupling of bromoalkynes (S)-63, (S)-66, (S)-69, and (S)-72 with 
the previously prepared (R)-22 yielded Compounds 53-56 respectively (Figure 2.6). 
 
Figure 2.6:  Structures of compounds 53-56. 
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2.6.2  Antileishmanial activity of fifth round SAR compounds 
 
Table 2.13:  Biological activity of fifth-round SAR compounds against L. donovani  in infected 
macrophages. 
 
Table 2.13 shows the results of the anti-Leishmania testing done of the fifth-round 
SAR compounds.  Compounds 49-52 all retained potent antileishmanial activity as the 
IC50 values ranged from 0.010-0.030 uM.  Although still potent, these IC50 values 
represent a decrease in activity as compared with the closely related Compound 23 which 
had an IC50 value of 0.003 uM.  Changing the butylamino group of Compound 23 to the 
ethylamino group of Compound 51 caused a 10-fold reduction in antileishmanial activity.  
Compounds 50 and 51 have relatively similar IC50 values indicating the interchanging of 
an amide for an amine at the C-8 position does not have a significant effect on 
antileishmanial activity. 
Whereas Compounds 49-52 had a narrow range of IC50 values, Compounds 53-56 
had a wide range of antileishmanial activity with IC50 values ranging from 0.031-
0.722uM.  All four compounds had higher IC50 values that Compound 23.  The wide 
range indicates the importance of the functional group at the alkene position.  The 
installation of the methyl group onto the alkene in Compound 54 caused a 10-fold 
Compound
IC50 L. donovani  in infected 
macrophages [uM]
(3S,8R )-49 0.010
(3S,8R )-50 0.018
(3S,8R )-51 0.030
(3S,8R )-52 0.011
(1S,6R )-53 0.722
(4S,9R )-54 0.031
(1S,6R )-55 0.113
(1S,6R )-56 0.443
 63 
reduction in antileishmanial activity as compared to Compound 23.  Switching the alkene 
to a cyclopropyl group in Compound 53 caused a whopping 240-fold decrease in 
antileishmanial activity.   Switching the alkene to a phenyl group (Compound 55) caused 
a 38-fold decrease in activity whereas the inclusion of a para-ethoxy phenyl group 
(Compound 56) caused a 148-fold decrease in activity.  These data demonstrate the 
importance of the alkene position to the antileishmanial activity of the analogues.  It was 
expected that changes at the alkene position could lead to dramatic changes in 
antiprotozoal activity as Senn and colleagues showed that Compound MS-1 had 
significantly less antiprotozoal activity than MS-2.  The only difference between MS-1 
and MS-2 is the presence of the alkene in MS-2 that is absent in MS-1. 
2.7  In Vivo evaluation 
Compounds 13, 14, and 16 were evaluated for in vivo efficacy in BALB/c mice 
infected with Leishmania donovani.  As can be seen in Figure 2.6 below, all three 
compounds significantly reduced the liver parasite load as compared to the untreated 
control and the vehicle control.  Miltefosine was evaluated in the same study for 
comparison purposes.  Whereas Miltefosine treatment led to a 97.8% reduction in liver 
13 14 16 13 14 16
Figure 2.6  In Vivo results from testing of compounds 13, 14, and 16 in BALB/c mice infected with Leishmania donovani. 
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parasitemia, compounds 13, 14, and 16 led to reductions of 26.0%, 32.4%, and 41.2% 
respectively.  
 
 
2.8 Cytotoxicity 
Table 2.14 shows the antileishmanial testing results for all of the compounds we 
had tested.  The table also shows IC50 values for our compounds which were screened 
against non-infected J774 macrophages.  The selectivity index value was calculated by 
dividing the IC50 value against the J774 cell line by the IC50 value against the Leishmania 
species assayed.  When looking at a series of compounds, the ones with the higher 
selectivity index values often represent the more promising drug candidates as the high 
selectivity values indicate the ability of a compound to damage or destroy the parasite 
while having minimal impact on the healthy cells of the host.  As can be seen in the table, 
compound 23 has the highest selectivity index value at 116.3.  This is a marked 
improvement (greater than 1000-fold) as compared to the 0.1 selectivity index value for 
(3S,8R)-1 which has the same stereochemistry as compound 23.  Another intriguing 
comparison is seen in the selectivity index values of compounds 9 and 10 which are 18.3 
and 0.2 respectively.  This signifies that compound 9 is more than 90 times more 
selective than compound 10.  The only difference in their structures is that compound 9 
has an n-butyl side chain whereas compound 10 has an n-hexadecyl side chain.  
Interestingly, the IC50 values of 9 and 10 against Leishmania donovani are similar with 
values of 0.197 uM and 0.287 uM respectively.  The selectivity difference thus arises 
from their significantly differing IC50 values against the non-infected J774 macrophage 
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cell line with values of 3.61 uM and 0.05 uM for compounds 9 and 10 respectively.  This 
indicates the promising prospect that it could be possible to reduce the cytotoxicity of 
other compounds of ours without reducing their antileishmanial activity, thus increasing 
their selectivity index.  For example, it would be interesting to modify compound 23 so 
that it contains an n-butyl side chain instead of the n-decyl side chain.  Ideally, this 
change would result in decreased cytotoxicity against the J774 macrophage cell line 
while maintaining its potent activity against Leishmania. 
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Table 2.14  Results from antileishmanial and cytotoxicity assays. 
 
 
 
Compound Leishmania sp. IC50 (uM)
a J774 IC50 (uM) Selectivity Index
b
(3S,8R )-1 0.63 0.056 0.1
(3S,8S )-1 1.28 0.209 0.2
(3R,8R )-1 >10 3.25 N/A
(3R,8S )-1 >10 5.81 N/A
9 0.197 3.610 18.3
10 0.287 0.050 0.2
12 0.055 NT N/A
13 0.035 NT N/A
14 0.034 1.460 42.9
15 0.061 0.652 10.7
16 0.013 NT N/A
21 0.005 0.131 26.2
23 0.003 0.349 116.3
24 0.112 0.983 8.8
25 0.428 1.220 2.9
26 0.126 1.486 11.8
27 0.165 1.327 8.0
28 0.027 0.393 14.6
37 0.184 0.676 3.7
38 0.120 0.596 5.0
39 0.191 0.700 3.7
40 0.252 0.721 2.9
41 0.077 0.515 6.7
42 0.089 0.673 7.6
43 0.042 0.359 8.5
44 0.050 0.388 7.8
45 0.109 0.674 6.2
46 0.072 0.805 11.2
47 0.529 1.113 2.1
48 21.65 NT N/A
49 0.010 NT N/A
50 0.018 NT N/A
51 0.030 NT N/A
52 0.011 NT N/A
53 0.722 NT N/A
54 0.031 NT N/A
55 0.113 NT N/A
56 0.443 NT N/A
bSelectivity Index = IC50 J744 / IC50 Leishmania sp.
NT = Not tested
N/A = Not available
aThe four stereoisomers of compound 1 were screened against Leishmania 
amazonensis .  All other compounds were screened against Leishmania donovani.
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Chapter 3:  Anticancer evaluation of natural product analogues 
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3.1  Compounds possessing antiprotozoal and anticancer activity 
 There are many reported examples of antileishmanial compounds that also 
possess significant anticancer activity.  As discussed in chapter 1, Miltefosine was 
originally developed as an anticancer compound before its antileishmanial activity was 
serendipitously discovered.  Another example is Kahalalide F (Figure 3.1) which is 
currently in Phase II clinical trials for treatment of prostate cancer and has also shown 
potent antileishmanial activity.149  A third example is the series of dihydroartemisinin 
acetal dimers synthesized by Slade and colleagues.  Their compound shown in Figure 3.2 
had an IC50 value of 2.5 uM against L. donovani and IC50 values of 0.24 uM, 0.16 uM, 
and 0.08 uM against cancer cell lines SK-MEL (human malignant melanoma), KB 
(human epidermal carcinoma), and BT-549 (human ductal breast carcinoma) 
respectively.150 
 
Figure 3.1: Kahalalide F 
 
In addition to the examples discussed above, there are numerous other literature reports 
of compounds which possess both potent antiprotozoal and anticancer activity.151,152 
 For this reason, we sought the collaborative efforts of the National Cancer 
Institute (NCI) to test our compounds for anticancer activity.  The NCI screened twenty-
four of our compounds for biological activity against the cell lines in their NCI60 one-
dose first-level screening process and numerous of these compounds were chosen by NCI 
Figure 3.2: Dihydroartemisinin dimer 
prepared by Slade and colleagues.2 
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to move on to advanced levels of screening.  As the NCI60 one-dose screen involves each 
compound being testing against approximately sixty cell lines at a 10 uM concentration, 
this testing produced a large volume of data and showed that many of our compounds 
possess potent anti-neoplastic activity.  The goal of this chapter is to highlight the 
conclusions gleaned from the testing done by the NCI. 
 
Figure 3.3 
  
 The compounds tested exhibited a wide range of activity against the numerous 
cell lines screened.  Figure 3.3 shows the average mean growth percents of the 
compounds against the different types of cancers screened.  A lower mean growth percent 
correlates with increased anticancer activity.  As can be seen in the figure, melanoma cell 
lines were most susceptible to our compounds with an average mean growth percent of -
21.0.  Against the renal cancer, colon cancer, and lung cancer cell lines tested, the 
compounds had average mean growth percents of around zero with values of -2.7, 0.9, 
and 5.2 respectively.  Against the breast cancer, CNS cancer, leukemia, ovarian cancer, 
-30.0
-20.0
-10.0
0.0
10.0
20.0
30.0
40.0
Melanoma Renal Colon Lung Leukemia CNS Prostate Ovarian Breast
Average Mean Growth Percent
Cancer Type
Average Mean 
Growth Percent
Melanoma -21.0
Renal -2.7
Colon 0.9
Lung 5.2
Leukemia 19.5
CNS 21.7
Prostate 24.4
Ovarian 25.7
Breast 35.6
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and prostate cancer, the average mean growth percents ranged from 19.5 to 35.6.  Figure 
3.3 shows a superficial view of the anticancer activity as there is much information to be 
gleaned when looking deeper into the results at the individual cell lines tested in each 
cancer type category. 
 
 
Table 3.1:  Mean growth percent values (listed in order of most active to least active) for each of our compounds 
against the cell lines screen in the NCI60 cancer cell panel.  
 
3.2  Stereochemistry 
 Upon analyzing the growth percent values (Table 3.1) of each of our compounds 
screened at the NCI, the first obvious conclusion is that the stereochemistry of our lead 
Compound ID Mean Growth Percent
16 -55.3
12 -53.3
(3S,8R )-1 -49.3
10 -47.5
15 -44.5
(3S,8S )-1 -35.9
43 -27.9
41 -23.4
44 -19.9
42 -8.7
13 -8.3
47 -5.5
45 -1.7
14 5.1
46 14.6
38 20.8
37 41.5
11 49.0
39 61.8
40 74.4
(3R,8R )-1 86.3
(3R,8S )-1 91.6
48 96.2
9 104.9
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compound is extremely important and follows the same activity profile as seen in the 
antiLeishmanial activity profile.  Compounds (3S,8R)-1 and (3S,8S)-1 showed significant 
anticancer activity whereas the (3R,8R)-1 and (3R,8S)-1 showed very little activity.  In 
the NCI60 one-dose screen, (3S,8R)-1 and (3S,8S)-1 had mean growth percents of -49.26 
and -35.88 respectively.  In contrast, the mean growth percents of (3R,8R)-1 and (3R,8S)-
1 were 86.25 and 91.59 respectively.  When the results from individual cell lines are 
analyzed, the importance of the stereochemistry is even more striking.  For example, in 
the lung cancer cell line HOP-62, the growth percents for (3S,8R)-1 and (3S,8S)-1 are -
93.3 and -84.7 respectively whereas (3R,8R)-1 and (3R,8S)-1 had growth percents of 
96.3 and 107.9 respectively.   
Interestingly, there was one cell line in the panel where the stereochemistry 
appeared to be relatively unimportant.  The MALME-3M melanoma line was similarly 
inhibited by all four stereoisomers of compound 1 with growth percent values ranging 
from -46.9 to -62.0 (Table 3.2).  This was the only cell line tested in which (3R,8R)-1 and 
(3R,8S)-1 had negative growth percents.  The unique activity against this cell line is 
highlighted by the narrow range of 15.1 between the highest and lowest growth percents 
across the four stereoisomers.  The average range of growth percents for these 
stereoisomers against all other cell lines was 140.8.  Following the range of 15.1 against 
the MALME-3M cell line, the next lowest range was 60.2 against the MCF7 breast 
cancer cell line (Table 3.2).  The highest range of 213.2 was observed against the 
COLO205 colon cancer cell line (Table 3.2).   
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Table 3.2 
3.3  Lipophilicity 
 
Table 3.3 
 Whereas the stereochemistry was unimportant for activity against the MALME-
3M cell line, the lipophilicity was shown to be very important.  Compounds (3S,8R)-1, 9, 
and 10 have the same functional groups and stereochemistry but different length carbon 
chains with lengths of ten carbons, four carbons, and sixteen carbons respectively.   The 
growth percents against MALME-3M for (3S,8R)-1, 9, and 10 are -59.8, 100.4, and -71.0 
respectively (Table 3.3).   
In addition to the results from the MALME-3M cell line, the lipophilicity was 
shown to be extremely important for anticancer activity across the entire spectrum of the 
NCI60.  Compounds (3S,8R)-1 and 10 have significant broad spectrum anticancer 
activity with mean growth percents of -49.3 and -47.5 respectively.  The shorter carbon 
chain of Compound 9 causes nearly a complete loss of anticancer activity as its mean 
growth percent is 104.9.  The importance of lipophilicity is further highlighted when 
looking at the results of colon cancer line COLO205 where Compound 10 has a growth 
(3S,8S )-1 -62.0 (3S,8R )-1 19.8 (3S,8R )-1 -92.5
(3S,8R )-1 -59.8 (3S,8S )-1 33.3 (3S,8S )-1 -84.4
(3R,8R )-1 -57.0 (3R,8R )-1 49.7 (3R,8R )-1 117.8
(3R,8S )-1 -46.9 (3R,8S )-1 80.0 (3R,8S )-1 120.7
Range 15.1 Range 60.2 Range 213.2
MALME-3M (Melanoma) MCF7 (Breast Cancer) COLO205 (Colon Cancer)
Compound Growth Percent Compound Growth Percent Compound Growth Percent
Compound
Carbon Chain 
Length
MALME-3M 
Growth Percent
COLO205 
Growth Percent
10 16 -71.0 -97.2
(3S,8R )-1 10 -59.8 -92.5
9 4 100.4 121.6
Range 171.4 218.8
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percent of -97.2 whereas Compound 9 has a growth percent of 121.6 meaning Compound 
10 kills nearly all the cells and Compound 9 actually stimulates cell growth with its 
growth percent higher than 100.   
 
3.4  Isothiocyanate 
 In addition to the aforementioned compounds with little anticancer activity 
((3R,8R)-1, (3R,8S)-1, 9), isothiocyanate compound 48 also had extremely low activity 
with a mean growth percent of 98.2.  This highlights the importance of the functional 
group at the C-8 position as converting the C-8 group from an alcohol (Compound 
(3S,8R)-1) to an isothiocyanate (Compound 48) significantly drops the anticancer activity 
as the mean growth percents for (3S-8R)-1 and 48 are -49.3 and 98.2 respectively.   
 
3.5  Analysis of different cell line categories 
 
 
Table 3.4:  Average mean growth percent values of compounds screened against each cancer cell line category. 
  
 
Cancer Type Average Mean Growth Percent
Melanoma -21.0
Renal -2.7
Colon 0.9
Lung 5.2
Leukemia 19.5
CNS 21.7
Prostate 24.4
Ovarian 25.7
Breast 35.6
Color Growth Percent
Most Active < -50
-50 to 0
0 to 50
Least Active > 50
Figure Key
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Chapter 4:  Breast Cancer  
4.1 Overview 
 Our compounds were screened against six different breast cancer cell lines.  The 
average mean growth percent across the six different breast cancer cell lines was 35.6.  
As shown in Table 4.1, the breast cancer cell lines had the highest average mean growth 
percent of the different cell types tested meaning that overall, our compounds were least 
active across the breast cancer cell lines.  However, this relatively high average mean 
growth percent hides some of the potent activity some of our compounds exhibited 
against specific cell lines.   
 
Table 4.1 
Table 4.1 shows the average mean growth percent of our compounds against each of the 
six breast cell lines screened as well as their molecular classification, clinically relevant 
protein expression, and cell line source information.  As shown in Table 4.1, the most 
activity was seen against the MDA-MB-231 cell line which is an adenomatous breast 
Cell Line
Average Mean 
Growth Percent
Molecular Classification ER PGR HER2 EGFR CK5 CK8-18 CK19 CK14
Patient 
Age
Sex Ethnicity
MDA-MB-231 -21.3 Normal-like/claudin-low - - - + - - - - 51 Female Caucasian
BT-549 12.2 Normal-like/claudin-low - - - + - - - - 72 Female Caucasian
HS 578T 47.8 Normal-like/claudin-low - - - + - - - - 74 Female Caucasian
T-47D 51.4 Luminal + + - + - + + - 54 Female N/A
MCF7 56.3 Luminal + + - - - + ND - 69 Female Caucasian
MDA-MB-468 67.1 Basal-like - - - + + + + - 51 Female Black
Average 35.6
ER = estrogen receptor
PGR = progesterone receptor
HER2 = human epidermal growth factor receptor 2
EGFR = epidermal growth factor receptor
CK = cytokeratin
+ = expression
- = no expression
ND = not determined
N/A = data not available
"Clinically relevant protein expression" portion of table adapted from reference 153.
Unless otherwise referenced above, cell line information was gathered from references 154-157.
Clinically relevant protein expression153
Color Growth Percent
Most Active < -50
-50 to 0
0 to 50
Least Active > 50
Figure Key
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cancer cell line derived from a 51 year-old Caucasian female.  The least activity was seen 
against the MDA-MB-468 cell line which is also an adenomatous breast cancer cell line 
derived from a 51 year-old black female.  Both the MDA-MB-231 line and the MDA-
MB-468 line expressed receptors for epidermal growth factor (EGF) and transforming 
growth factor alpha (TGF-α).  As is shown in Table 4.1, MDA-MB-468 also expresses 
proteins CK5, CK8-18, and CK19 which are absent in the MDA-MB-231 cell line. 
 Table 4.2 shows the results for each compound against each breast cancer cell 
line.  As discussed in section 3.3, the stereochemistry played a key role in the activity of 
the stereoisomers of Compound 1.  (3S,8R)-1 and (3S,8S)-1 had average growth percents 
of -25.8 and 11.9 respectively against the breast cancer cell lines screened.  (3R,8S)-1 and 
(3R,8R)-1 were significantly less active with average growth percents of 91.4 and 83.3 
respectively.  Lipophilicity was also shown to be important as Compound 9 (4 carbon 
length chain), (3S,8R)-1 (10 carbon length chain), and 10 (16 carbon length chain) had 
average growth percents of 99.4, -25.8, and -14.5 respectively. 
 Substituting an alcohol for the acetate at the C-3 position in (3S,8R)-1 produced 
little change in the average growth percent as Compound 16 had an average growth 
percent of -21.8 as compared to -25.8 for (3S,8R)-1.  Though the average growth percents 
were similar, Compound 16 was significant more active against the BT-549 cell line with 
a growth percent of -90.9 compared to -47.2 for (3S,8R)-1.  On the other hand, (3S,8R)-1 
was significantly more active against MDA-MB-231 with a growth percent of -93.2 as 
compared to -69.2 for compound 16. 
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Table 4.2 
4.2  Hansch Cluster Analysis on Breast Cancer Cell Lines Data 
 
Table 4.3 
 Table 4.3 shows the breast cancer testing results organized to assess the results 
per Hansch cluster analysis theory at the C-8 position.  As shown in the table, the range 
of activity is wide over the six clusters tested.  The alcohol compound (3S,8R)-1 from 
Compound ID MCF7 MDA-MB-231 HS 578T BT-549 T-47D MDA-MB-468 Average Minimum Maximum Range
(3R,8S )-1 80.0 97.7 92.8 99.8 84.2 94.0 91.4 80.0 99.8 19.8
(3S,8R )-1 19.8 -93.2 25.2 -47.2 -42.8 -16.5 -25.8 -93.2 25.2 118.4
(3R,8R )-1 49.7 104.6 121.4 88.5 64.9 70.8 83.3 49.7 121.4 71.8
(3S,8S )-1 33.3 -74.2 31.5 8.5 38.3 34.3 11.9 -74.2 38.3 112.4
9 105.8 109.7 95.9 98.6 94.7 91.5 99.4 91.5 109.7 18.1
10 24.9 -60.8 -2.1 -54.4 -32.4 37.7 -14.5 -60.8 37.7 98.6
11 75.8 -41.2 91.4 53.0 84.8 94.7 59.7 -41.2 94.7 135.9
12 14.4 -62.8 8.7 -56.5 -18.9 10.5 -17.4 -62.8 14.4 77.2
13 60.7 -56.5 48.5 -33.3 68.0 87.3 29.1 -56.5 87.3 143.8
14 27.1 -52.8 39.2 19.4 33.8 17.8 14.1 -52.8 39.2 92.0
15 25.2 -62.8 45.7 -39.2 -27.3 -11.3 -11.6 -62.8 45.7 108.6
16 16.2 -69.2 41.2 -90.9 -38.2 10.0 -21.8 -90.9 41.2 132.1
37 77.3 -25.6 NT 63.9 82.1 95.5 58.7 -25.6 95.5 121.1
38 71.6 -25.2 57.2 18.4 72.2 101.1 49.2 -25.2 101.1 126.4
39 75.8 15.0 NT 68.3 85.2 94.0 67.7 15.0 94.0 78.9
40 80.7 16.9 94.9 76.7 91.4 95.6 76.0 16.9 95.6 78.6
41 36.1 -32.1 21.0 -5.5 42.4 73.1 22.5 -32.1 73.1 105.1
42 76.2 -52.5 47.4 -18.8 89.2 93.2 39.1 -52.5 93.2 145.7
43 43.5 -72.5 12.6 -42.7 66.2 85.9 15.5 -72.5 85.9 158.4
44 59.2 -71.0 -4.1 -0.6 76.6 71.6 22.0 -71.0 76.6 147.6
45 76.9 -39.4 33.4 6.7 87.6 94.3 43.3 -39.4 94.3 133.7
46 74.5 -37.0 30.9 4.8 74.4 97.0 40.8 -37.0 97.0 134.0
47 61.5 -35.0 26.7 -29.1 66.2 97.7 31.3 -35.0 97.7 132.7
48 85.7 108.0 92.2 105.0 90.7 90.2 95.3 85.7 108.0 22.3
Average 56.3 -21.3 47.8 12.2 51.4 67.1
Minimum 14.4 -93.2 -4.1 -90.9 -42.8 -16.5
Maximum 105.8 109.7 121.4 105.0 94.7 101.1
Range 91.4 202.9 125.5 195.9 137.6 117.6
NT = Not Tested
Color Growth Percent
Most Active < -50
-50 to 0
0 to 50
Least Active > 50
Figure Key
Breast Cancer Cell Lines
Compound ID Cluster MCF7 MDA-MB-231 HS 578T BT-549 T-47D MDA-MB-468 Average Minimum Maximum Range
(3S,8R)-1 5 19.8 -93.2 25.2 -47.2 -42.8 -16.5 -25.8 -93.2 25.2 118.4
11 5 75.8 -41.2 91.4 53.0 84.8 94.7 59.7 -41.2 94.7 135.9
12 4b 14.4 -62.8 8.7 -56.5 -18.9 10.5 -17.4 -62.8 14.4 77.2
13 8 60.7 -56.5 48.5 -33.3 68.0 87.3 29.1 -56.5 87.3 143.8
14 9 27.1 -52.8 39.2 19.4 33.8 17.8 14.1 -52.8 39.2 92.0
15 7 25.2 -62.8 45.7 -39.2 -27.3 -11.3 -11.6 -62.8 45.7 108.6
48 6 85.7 108.0 92.2 105.0 90.7 90.2 95.3 85.7 108.0 22.3
Average 44.1 -37.3 50.1 0.2 26.9 39.0
Minimum 14.4 -93.2 8.7 -56.5 -42.8 -16.5
Maximum 85.7 108.0 92.2 105.0 90.7 94.7
Range 71.3 201.3 83.5 161.5 133.6 111.2
Color Growth Percent
Most Active < -50
-50 to 0
0 to 50
Least Active > 50
Figure Key
Breast Cancer Cell Lines
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cluster 5 was the most active compound against the MDA-MB-231, T-47D, and MDA-
MB-468 cell lines while the mesyl amide compound 12 from cluster 4b was the most 
active against the remaining cell lines as shown in Table 4.4.  Based on these results, it 
would make sense to synthesize more compounds with C-8 substituents from clusters 4b 
and 5 in an effort to seek even more active compounds.  Across the whole set of breast 
cancer cell lines tested, compound (3S,8R)-1 from cluster 5 was the most active with an 
average growth percent of -25.8.  On the other end of the activity spectrum, the 
isothiocyanate compound 48 from cluster 6 was the least active compound against all of 
the cell lines except for the MDA-MB-468 cell line in which it was the second least 
active compound.   
 
 
Table 4.4 
 
4.3  Breast Cancer SAR Analysis of Amide Compounds  
 Eleven of the compounds we had tested by NCI have an acetate at the C-3 
position and different amide functionalities with aromatic or heteroaromatic groups 
directly connected to the amide carbonyl group in the C-8 position as shown in Figure 
4.1. 
 
Color Growth Percent
Most Active < -50
-50 to 0
0 to 50
Least Active > 50
Figure Key
MCF7 4b -NHSO2Me 14.4
MDA-MB-231 5 -OH -93.2
HS 578T 4b -NHSO2Me 8.7
BT-549 4b -NHSO2Me -56.5
T-47D 5 -OH -42.8
MDA-MB-468 5 -OH -16.5
Most Active 
Cluster
Cell Line C-8 Substituent Growth Percent
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Figure 4.1  Generic structure of amides screened by NCI. 
 
Table 4.5 
Some of the breast cancer cell lines were very sensitive to changes in the amide R group 
structure (Table 4.5).  For example, the most active amide compound against BT-549 was 
Compound 43 which had a growth percent of -42.7 whereas the least active Compound 
40 had a growth percent of 76.7.  Of the breast cancer cell lines screened, our amide 
compounds had the widest range of activity against the BT-549 cell line with a range of 
119.3 between the minimum and maximum growth percent.   
 Table 4.7 shows the R group of each compound and the corresponding BT-549 
growth percent.  As can be seen, incorporation of the pyrazinyl R group produced the 
most active compound with a growth percent of -42.7.  The related 2-pyridyl compound 
showed a drop in activity down to a growth percent of -18.8.  With a phenyl group in the 
R position, Compound 13 had a growth percent of -33.3.  Placing groups in the 3-position 
of the phenyl group caused a marked reduction in activity with the 3-methyl, 3-bromo, 3-
Compound ID MCF7 MDA-MB-231/ATCC HS 578T BT-549 T-47D MDA-MB-468 Average Minimum Maximum Range
13 60.7 -56.5 48.5 -33.3 68.0 87.3 29.1 -56.5 87.3 143.8
37 77.3 -25.6 NT 63.9 82.1 95.5 58.7 -25.6 95.5 121.1
38 71.6 -25.2 57.2 18.4 72.2 101.1 49.2 -25.2 101.1 126.4
39 75.8 15.0 NT 68.3 85.2 94.0 67.7 15.0 94.0 78.9
40 80.7 16.9 94.9 76.7 91.4 95.6 76.0 16.9 95.6 78.6
41 36.1 -32.1 21.0 -5.5 42.4 73.1 22.5 -32.1 73.1 105.1
42 76.2 -52.5 47.4 -18.8 89.2 93.2 39.1 -52.5 93.2 145.7
43 43.5 -72.5 12.6 -42.7 66.2 85.9 15.5 -72.5 85.9 158.4
44 59.2 -71.0 -4.1 -0.6 76.6 71.6 22.0 -71.0 76.6 147.6
45 76.9 -39.4 33.4 6.7 87.6 94.3 43.3 -39.4 94.3 133.7
46 74.5 -37.0 30.9 4.8 74.4 97.0 40.8 -37.0 97.0 134.0
Average 66.6 -34.5 38.0 12.5 76.0 89.9
Minimum 36.1 -72.5 -4.1 -42.7 42.4 71.6
Maximum 80.7 16.9 94.9 76.7 91.4 101.1
Range 44.6 89.4 98.9 119.3 49.0 29.5
NT= Not Tested
Breast Cancer Cell Lines
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trifluoromethyl, and 3,5-dichloro compounds having growth percents of 18.4, 63.9, 68.3, 
and 76.7 respectively. 
 
Table 4.6 
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Table 4.7 
 
 
As shown in Table 4.6, against the MDA-MB-231 cell line, the pryazinyl compound was 
once again the most active with a growth percent of -72.5.  The 2-furyl compound was 
 82 
nearly as active as the pyrazinyl compound with a growth percent of -71.0.  Adding 
substituents into the 3-position of the phenyl compound once again markedly decreased 
activity with the phenyl, 3-bromo, 3-methyl, 3-trifluoromethyl, and 3,5-dichloro 
compounds having growth percents of -56.5, -25.6, -25.2, 15.0, and 16.9 respectively.   
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Chapter 5: Prostate Cancer 
5.1 Overview 
Our compounds were screened two different prostate cancer cell lines.  The 
average mean growth percent for all of the compounds against the two cell lines was 
24.4.  The two cell lines screen were DU-145 and PC-3 and their cell line characteristics 
and source information are shown in Table 5.1.154-162 As can be seen in Table 5.1, both 
cell lines are androgen insensitive, possess p53 mutations, and do not express either 
prostate-specific antigen or 5α-reductase.  One difference is that the PC-3 line is more 
aggressive than the DU-145 line and thus the PC-3 line has higher metastatic potential.  
Overall, these cell lines appear relatively similar when looking at the commonly 
discussed characteristics shown in Table 5.1.   
 
Table 5.1:  Biological activity, characteristics, and source information for prostate cancer cell lines screened. 
However, the cell lines are clearly biologically unique as there are numerous published 
reports of their differing susceptibilities to different therapeutics.  One example is their 
differing response to treatment with tumor necrosis factor related apoptosis inducing 
ligand (TRAIL).  TRAIL (structure shown in Figure 5.1) is known as a “death ligand” 
that can induce apoptosis in cells regardless of the functionality of the tumor suppressor 
gene p53.  As shown in Table 5.1, both DU-145 and PC-3 have mutated p53.  TRAIL 
Color Growth Percent
Most Active < -50
-50 to 0
0 to 50
Least Active > 50
Figure Key
Cell Line
Average Mean 
Growth Percent
Androgen 
Sensitivity PSA 5α-Reductase p53
Metastatic 
Potential
Isolation 
Site
Patient 
Age Sex Ethnicity
DU-145 13.6 AI - -
Deletion 
mutation of p53
Moderate Brain 69 Male Caucasian
PC-3 35.2 AI - - Mutated p53 High Bone 62 Male Caucasian
Average 24.4
AI = Androgen insensitive
PSA = Prostate-specific antigen
+ = expression
- = no expression
Cell line information was gathered from references 154-162.
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exerts its effects via binding to TRAIL receptors which are also known as “death 
receptors”.  This binding interaction triggers a signaling cascade resulting in apoptosis.163  
More importantly, TRAIL has been shown to selectively kill cancer cells while sparing 
normal cells though the mechanism of this selectivity is not well understood.163,164  Figure 
5.2 shows the differing expression levels of TRAIL receptors between DU-145 and PC-3.  
The arrow in Figure 5.2 highlights the absence of TR4 in the PC-3 cell line.  Their 
differing susceptibilities to treatment with TRAIL are clearly exhibited in the fluorescent 
micrographs and bar graphs shown in Figure 5.3.  PC-3 viability is dramatically reduced 
as compared to DU-145 viability as the multiplicity of infection (MOI) values increase.163 
 
Figure 5.1:  TRAIL structure165 
 
Figure 5.2:  Trail Receptor (TR) expression163.  Arrow 
indicates absence of TR4 expression in PC-3 cell line. 
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Figure 5.3:  Fluorescent micrographs and bar graphs displaying the increased sensitivity of the PC-3 cell line to 
TRAIL treatment as compared to the DU-145 cell line.  LacZ was delivered via AdCMV and was used as a control.163  
MOI = Multiplicity of Infection. 
Table 5.2 shows the results for each compound against each prostate cancer cell line.  
Once again, the stereochemistry played a key role in the activity of the stereoisomers of 
Compound 1.  (3S,8R)-1 and (3S,8S)-1 had average growth percents of -65.9 and -51.7 
respectively against the two prostate cancer cell lines screened.  (3R,8S)-1 and (3R,8R)-1 
were significantly less active with average growth percents of 92.4 and 82.8 respectively.  
Lipophilicity was also shown to be important as Compound 9 (4 carbon length chain), 
(3S,8R)-1 (10 carbon length chain), and 10 (16 carbon length chain) had average growth 
percents of 106.3, -65.9, and -53.6 respectively. 
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Substituting an alcohol for the acetate at the C-3 position in (3S,8R)-1 produced 
little change in the average growth percent as Compound 16 had an average growth 
percent of -65.3 as compared to -65.9 for (3S,8R)-1.  When looking at the individual cell 
lines, Compound 16 and (3S,8R)-1 had very similar growth percents against both the PC-
3 and DU-145 cell lines.  For PC-3, the growth percents for Compound 16 and (3S,8R)-1 
were -41.4 and -43.1 respectively while  for PC-3, the growth percents were -89.3 and -
88.8 respectively.  This similarity is in contrast to cell lines of other cancer types where 
Compound 16 and (3S,8R)-1 often showed significantly different toxicities to the same 
cell line. 
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Table 5.2 
5.2 Hansch Cluster Analysis on Prostate Cancer Cell Lines Data 
Table 5.3 shows the prostate cancer testing results organized to assess the results per 
Hansch cluster analysis theory at the C-8 position.  As shown in the table, the range of 
activity is wide over the six clusters tested.  For the PC-3 cell line, the alcohol compound 
(3S,8R)-1 from cluster 5 is the most active whereas for the DU-145 cell line, the mesyl 
amide compound 12 from cluster 4b is the most active.  Interesting, the amine compound 
11 which is also in cluster 5 has dramatically different activity against both cell lines as 
compared to its cluster 5 mate (3S,8R)-1.  For the DU-145 cell line, the growth percent of 
Compound ID PC-3 DU-145 Average Minimum Maximum Range
(3R,8S )-1 75.4 109.4 92.4 75.4 109.4 34.0
(3S,8R )-1 -43.1 -88.8 -65.9 -88.8 -43.1 45.7
(3R,8R )-1 72.8 92.8 82.8 72.8 92.8 20.0
(3S,8S )-1 -17.9 -85.6 -51.7 -85.6 -17.9 67.6
9 107.1 105.5 106.3 105.5 107.1 1.6
10 -18.0 -89.1 -53.6 -89.1 -18.0 71.1
11 71.3 70.2 70.7 70.2 71.3 1.1
12 -23.3 -96.6 -59.9 -96.6 -23.3 73.2
13 35.3 18.1 26.7 18.1 35.3 17.2
14 16.2 4.9 10.6 4.9 16.2 11.3
15 -40.1 -95.9 -68.0 -95.9 -40.1 55.8
16 -41.4 -89.3 -65.3 -89.3 -41.4 47.9
37 54.0 81.5 67.8 54.0 81.5 27.5
38 57.3 57.2 57.2 57.2 57.3 0.1
39 71.1 96.9 84.0 71.1 96.9 25.9
40 98.5 101.9 100.2 98.5 101.9 3.3
41 20.0 -6.7 6.7 -6.7 20.0 26.7
42 48.6 15.0 31.8 15.0 48.6 33.6
43 13.2 -49.5 -18.2 -49.5 13.2 62.7
44 20.6 -60.8 -20.1 -60.8 20.6 81.4
45 50.2 25.0 37.6 25.0 50.2 25.2
46 58.7 61.5 60.1 58.7 61.5 2.8
47 59.0 47.0 53.0 47.0 59.0 12.0
48 99.5 102.2 100.8 99.5 102.2 2.7
Average 35.2 13.6
Minimum -43.1 -96.6
Maximum 107.1 109.4
Range 150.2 206.0
Color Growth Percent
Most Active < -50
-50 to 0
0 to 50
Least Active > 50
Prostate Cancer Cell Line
Figure Key
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compound 11 is 70.2 compared to a growth percent of -88.8 for (3S,8R)-1.  Hansch 
cluster theory would not predict that two substituents from the same cluster would have 
such drastically different biological activities as changing the substituents within a cluster 
is theorized to “fine-tune” the activity.  It would be interesting to evaluate more 
compounds from this cluster and several substituents from cluster 5 would be readily 
accessible synthetically as the methylamine, ethylamine, hydrazine, and methyl ether 
substituents would be relatively easy to substitute into the C-8 position. 
 
 
Table 5.3 
 
 
Table 5.4 
 
Compound ID Cluster PC-3 DU-145 Average Minimum Maximum Range
(3S,8R )-1 5 -43.1 -88.8 -65.9 -88.8 -43.1 45.7
11 5 71.3 70.2 70.7 70.2 71.3 1.1
12 4b -23.3 -96.6 -59.9 -96.6 -23.3 73.2
13 8 35.3 18.1 26.7 18.1 35.3 17.2
14 9 16.2 4.9 10.6 4.9 16.2 11.3
15 7 -40.1 -95.9 -68.0 -95.9 -40.1 55.8
48 6 99.5 102.2 100.8 99.5 102.2 2.7
Average 35.2 13.6
Minimum -43.1 -96.6
Maximum 107.1 109.4
Range 150.2 206.0
Color Growth Percent
Most Active < -50
-50 to 0
0 to 50
Least Active > 50
Prostate Cancer Cell Line
Figure Key
PC-3 5 -OH -43.1
DU-145 4b -NHSO2Me -96.6
Cell Line
Most Active 
Cluster
C-8 Substituent Growth Percent
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5.3 Prostate Cancer SAR Analysis of Amide Compounds  
Eleven of the compounds we had tested by NCI have an acetate at the C-3 position and 
different amide functionalities with aromatic or heteroaromatic groups directly connected 
to the amide carbonyl group in the C-8 position as shown in Figure 5.4. 
 
Figure 5.4  Generic structure of amides screened by NCI. 
 
Table 5.5 
Across the set of amide compounds (Table 5.5), there was a wide range of activity 
against the DU-145 cell line.  The most active compound was the 2-furyl compound 44 
which had a growth percent of -60.8.  The least active compound was the 3,5-dichloro 
compound 40 which exhibited virtually no activity with a growth percent of 101.9.  Table 
5.6 shows the growth percent of the DU-145 cell line and the associated R group for each 
Compound ID PC-3 DU-145 Average Minimum Maximum Range
13 35.3 18.1 26.7 18.1 35.3 17.2
37 54.0 81.5 67.8 54.0 81.5 27.5
38 57.3 57.2 57.2 57.2 57.3 0.1
39 71.1 96.9 84.0 71.1 96.9 25.9
40 98.5 101.9 100.2 98.5 101.9 3.3
41 20.0 -6.7 6.7 -6.7 20.0 26.7
42 48.6 15.0 31.8 15.0 48.6 33.6
43 13.2 -49.5 -18.2 -49.5 13.2 62.7
44 20.6 -60.8 -20.1 -60.8 20.6 81.4
45 50.2 25.0 37.6 25.0 50.2 25.2
46 58.7 61.5 60.1 58.7 61.5 2.8
Average 48.0 30.9
Minimum 13.2 -60.8
Maximum 98.5 101.9
Range 85.3 162.7
Prostate Cancer Cell Line
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of the eleven amide compounds.  Interestingly, the four most active compounds were the 
four compounds with heteroaromatic rings.  Since the most active compound has the 2-
furyl group, it would be interesting to evaluate the 3-furyl substituent as well as other 5-
membered heteroaromatic rings such as thiophene and pyrrole.  With the pyrazine 
compound also being very active, it would be intriguing to evaluate the effect of 
changing the spacing of the nitrogen atoms in the ring by substituting in pyrimidine and 
pyridazine rings.  Triazine and tetrazine isomers could also easily be synthesized and 
evaluated.  On the other side of the activity spectrum, four of the five least active 
compounds had substituents in the 3-position of the phenyl ring indicating that the steric 
bulk in the 3-position may have a negative impact on activity.   Changing the phenyl 
group in compound 13 to the 3,5-dichlorophenyl group in compound 40 dropped the 
growth percent from 18.1 down to 101.9.   
As shown in Table 5.5, the range of activity across the amide set was not as large 
against the PC-3 cell line.  The most active compound was the pyrazyl compound 43 with 
a growth percent of 13.2.  Once again, the 3,5-dichlorophenyl compound 40 had the least 
activity with a growth percent of 98.5.  The activity of the 2-furyl compound dropped to 
20.6 against the PC-3 cell line as compared to the growth percent of -60.8 against the 
DU-145 cell line. 
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Chapter 6:  Renal Cancer 
6.1 Renal Cancer Overview 
Our compounds were screened against eight different renal cancer cell lines.  The average 
mean growth percent across the eight renal cancer cell lines was -2.7.  As shown in Table 
3.4, our compounds had the second most broad spectrum activity against renal cancer cell 
lines with only melanoma cell lines being more susceptible to our compounds.  Table 6.1 
shows the average mean growth percent of our compounds against each of the eight renal 
cancer cell lines screened.  Table 6.1 also shows molecular characteristics and cell line 
source information for each of the eight cell lines. 
 
 
Table 6.1  
 
Cell Line
Average Mean 
Growth Percent Mutations/variants166 TP53167
p53 Amino Acid 
Codon Change167
Patient 
Age Sex Ethnicity
SN12C -29.1 TP53 336 GAG → TAG E → STOP 43 Male N/A
UO-31 -13.7 CDKN2A wild-type wild-type N/A Female N/A
786-0 -11.2
CDKN2A, PTEN, 
TP53, VHL
278 CCT → GCT P → A 58 Male Caucasian
RXF 393 -8.1 CDKN2A, PTEN, TP53 275 CGC → CAC R → H 54 Male N/A
A498 -3.0 CDKN2A, VHL wild-type wild-type 52 Female N/A
CAKI-1 9.9 CDKN2A wild-type wild-type 49 Male Caucasian
TK-10 14.1 TP53 264 CTA → CGA L → R 43 Male N/A
ACHN 19.5 CDKN2A wild-type wild-type 22 Male Caucasian
Average -2.7
N/A: Data not available
CDKN2A: Cyclin-dependent kinase inhibitor 2A
PTEN: Phosphatase and tensin homologue
TP53: Tumor protein p53
VHL: von Hippel-Lindau tumor suppressor
Unless otherwise referenced above, cell line information was gathered from references 154-157.
Color Growth Percent
Most Active < -50
-50 to 0
0 to 50
Least Active > 50
Figure Key
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Table 6.2 shows the results for each compound against each renal cancer cell line.  The 
stereochemistry played a key role in the activity of the stereoisomers of Compound 1.  
(3S,8R)-1 and (3S,8S)-1 had average growth percents of -67.5 and -59.9 respectively 
against the eight renal cancer cell lines screened.  (3R,8S)-1 and (3R,8R)-1 were 
significantly less active with average growth percents of 86.6 and 92.1 respectively.  
Lipophilicity was also shown to be important as Compound 9 (4 carbon length chain), 
(3S,8R)-1 (10 carbon length chain), and 10 (16 carbon length chain) had average growth 
percents of 103.8, -67.5, and –73.8 respectively. 
 Substituting an alcohol for the acetate at the C-3 position in (3S,8R)-1 produced 
little change in the average growth percent as Compound 16 had an average growth 
percent of -66.3 as compared to -67.5 for (3S,8R)-1.  Even when looking at individual 
renal cancer cell lines, (3S,8R)-1 and 16 had remarkably similar cytotoxicities with the 
largest difference in growth percent being seen in the SN12C cell line where the growth 
percents were -94.9 and -63.9 respectively. 
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Table 6.2 
 
6.2  Hansch Cluster Analysis on Renal Cancer Cell Lines Data 
Table 6.3 shows the renal cancer testing results organized to assess the results per Hansch 
cluster analysis theory at the C-8 position.  As shown in the table, the range of activity is 
wide over the six clusters tested.  Isothiocyanate compound 48 clearly has the least 
activity across the board.  Interestingly, the amino compound 11 mirrors the low activity 
of compound 48 against five of the seven common cell lines tested (compound 11 not 
screened against RXF 393).  Yet for cell lines 786-0 and SN12C, compound 11 has 
potent activity with growth percents of -50.1 and -49.0 respectively whereas compound 
48 maintains minimal activity against these same cell lines with growth percents of 97.6 
and 91.8 respectively.  Table 6.4 shows the most active cluster and substituent against 
each cell line. 
Compound ID 786-0 A498 ACHN CAKI-1 RXF 393 SN12C TK-10 UO-31 Average Minimum Maximum Range
(3R,8S)-1 96.0 96.8 96.6 95.4 NT 74.8 94.1 52.6 86.6 52.6 96.8 44.2
(3S,8R)-1 -38.9 -87.6 -40.0 -11.1 -79.9 -94.9 -93.4 -94.3 -67.5 -94.9 -11.1 83.9
(3R,8R)-1 90.2 108.2 98.1 100.0 NT 74.3 106.0 67.8 92.1 67.8 108.2 40.4
(3S,8S)-1 -44.6 -73.2 -37.8 -18.9 NT -59.0 -91.3 -94.2 -59.9 -94.2 -18.9 75.3
9 98.8 94.9 104.7 103.9 99.7 100.5 119.5 108.2 103.8 94.9 119.5 24.6
10 -82.1 -78.6 -67.5 -34.6 -81.7 -65.2 -88.0 -93.0 -73.8 -93.0 -34.6 58.4
11 -50.1 101.6 81.3 98.0 NT -49.0 114.4 63.4 51.4 -50.1 114.4 164.5
12 -62.2 -86.8 -43.1 -11.6 -85.2 -50.6 -95.7 -90.4 -65.7 -95.7 -11.6 84.2
13 -37.1 -69.2 14.9 8.9 6.8 -57.8 3.6 -23.1 -19.1 -69.2 14.9 84.1
14 -72.9 11.4 23.5 26.9 NT -43.2 58.7 -90.7 -12.3 -90.7 58.7 149.4
15 -48.5 -62.9 -75.6 -41.7 -74.7 -53.5 -88.6 -85.6 -66.4 -88.6 -41.7 46.8
16 -59.3 -86.0 -47.8 -27.5 -71.1 -63.9 -92.6 -82.4 -66.3 -92.6 -27.5 65.2
37 23.6 69.8 28.2 61.9 72.1 -33.3 67.4 35.1 40.6 -33.3 72.1 105.4
38 19.7 14.5 23.4 -12.7 51.6 -68.1 29.0 27.8 10.6 -68.1 51.6 119.7
39 28.7 68.3 46.8 66.9 80.4 10.8 139.7 43.4 60.6 10.8 139.7 128.9
40 47.2 97.0 67.0 70.9 83.7 27.3 101.6 51.5 68.3 27.3 101.6 74.3
41 -46.9 -73.2 13.5 -52.7 -68.3 -25.1 -38.2 -53.8 -43.1 -73.2 13.5 86.7
42 -70.5 -46.5 10.8 -48.8 -37.8 -75.9 4.0 -19.5 -35.5 -75.9 10.8 86.6
43 -90.6 -76.8 -0.1 -39.7 -63.1 -59.5 -25.2 -86.6 -55.2 -90.6 -0.1 90.6
44 -40.1 -75.4 12.6 -40.1 -44.5 -61.6 -13.2 -47.3 -38.7 -75.4 12.6 88.0
45 11.0 -73.2 19.6 -50.4 -14.5 -72.4 5.8 12.1 -20.2 -73.2 19.6 92.8
46 7.1 42.6 18.9 -43.3 15.1 -73.3 0.4 10.5 -2.7 -73.3 42.6 115.9
47 -46.0 6.9 15.5 -58.6 -27.7 -72.0 1.7 -11.6 -24.0 -72.0 15.5 87.5
48 97.6 104.8 104.5 97.5 84.9 91.8 118.9 70.6 96.3 70.6 118.9 48.3
Average -11.2 -3.0 19.5 9.9 -8.1 -29.1 14.1 -13.7
Minimum -90.6 -87.6 -75.6 -58.6 -85.2 -94.9 -95.7 -94.3
Maximum 98.8 108.2 104.7 103.9 99.7 100.5 139.7 108.2
Range 189.4 195.8 180.3 162.6 185.0 195.5 235.4 202.5
NT = Not Tested
Color Growth Percent
Most Active < -50
-50 to 0
0 to 50
Least Active > 50
Figure Key
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Table 6.3 
 
 
Table 6.4 
 
6.3  Renal Cancer SAR Analysis of Amide Compounds  
Eleven of the compounds we had tested by NCI have an acetate at the C-3 position and 
different amide functionalities with aromatic or heteroaromatic groups directly connected 
to the amide carbonyl group in the C-8 position as shown in Figure 6.1. 
 
Figure 6.1  Generic structure of amides screened by NCI. 
Compound ID Cluster 786-0 A498 ACHN CAKI-1 RXF 393 SN12C TK-10 UO-31 Average Minimum Maximum Range
(3S,8R)-1 5 -38.9 -87.6 -40.0 -11.1 -79.9 -94.9 -93.4 -94.3 -67.5 -94.9 -11.1 83.9
11 5 -50.1 101.6 81.3 98.0 NT -49.0 114.4 63.4 51.4 -50.1 114.4 164.5
12 4b -62.2 -86.8 -43.1 -11.6 -85.2 -50.6 -95.7 -90.4 -65.7 -95.7 -11.6 84.2
13 8 -37.1 -69.2 14.9 8.9 6.8 -57.8 3.6 -23.1 -19.1 -69.2 14.9 84.1
14 9 -72.9 11.4 23.5 26.9 NT -43.2 58.7 -90.7 -12.3 -90.7 58.7 149.4
15 7 -48.5 -62.9 -75.6 -41.7 -74.7 -53.5 -88.6 -85.6 -66.4 -88.6 -41.7 46.8
48 6 97.6 104.8 104.5 97.5 84.9 91.8 118.9 70.6 96.3 70.6 118.9 48.3
Average -30.3 -12.7 9.4 23.9 -29.6 -36.8 2.6 -35.7
Minimum -72.9 -87.6 -75.6 -41.7 -85.2 -94.9 -95.7 -94.3
Maximum 97.6 104.8 104.5 98.0 84.9 91.8 118.9 70.6
Range 170.5 192.4 180.1 139.8 170.1 186.8 214.6 164.9
NT = Not Tested
Color Growth Percent
Most Active < -50
-50 to 0
0 to 50
Least Active > 50
Figure Key
Renal Cancer Cell Lines
786-0 9 -NHBu -72.9
A498 5 -OH -87.6
ACHN 7 -OSO2Me -75.6
CAKI-1 7 -OSO2Me -41.7
RXF 393 4b -NHSO2Me -85.2
SN12C 5 -OH -94.9
TK-10 4b -NHSO2Me -95.7
UO-31 5 -OH -94.3
Cell Line
Most Active 
Cluster
C-8 Substituent Growth Percent
 98 
 Table 6.5 shows the activity of our amide compounds against each of the different 
renal cell lines.  The set of amide compounds showed a wide range of activity against the 
different cell lines indicating that changing the amide R group has a significant impact on 
activity.  The ACHN cell line results stand out as our compounds had the narrowest range 
of activity against this cell line and only compound 43 had a growth percent below zero 
with a value of -0.1.  One trend across all of the renal cell lines is that the five heterocycle 
R-groups are typically among the most active compounds.  In seven of the eight cell 
lines, the five heterocycles compounds are amongst the top six most active compounds.  
It is only in the SN12C cell line where the isoxazole compound ranks below the top six 
most active compounds as it is the eighth most active.  Another trend is that the phenyl R-
groups with a substituent in the meta-position are most often the least active compounds.  
All of the meta-substituted compounds rank in the bottom five least active compounds 
against all cell lines except the SN12C cell line.  Against the SN12C cell line, Compound 
38 with a methyl group in the meta-position ranks fourth with a growth percent of -68.1.  
The fact that our compounds exhibit significantly different activity against the SN12C 
cell line is not surprising since it is a unique renal cell line in that it is the only one in the 
NCI60 panel that expresses neuronal system-specific enolases.  In addition, the SN12C 
line does not express several renal specific miRNAs that are seen in the other cell 
lines.168,169 
  
 
 99 
 
Table 6.5 
 
 
Table 6.6 
 
Compound ID 786-0 A498 ACHN CAKI-1 RXF 393 SN12C TK-10 UO-31 Average Minimum Maximum Range
13 -37.1 -69.2 14.9 8.9 6.8 -57.8 3.6 -23.1 -19.1 -69.2 14.9 84.1
37 23.6 69.8 28.2 61.9 72.1 -33.3 67.4 35.1 40.6 -33.3 72.1 105.4
38 19.7 14.5 23.4 -12.7 51.6 -68.1 29.0 27.8 10.6 -68.1 51.6 119.7
39 28.7 68.3 46.8 66.9 80.4 10.8 139.7 43.4 60.6 10.8 139.7 128.9
40 47.2 97.0 67.0 70.9 83.7 27.3 101.6 51.5 68.3 27.3 101.6 74.3
41 -46.9 -73.2 13.5 -52.7 -68.3 -25.1 -38.2 -53.8 -43.1 -73.2 13.5 86.7
42 -70.5 -46.5 10.8 -48.8 -37.8 -75.9 4.0 -19.5 -35.5 -75.9 10.8 86.6
43 -90.6 -76.8 -0.1 -39.7 -63.1 -59.5 -25.2 -86.6 -55.2 -90.6 -0.1 90.6
44 -40.1 -75.4 12.6 -40.1 -44.5 -61.6 -13.2 -47.3 -38.7 -75.4 12.6 88.0
45 11.0 -73.2 19.6 -50.4 -14.5 -72.4 5.8 12.1 -20.2 -73.2 19.6 92.8
46 7.1 42.6 18.9 -43.3 15.1 -73.3 0.4 10.5 -2.7 -73.3 42.6 115.9
Average -13.5 -11.1 23.2 -7.2 7.4 -44.4 25.0 -4.5
Minimum -90.6 -76.8 -0.1 -52.7 -68.3 -75.9 -38.2 -86.6
Maximum 47.2 97.0 67.0 70.9 83.7 27.3 139.7 51.5
Range 137.8 173.7 67.0 123.7 152.0 103.2 177.9 138.1
Renal Cancer Cell Lines
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Chapter 7: Ovarian Cancer 
7.1  Ovarian Cancer Overview 
Our compounds were screened against seven different ovarian cancer cell lines.  The 
average mean growth percent across the seven ovarian cancer cell lines was 25.7.  As 
shown in Table 3.4, the activity of our compounds against ovarian cancer was less than 
all of the other types of cancer tested except for breast cancer.  Table 7.1 shows the 
average growth percent of our compounds against each of the seven ovarian cancer cell 
lines screened.  Table 7.1 also shows molecular characteristics and cell line source 
information for each of the seven cell lines.  As shown in Table 7.1, there is disagreement 
amongst publications on the mutation status of TP53 in the IGROV1, OVCAR-4, and 
OVCAR-5 cell lines.166,167 
 
 
Table 7.1 
 
Table 7.2 shows the results for each compound against each ovarian cancer cell line.  The 
stereochemistry played a key role in the activity of the stereoisomers of Compound 1.  
(3S,8R)-1 and (3S,8S)-1 had average growth percents of -34.2 and -24.3 respectively 
against the seven ovarian cancer cell lines screened.  (3R,8S)-1 and (3R,8R)-1 were 
Cell Line
Average Growth 
Percent
Endogenous 
Estrogen Level171 
(pg/106 cells) Mutations/variants166 TP53167
p53 Amino Acid 
Codon Change167 Patient Age Sex
IGROV1 0.6 37.9 TP53, BRCA1, SMAD4, PTEN wild-type wild-type 47 Female
OVCAR-8 17.7 50.7 TP53, ERBB2 deletion 126-132 deletion 126-132 64 Female
OVCAR-5 17.7 123.8 CDKN2A, KRAS insertion 224 insertion 224 N/A N/A
OVCAR-4 29.1 168.9 TP53 wild-type wild-type 42 Female
NCI/ADR-RES 32.2 97.6 TP53, ERBB2 N/A N/A
OVCAR-3 36.0 43.0 TP53 248 CGG → CAG R → Q 60 Female
SK-OV-3 46.8 152.4 TP53, CDKN2A, PIK3CA, APC 179 CAT → CGT H → R 64 Female
Average 25.7
N/A: Data not available
APC: Adenomatous polyposis coli
CDKN2A: Cyclin-dependent kinase inhibitor 2A
ERBB2: v-erb-b2 erythroblastic leukemia viral oncogene homologue 2
PTEN: Phosphatase and tensin homologue
TP53: Tumor protein p53
VHL: von Hippel-Lindau tumor suppressor
Unless otherwise referenced above, cell line information was gathered from references 154-157.
Derived from OVCAR-8170
Color Growth Percent
Most Active < -50
-50 to 0
0 to 50
Least Active > 50
Figure Key
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significantly less active with average growth percents of 97.6 and 103.3 respectively.  
Lipophilicity was also shown to be important as Compound 9 (4 carbon length chain), 
(3S,8R)-1 (10 carbon length chain), and 10 (16 carbon length chain) had average growth 
percents of 107.7, -34.2, and –22.6 respectively. 
 Substituting an alcohol for the acetate at the C-3 position in (3S,8R)-1 produced 
little change in the average growth percent as Compound 16 had an average growth 
percent of -37.8 as compared to -34.2 for (3S,8R)-1.  Even when looking at individual 
ovarian cancer cell lines, (3S,8R)-1 and 16 had remarkably similar cytotoxicities with the 
largest difference in growth percent being seen in the OVCAR-8 cell line where the 
growth percents were 8.8 and -27.6 respectively. 
 
 
Table 7.2 
 
Compound ID IGROV1 OVCAR-3 OVCAR-4 OVCAR-5 OVCAR-8 NCI/ADR-RES SK-OV-3 Average Minimum Maximum Range
(3R,8S)-1 76.5 108.4 99.6 95.4 104.8 94.0 104.4 97.6 76.5 108.4 31.8
(3S,8R)-1 -64.8 -83.3 0.4 -92.1 8.8 5.3 -13.5 -34.2 -92.1 8.8 101.0
(3R,8R)-1 103.4 109.6 106.5 109.6 79.1 103.3 111.5 103.3 79.1 111.5 32.5
(3S,8S)-1 -65.8 -40.9 -10.9 -76.5 7.4 13.7 3.2 -24.3 -76.5 13.7 90.3
9 120.7 123.4 100.1 101.0 104.4 94.4 109.8 107.7 94.4 123.4 29.0
10 -52.7 -31.4 -14.4 -60.3 2.3 9.6 -10.8 -22.6 -60.3 9.6 70.0
11 18.4 81.4 63.2 93.6 8.5 13.7 120.6 57.1 8.5 120.6 112.2
12 -56.1 -71.3 -24.8 -93.2 -5.0 4.6 -19.4 -37.9 -93.2 4.6 97.9
13 -3.9 57.2 9.2 1.3 -22.5 23.6 56.3 17.3 -22.5 57.2 79.7
14 20.6 11.0 -2.2 52.7 10.2 22.9 70.9 26.6 -2.2 70.9 73.1
15 -70.9 -82.7 4.6 -81.3 -4.9 13.2 15.4 -29.5 -82.7 15.4 98.1
16 -69.1 -92.2 -1.8 -88.7 -27.6 11.2 3.6 -37.8 -92.2 11.2 103.4
37 49.1 101.5 27.6 61.0 23.4 NT 61.2 54.0 23.4 101.5 78.1
38 14.8 82.0 44.3 46.0 -5.9 22.3 61.9 37.9 -5.9 82.0 87.8
39 75.8 97.8 55.2 91.9 33.3 NT 74.7 71.4 33.3 97.8 64.5
40 92.7 102.0 67.7 123.0 61.4 81.9 76.4 86.5 61.4 123.0 61.6
41 -64.8 19.0 3.0 9.0 -48.4 15.5 8.6 -8.3 -64.8 19.0 83.8
42 -49.9 47.5 2.5 2.9 3.0 14.1 37.7 8.3 -49.9 47.5 97.4
43 -67.3 12.3 0.2 -59.0 0.4 6.6 9.9 -13.8 -67.3 12.3 79.6
44 -53.8 13.5 19.8 -14.1 4.4 18.1 31.8 2.8 -53.8 31.8 85.6
45 49.6 15.6 32.4 -4.6 17.5 42.1 25.5 -4.6 49.6 54.2
46 3.8 78.4 32.1 41.9 -0.5 20.6 38.5 30.7 -0.5 78.4 78.9
47 -44.3 68.0 13.0 18.7 2.4 12.2 21.4 13.0 -44.3 68.0 112.3
48 101.7 103.4 87.9 110.9 90.4 90.4 107.5 98.9 87.9 110.9 23.0
Average 0.6 36.0 29.1 17.7 17.7 32.2 46.8
Minimum -70.9 -92.2 -24.8 -93.2 -48.4 4.6 -19.4
Maximum 120.7 123.4 106.5 123.0 104.8 103.3 120.6
Range 191.6 215.6 131.3 216.2 153.3 98.7 140.1
NT = Not Tested
Color Growth Percent
Most Active < -50
-50 to 0
0 to 50
Least Active > 50
Ovarian Cancer Cell Lines
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7.2  Hansch Cluster Analysis on Ovarian Cancer Cell Lines Data 
Table 7.3 shows the ovarian cancer testing results organized to assess the results per 
Hansch cluster analysis theory at the C-8 position.  As shown in the table, the range of 
activity is wide over the six clusters tested.  Isothiocyanate compound 48 of cluster 6 
clearly has the least activity across the board with an average growth percent of 98.9.  
Selectivity against certain cell lines is evident for many of the compounds.  (3S,8R)-1 and 
11 both have similar growth percents against the OVCAR-8 line (8.8 and 8.5, 
respectively) and NCI/ADR-RES line (5.3 and 13.7, respectively).  Yet the growth 
percents for (3S,8R)-1 and 11 against OVCAR-3 (-83.3 and 81.4, respectively) and 
OVCAR-5 (-92.1 and 93.6, respectively) are strikingly different.  Both (3S,8R)-1 and 11 
are cluster 5 compounds with (3S,8R)-1 having a C-8 alcohol whereas 11 has a C-8 
amino group.  (3S,8R)-1 (cluster 5), 12 (cluster 4b), and 15 (cluster 7) all had average 
growth percents below zero across the seven cell lines. Table 7.4 shows the most active 
cluster and substituent against each cell line. 
 
 
 
Table 7.3 
 
Compound ID Cluster IGROV1 OVCAR-3 OVCAR-4 OVCAR-5 OVCAR-8 NCI/ADR-RES SK-OV-3 Average Minimum Maximum Range
(3S,8R)-1 5 -64.8 -83.3 0.4 -92.1 8.8 5.3 -13.5 -34.2 -92.1 8.8 101.0
11 5 18.4 81.4 63.2 93.6 8.5 13.7 120.6 57.1 8.5 120.6 112.2
12 4b -56.1 -71.3 -24.8 -93.2 -5.0 4.6 -19.4 -37.9 -93.2 4.6 97.9
13 8 -3.9 57.2 9.2 1.3 -22.5 23.6 56.3 17.3 -22.5 57.2 79.7
14 9 20.6 11.0 -2.2 52.7 10.2 22.9 70.9 26.6 -2.2 70.9 73.1
15 7 -70.9 -82.7 4.6 -81.3 -4.9 13.2 15.4 -29.5 -82.7 15.4 98.1
48 6 101.7 103.4 87.9 110.9 90.4 90.4 107.5 98.9 87.9 110.9 23.0
Average -7.9 2.2 19.8 -1.2 12.2 24.8 48.3
Minimum -70.9 -83.3 -24.8 -93.2 -22.5 4.6 -19.4
Maximum 101.7 103.4 87.9 110.9 90.4 90.4 120.6
Range 172.6 186.8 112.7 204.1 112.8 85.8 140.1
NT = Not Tested
Color Growth Percent
Most Active < -50
-50 to 0
0 to 50
Least Active > 50
Ovarian Cancer Cell Lines
Figure Key
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Table 7.4 
 
7.3  SAR Analysis of Amide Compounds against Ovarian Cancer Cell Lines 
 
Eleven of the compounds we had tested by NCI have an acetate at the C-3 position and 
different amide functionalities with aromatic or heteroaromatic groups directly connected 
to the amide carbonyl group in the C-8 position as shown in Figure 7.1. 
 
Figure 7.1  Generic structure of amides screened by NCI. 
 Table 7.5 shows the activity of our amide compounds against each of the different 
ovarian cancer cell lines.  The set of amide compounds showed a wide range of activity 
against the different cell lines indicating that changing the amide R group has a 
significant impact on activity.   
IGROV1 7 -OSO2Me -70.9
OVCAR-3 5 -OH -83.3
OVCAR-4 4b -NHSO2Me -24.8
OVCAR-5 4b -NHSO2Me -93.2
OVCAR-8 8 -NHCOPh -22.5
NCI/ADR-RES 4b -NHSO2Me 4.6
SK-OV-3 4b -NHSO2Me -19.4
Cell Line
Most Active 
Cluster
C-8 Substituent Growth Percent
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Table 7.5 
 
As a set, the amides were most active against the IGROV1 cell line in which the average 
growth percent was -0.3.  The four heterocyclic compounds were most active against 
IGROV1 and all had growth percents of -49.9 or less.  The unique activity against the 
IGROV1 cell line may be explained by its own uniqueness as a “hypermutated” cell line.  
There is evidence that the IGROV1 cell line may not be a good model cell line for 
ovarian cancer as most tumor cells from patients do not exhibit the high rate of mutation 
seen in IGROV1.  Figure 7.2 plots cell lines and tumor cells based on mutation rates and 
fraction of genome altered and it is very evident that the IGROV1 line is an outlier.172  
The fraction of genome altered is a measure of copy number alterations (CNAs) where 
chromosomes acquire or lose extra copies of the same gene.  As can be seen in Figure 
7.2, many of the ovarian cancer cell lines (red dots) used in research fall well outside of 
the grouping of blue dots representing actual tumor cells.  This had led many people to 
question the validity of the cell line models commonly used in ovarian cancer 
research.172,173 
Compound ID IGROV1 OVCAR-3 OVCAR-4 OVCAR-5 OVCAR-8 NCI/ADR-RES SK-OV-3 Average Minimum Maximum Range
13 -3.9 57.2 9.2 1.3 -22.5 23.6 56.3 17.3 -22.5 57.2 79.7
37 49.1 101.5 27.6 61.0 23.4 NT 61.2 54.0 23.4 101.5 78.1
38 14.8 82.0 44.3 46.0 -5.9 22.3 61.9 37.9 -5.9 82.0 87.8
39 75.8 97.8 55.2 91.9 33.3 NT 74.7 71.4 33.3 97.8 64.5
40 92.7 102.0 67.7 123.0 61.4 81.9 76.4 86.5 61.4 123.0 61.6
41 -64.8 19.0 3.0 9.0 -48.4 15.5 8.6 -8.3 -64.8 19.0 83.8
42 -49.9 47.5 2.5 2.9 3.0 14.1 37.7 8.3 -49.9 47.5 97.4
43 -67.3 12.3 0.2 -59.0 0.4 6.6 9.9 -13.8 -67.3 12.3 79.6
44 -53.8 13.5 19.8 -14.1 4.4 18.1 31.8 2.8 -53.8 31.8 85.6
45 NT 49.6 15.6 32.4 -4.6 17.5 42.1 25.5 -4.6 49.6 54.2
46 3.8 78.4 32.1 41.9 -0.5 20.6 38.5 30.7 -0.5 78.4 78.9
Average -0.3 60.1 25.2 30.6 4.0 24.5 45.4
Minimum -67.3 12.3 0.2 -59.0 -48.4 6.6 8.6
Maximum 92.7 102.0 67.7 123.0 61.4 81.9 76.4
Range 160.1 89.7 67.5 181.9 109.9 75.3 67.8
NT = Not Tested
Color Growth Percent
Most Active < -50
-50 to 0
0 to 50
Least Active > 50
Ovarian Cancer Cell Lines
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Figure 7.2: Mutation rates and fraction of genome alteration rates for different ovarian cancer cell lines.172 
 The activity of the amides of against the OVCAR-5 line is also interesting.  
Pyrazine compound 43 (growth percent = -59.0) is much more active than pyridine 
compound 42 (growth percent = 2.9) indicating the importance of the second nitrogen 
atom in the pyrazine ring.  Across all of the other ovarian cancer cell lines, the activities 
of 42 and 43 fall much closer together.  Future research against the OVCAR-5 cell line 
could involve increasing the number of nitrogen atoms in the ring as well as changing 
their location. 
 The OVCAR-3 cell line results are remarkable for the inactivity of our amide 
compounds which had an average growth percent of 60.1.  Though the amides were 
relatively inactive, there were compounds outside of the amide set that were quite active 
such as sulfonamide compound 12 which had a growth percent of -71.3.  It would be 
interesting to synthesize and evaluate the methyl amide analogue to determine the 
importance of the sulfonyl group versus the carbonyl group. 
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Chapter 8:  CNS Cancer 
8.1  CNS Cancer Overview 
Our compounds were screened against six different central nervous system (CNS) cancer 
cell lines.  The average mean growth percent across the six CNS cancer cell lines was 
21.7.  Table 8.1 shows the average growth percent of our compounds against each of the 
six CNS cancer cell lines screened.  Table 8.1 also shows molecular characteristics and 
cell line source information for each of the six cell lines.  Five of the six cell lines had 
relatively similar average mean growth percents ranging from 0.7 to 28.1.  The outlier 
was the SNB-19 glioblastoma cell line which had a growth percent of 72.4. 
 
Table 8.1 
 
Table 8.2 shows the results for each compound against each CNS cancer cell line.  The 
stereochemistry played a key role in the activity of the stereoisomers of Compound 1.  
(3S,8R)-1 and (3S,8S)-1 had average growth percents of -37.5 and -29.5 respectively 
against the six CNS cancer cell lines screened.  (3R,8S)-1 and (3R,8R)-1 were 
significantly less active with average growth percents of 89.1 and 88.6 respectively.  
Lipophilicity was also shown to be important as Compound 9 (4 carbon length chain), 
Cell Line
Average Mean 
Growth Percent
Cancer Type Mutations/variants166 TP53167
p53 Amino Acid 
Codon Change167
MDR Rating174
Patient 
Age
Sex
SF-539 0.7 Gliosarcoma TP53, PTEN, RB1 wild-type wild-type 6.6 34 Female
U251 7.7 Glioblastoma TP53, CDKN2A, PTEN 273 CGT → CAT R → H -12.3 75 Male
SF-295 8.3 Glioblastoma TP53, CDKN2A, PTEN 248 CGG → CAG R → Q 4.8 67 Female
SF-268 12.8
Highly anaplastic 
astrocytoma
TP53, CDKN2A 273 CGT → CAT R → H 16.9 24 Female
SNB-75 28.1 Glioblastoma TP53 258 GAA → AAA E → K 1.8 78 Female
SNB-19 72.4 Glioblastoma TP53, CDKN2A, PTEN 273 CGT → CAT R → H -10.8 47 Male
Average 21.7
N/A: Data not available
CDKN2A: Cyclin-dependent kinase inhibitor 2A
PTEN: Phosphatase and tensin homologue
RB1: Retinoblastoma 1
TP53: Tumor protein p53
Unless otherwise referenced above, cell line information was gathered from references 154-157.
Color Growth Percent
Most Active < -50
-50 to 0
0 to 50
Least Active > 50
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(3S,8R)-1 (10 carbon length chain), and 10 (16 carbon length chain) had average growth 
percents of 107.3, -37.5, and –44.3 respectively. 
 Substituting an alcohol for the acetate at the C-3 position in (3S,8R)-1 produced a 
significant change in the average growth percent as Compound 16 had an average growth 
percent of -64.6 as compared to -37.5 for (3S,8R)-1.  Compound 16 was remarkably 
active against the U251 cell line exhibiting a growth percent of -100.0.   
 
 
Table 8.2 
 
 
8.2  Hansch Cluster Analysis on CNS Cancer Cell Lines Data 
 
Table 8.3 shows the CNS cancer testing results organized to assess the results per Hansch 
cluster analysis theory at the C-8 position.  As shown in the table, the range of activity is 
wide over the six clusters tested.  Isothiocyanate compound 48 of cluster 6 clearly has the 
least activity across the board with an average growth percent of 94.3.  Selectivity against 
certain cell lines is evident for many of the compounds.  The C-8 mesyl amide compound 
Compound ID SF-268 SF-295 SF-539 SNB-19 SNB-75 U251 Average Minimum Maximum Range
(3R,8S)-1 87.3 103.7 102.3 71.5 74.1 95.5 89.1 71.5 103.7 32.2
(3S,8R)-1 -23.4 -22.9 -90.6 12.8 -47.9 -53.2 -37.5 -90.6 12.8 103.3
(3R,8R)-1 87.8 101.4 104.0 82.2 77.2 79.0 88.6 77.2 104.0 26.8
(3S,8S)-1 -11.7 -45.9 -76.6 58.1 -25.8 -74.9 -29.5 -76.6 58.1 134.7
9 116.7 105.2 100.9 119.8 95.0 105.8 107.3 95.0 119.8 24.8
10 -67.4 NT -86.5 54.7 -49.3 -73.1 -44.3 -86.5 54.7 141.2
11 56.3 NT 98.7 94.9 74.6 89.3 82.7 56.3 98.7 42.4
12 -64.3 -75.6 -95.6 -26.3 -37.5 -92.0 -65.2 -95.6 -26.3 69.4
13 18.5 31.4 21.4 95.4 30.3 51.9 41.5 18.5 95.4 76.9
14 -0.3 NT -7.8 85.8 14.8 21.9 22.9 -7.8 85.8 93.6
15 -49.7 -20.6 -56.6 6.0 -15.2 -96.2 -38.7 -96.2 6.0 102.3
16 -80.8 -57.9 -84.8 -1.2 -62.6 -100.0 -64.6 -100.0 -1.2 98.8
37 56.5 NT 68.7 88.8 79.3 74.9 73.6 56.5 88.8 32.3
38 38.7 48.1 45.8 93.0 86.5 NT 62.4 38.7 93.0 54.3
39 74.9 NT 89.9 87.6 73.8 78.6 81.0 73.8 89.9 16.0
40 73.4 NT 97.4 97.8 79.9 NT 87.1 73.4 97.8 24.4
41 -50.4 NT -92.4 78.9 -20.4 NT -21.1 -92.4 78.9 171.3
42 3.5 NT 23.1 96.6 34.4 NT 39.4 3.5 96.6 93.0
43 -32.6 NT -96.2 80.0 -22.8 NT -17.9 -96.2 80.0 176.2
44 -16.8 -72.5 -73.4 83.5 0.0 NT -15.8 -73.4 83.5 156.9
45 10.2 -4.0 -12.6 99.8 24.5 NT 23.6 -12.6 99.8 112.4
46 11.6 17.3 -1.8 89.5 69.7 NT 37.3 -1.8 89.5 91.3
47 -21.6 NT -63.2 92.5 52.5 NT 15.0 -63.2 92.5 155.7
48 89.7 NT 101.9 95.8 89.7 NT 94.3 89.7 101.9 12.2
Average 12.8 8.3 0.7 72.4 28.1 7.7
Minimum -80.8 -75.6 -96.2 -26.3 -62.6 -100.0
Maximum 116.7 105.2 104.0 119.8 95.0 105.8
Range 197.6 180.8 200.2 146.1 157.6 205.8
CNS Cancer Cell Lines
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12 from cluster 4b was the most active compound against four of the six CNS cell lines 
(SF-268, SF-295, SF-539, and SNB-19) and was also the most active overall with an 
average growth percent of -65.2 across the six cell lines.  The C-8 alcohol compound 
(3S,8R)-1 from cluster 5 was most active against the SNB-75 cell line and the C-8 
mesylate ester compound 15 from cluster 7 was the most active against the U251 cell 
line.  Table 8.4 shows the growth percents for the compounds from the most active 
cluster against each cell line. 
 
 
Table 8.3 
 
 
Table 8.4 
 
3.6.2.3.  SAR Analysis of Amide Compounds against CNS Cancer Cell Lines 
 Across the set of amide compounds, there was considerable variability in activity 
against the different CNS cancer cell lines (Table 8.5).  Very little activity was seen 
against the SNB-19 and U251 cell lines with the lowest growth percent against each cell 
line being 78.9 and 51.9 respectively.  The effect of changing the amide group on the 
activity against the U251 cell line is less conclusive as only four of the amide compounds 
were screened against the U251 cell line. 
Compound ID Cluster SF-268 SF-295 SF-539 SNB-19 SNB-75 U251 Average Minimum Maximum Range
(3S,8R)-1 5 -23.4 -22.9 -90.6 12.8 -47.9 -53.2 -37.5 -90.6 12.8 103.3
11 5 56.3 NT 98.7 94.9 74.6 89.3 82.7 56.3 98.7 42.4
12 4b -64.3 -75.6 -95.6 -26.3 -37.5 -92.0 -65.2 -95.6 -26.3 69.4
13 8 18.5 31.4 21.4 95.4 30.3 51.9 41.5 18.5 95.4 76.9
14 9 -0.3 NT -7.8 85.8 14.8 21.9 22.9 -7.8 85.8 93.6
15 7 -49.7 -20.6 -56.6 6.0 -15.2 -96.2 -38.7 -96.2 6.0 102.3
48 6 89.7 NT 101.9 95.8 89.7 NT 94.3 89.7 101.9 12.2
Average 3.8 -21.9 -4.1 52.1 15.5 -13.1
Minimum -64.3 -75.6 -95.6 -26.3 -47.9 -96.2
Maximum 89.7 31.4 101.9 95.8 89.7 89.3
Range 154.0 107.0 197.5 122.1 137.6 185.5
CNS Cancer Cell Lines
SF-268 4b -NHSO2Me 12 -64.3
SF-295 4b -NHSO2Me 12 -75.6
SF-539 4b -NHSO2Me 12 -95.6
SNB-19 4b -NHSO2Me 12 -26.3
SNB-75 5 -OH (3S,8R )-1 -47.9
U251 7 -OSO2Me 15 -96.2
Cell Line
Most Active 
Cluster
C-8 Substituent Growth PercentCompound ID
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 The SF-539 cell line was very sensitive to the nature of the amide group as the 
growth percents ranged from -96.2 for compound 43 all the way up to 97.4 for compound 
40.  Of particular interest for this cell line is the difference in growth percents between 
pyrazyl compound 43 (GP = -96.2) and 2-pyridine compound 42 (GP = 23.1).  This 
seems to indicate that the second aromatic nitrogen atom in the pyrazyl compound is 
extremely important for activity.  Isoxazole compound 41 (GP = -50.4) and 2-furyl 
compound 44 (GP = -72.5) were the most active compounds against the SF-268 and SF-
295 cell lines respectively. 
 
 
Table 8.5 
 
Compound ID SF-268 SF-295 SF-539 SNB-19 SNB-75 U251 Average Minimum Maximum Range
13 18.5 31.4 21.4 95.4 30.3 51.9 41.5 18.5 95.4 76.9
37 56.5 NT 68.7 88.8 79.3 74.9 73.6 56.5 88.8 32.3
38 38.7 48.1 45.8 93.0 86.5 NT 62.4 38.7 93.0 54.3
39 74.9 NT 89.9 87.6 73.8 78.6 81.0 73.8 89.9 16.0
40 73.4 NT 97.4 97.8 79.9 NT 87.1 73.4 97.8 24.4
41 -50.4 NT -92.4 78.9 -20.4 NT -21.1 -92.4 78.9 171.3
42 3.5 NT 23.1 96.6 34.4 NT 39.4 3.5 96.6 93.0
43 -32.6 NT -96.2 80.0 -22.8 NT -17.9 -96.2 80.0 176.2
44 -16.8 -72.5 -73.4 83.5 0.0 NT -15.8 -73.4 83.5 156.9
45 10.2 -4.0 -12.6 99.8 24.5 NT 23.6 -12.6 99.8 112.4
46 11.6 17.3 -1.8 89.5 69.7 NT 37.3 -1.8 89.5 91.3
Average 17.1 4.1 6.4 90.1 39.6 68.4
Minimum -50.4 -72.5 -96.2 78.9 -22.8 51.9
Maximum 74.9 48.1 97.4 99.8 86.5 78.6
Range 125.3 120.7 193.6 20.8 109.3 26.7
CNS Cancer Cell Lines
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Chapter 9: Melanoma 
9.1  Melanoma Overview 
Our compounds were screened against nine different melanoma cell lines.  The average 
mean growth percent across the nine melanoma cell lines was -21.0.  As shown in Table 
3.4, our compounds had the most broad spectrum activity against melanoma as compared 
to the eight other classes of cancers cell lines.  Table 9.1 shows the average mean growth 
percent of our compounds against each of the nine melanoma cell lines screened.  Table 
9.1 also shows molecular characteristics and cell line source information for each of the 
nine cell lines.  The range of biological activity against the different cell lines was broad 
as the average mean growth percent was -58.2 against the LOX IMVI cell line as 
compared to 10.9 against the SK-MEL-28 cell line. 
 
Table 9.1 
Table 9.2 shows the results for each compound against each melanoma cell line.  
As discussed in section 3.3, the stereochemistry played a key role in the activity of the 
stereoisomers of Compound 1.  (3S,8R)-1 and (3S,8S)-1 had average growth percents of -
Cell Line
Average Mean 
Growth Percent
Mutations/variants166 TP53167
p53 Amino Acid 
Codon Change167
Antigen Expression
Patient 
Age
Sex Ethnicity
LOX IMVI -58.2 BRAF, CDKN2A wild-type wild-type N/A 58 Male N/A
SK-MEL-5 -40.3 BRAF, CDKN2A wild-type wild-type
Blood Type O, Rh+, HLA 
A2, A11, B40, Bw16
24 Female Caucasian
MALME-3M -30.4 BRAF, CDKN2A wild-type wild-type
HLA A2, Aw30, B13, 
B40(+/-), DRw7
43 Male Caucasian
SK-MEL-2 -24.3 TP53, NRAS 245 GGC → AGC G → S Blood Type A, Rh+ 60 Male Caucasian
UACC-257 -19.5 BRAF wild-type wild-type N/A N/A N/A N/A
MDA-MB-435 -15.5 TP53, BRAF, CDKN2A N/A N/A N/A N/A N/A N/A
M14 -6.6 TP53, BRAF, CDKN2A 266 GGA → GAA G → E N/A N/A N/A N/A
UACC-62 -5.3 BRAF, CDKN2A, PTEN wild-type wild-type N/A N/A N/A N/A
SK-MEL-28 10.9 TP53, BRAF, EGFR 145 TGT → GTT C → V
Blood Type A, Rh+, HLA 
A11, A26, B40, DRw4
51 Male N/A
Average -21.0
N/A: Data not available
BRAF: v-raf murine sarcoma viral oncogene homologue B1
CDKN2A: Cyclin-dependent kinase inhibitor 2A
EGFR: Epidermal growth factor receptor
NRAS: Neuroblastoma RAS viral (v-ras) oncogene homologue
PTEN: Phosphatase and tensin homologue
TP53: Tumor protein p53
Unless otherwise referenced above, cell line information was gathered from references 154-157.
Color Growth Percent
Most Active < -50
-50 to 0
0 to 50
Least Active > 50
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68.4 and -58.4 respectively against the melanoma cell lines screened.  (3R,8S)-1 and 
(3R,8R)-1 were significantly less active with average growth percents of 71.0 and 66.8 
respectively.  Lipophilicity was also shown to be important as Compound 9 (4 carbon 
length chain), (3S,8R)-1 (10 carbon length chain), and 10 (16 carbon length chain) had 
average growth percents of 107.7, -68.4, and -80.3 respectively.  Substituting an alcohol 
for the acetate at the C-3 position in (3S,8R)-1 produced a slightly more active compound 
as Compound 16 had an average growth percent of -74.2 as compared to -68.4 for 
(3S,8R)-1.   
 
 
 
Table 9.2 
9.2  Hansch Cluster Analysis on Lung Cancer Cell Lines Data 
Table 9.3 shows the melanoma testing results organized to assess the results per Hansch 
cluster analysis theory at the C-8 position.  As shown in the table, the range of activity is 
wide over the six clusters tested.  The alcohol compound (3S,8R)-1 from cluster 5 was 
the most active compound against the LOX IMVI, SK-MEL-28, and UACC-62 cell lines. 
Compound ID LOX IMVI MALME-3M M14 MDA-MB-435 SK-MEL-2 SK-MEL-28 SK-MEL-5 UACC-257 UACC-62 Average Minimum Maximum Range
(3R,8S)-1 NT -46.9 104.4 99.6 NT 100.9 NT NT 97.1 71.0 -46.9 104.4 151.2
(3S,8R)-1 -94.3 -59.8 -76.4 -53.0 -57.4 -75.8 -95.2 -3.6 -99.7 -68.4 -99.7 -3.6 96.0
(3R,8R)-1 NT -57.0 100.7 88.3 NT 97.8 NT 85.9 85.1 66.8 -57.0 100.7 157.7
(3S,8S)-1 NT -62.0 -26.3 -75.8 NT -58.9 NT -47.0 -80.3 -58.4 -80.3 -26.3 54.0
9 92.3 100.4 101.7 105.0 135.8 113.9 97.6 117.9 104.4 107.7 92.3 135.8 43.5
10 -91.9 -71.0 -83.8 -74.2 -86.7 -85.4 -97.8 -64.2 -67.6 -80.3 -97.8 -64.2 33.5
11 -93.3 7.3 8.1 -44.1 84.4 96.9 13.2 NT 64.9 17.2 -93.3 96.9 190.2
12 -93.5 -56.3 -78.3 -62.3 -73.6 -66.3 -98.9 -67.3 -68.7 -73.9 -98.9 -56.3 42.6
13 -90.5 -62.5 -87.3 -37.2 -33.6 -37.9 -87.0 -83.0 -51.2 -63.3 -90.5 -33.6 57.0
14 -82.1 -30.9 6.8 -25.3 -25.6 27.0 -65.9 NT -14.4 -26.3 -82.1 27.0 109.1
15 -89.4 -53.7 -83.6 -30.7 -58.8 -27.9 -99.8 -76.1 -72.0 -65.8 -99.8 -27.9 72.0
16 -91.9 -45.2 -93.3 -51.4 -69.0 -58.1 -99.9 -92.7 -66.2 -74.2 -99.9 -45.2 54.6
37 -66.7 -3.6 27.6 16.3 -35.0 69.1 14.1 41.3 44.9 12.0 -66.7 69.1 135.8
38 -68.6 -42.0 1.8 -30.0 -56.2 58.7 NT -48.2 -3.2 -23.5 -68.6 58.7 127.2
39 -32.8 18.0 27.3 40.8 NT 91.1 76.4 76.5 80.1 47.2 -32.8 91.1 123.9
40 11.1 89.4 39.7 62.9 49.5 102.1 NT 91.0 97.6 67.9 11.1 102.1 91.0
41 -69.8 -65.5 -37.0 -65.5 -79.7 -64.1 NT -89.7 -37.9 -63.6 -89.7 -37.0 52.7
42 -71.3 -69.5 -24.6 -57.7 -55.3 -30.3 NT -62.3 -19.7 -48.8 -71.3 -19.7 51.6
43 -77.0 -68.2 -47.0 -56.8 -52.3 -65.9 NT -77.7 -40.7 -60.7 -77.7 -40.7 37.0
44 -81.7 -68.7 -19.6 -56.3 -49.7 -42.2 NT -77.6 -22.0 -52.2 -81.7 -19.6 62.1
45 -67.7 -60.0 0.2 -51.1 -44.2 -41.0 NT -56.2 -40.5 -45.1 -67.7 0.2 68.0
46 -75.8 -50.7 6.3 -49.0 -51.2 54.1 NT -32.8 -47.4 -30.8 -75.8 54.1 129.8
47 -69.3 -65.4 -21.5 -57.4 -46.1 1.6 NT -43.4 -69.7 -46.4 -69.7 1.6 71.3
48 81.8 93.4 95.4 94.0 117.7 103.4 NT 99.8 99.9 98.2 81.8 117.7 35.9
Average -58.2 -30.4 -6.6 -15.5 -24.3 10.9 -40.3 -19.5 -5.3
Minimum -94.3 -71.0 -93.3 -75.8 -86.7 -85.4 -99.9 -92.7 -99.7
Maximum 92.3 100.4 104.4 105.0 135.8 113.9 97.6 117.9 104.4
Range 186.6 171.4 197.7 180.8 222.5 199.3 197.5 210.7 204.1
NT = Not Tested
Color Growth Percent
Most Active < -50
-50 to 0
0 to 50
Least Active > 50
Melanoma Cell Lines
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The phenyl amide compound 13 from cluster 8 was the most active against the MALME-
3M, M14 and UACC-257 cell lines.   The mesyl amide compound 12 from cluster 4b was 
the most active against the MDA-MB-435 and SK-MEL-2 cell lines.   The mesyl ester 
compound 15 from cluster 7 was the most active against the SK-MEL-5 cell line.   
Across the whole set of melanoma cell lines tested, compound 12 from cluster 4b was the 
most active with an average growth percent of -73.9.  On the other end of the activity 
spectrum, the isothiocyanate compound 48 from cluster 6 was the least active compound 
against all of the melanoma cell lines which it was screened against.   
 
 
Table 9.3 
 
 
Table 9.4 
9.3  SAR Analysis of Amide Compounds against Melanoma Cell Lines 
Eleven of the compounds we had tested by NCI have an acetate at the C-3 position and 
different amide functionalities with aromatic or heteroaromatic groups directly connected 
to the amide carbonyl group in the C-8 position as shown in Figure 9.1. 
Compound ID Cluster LOX IMVI MALME-3M M14 MDA-MB-435 SK-MEL-2 SK-MEL-28 SK-MEL-5 UACC-257 UACC-62 Average Minimum Maximum Range
(3S,8R)-1 5 -94.3 -59.8 -76.4 -53.0 -57.4 -75.8 -95.2 -3.6 -99.7 -68.4 -99.7 -3.6 96.0
11 5 -93.3 7.3 8.1 -44.1 84.4 96.9 13.2 NT 64.9 17.2 -93.3 96.9 190.2
12 4b -93.5 -56.3 -78.3 -62.3 -73.6 -66.3 -98.9 -67.3 -68.7 -73.9 -98.9 -56.3 42.6
13 8 -90.5 -62.5 -87.3 -37.2 -33.6 -37.9 -87.0 -83.0 -51.2 -63.3 -90.5 -33.6 57.0
14 9 -82.1 -30.9 6.8 -25.3 -25.6 27.0 -65.9 NT -14.4 -26.3 -82.1 27.0 109.1
15 7 -89.4 -53.7 -83.6 -30.7 -58.8 -27.9 -99.8 -76.1 -72.0 -65.8 -99.8 -27.9 72.0
48 6 81.8 93.4 95.4 94.0 117.7 103.4 NT 99.8 99.9 98.2 81.8 117.7 35.9
Average -65.9 -23.2 -30.7 -22.7 -6.7 2.8 -72.3 -26.0 -20.2
Minimum -94.3 -62.5 -87.3 -62.3 -73.6 -75.8 -99.8 -83.0 -99.7
Maximum 81.8 93.4 95.4 94.0 117.7 103.4 13.2 99.8 99.9
Range 176.1 155.9 182.7 156.3 191.3 179.2 113.0 182.7 199.6
NT = Not Tested
Melanoma Cell Lines
LOX IMVI 5 -OH (3S,8R )-1 -94.3
MALME-3M 8 -NHCOPh 13 -62.5
M14 8 -NHCOPh 13 -87.3
MDA-MB-435 4b -NHSO2Me 12 -62.3
SK-MEL-2 4b -NHSO2Me 12 -73.6
SK-MEL-28 5 -OH (3S,8R )-1 -75.8
SK-MEL-5 7 -OSO2Me 15 -99.8
UACC-257 8 -NHCOPh 13 -83.0
UACC-62 5 -OH (3S,8R )-1 -99.7
Cell Line
Most Active 
Cluster
C-8 Substituent Growth PercentCompound ID
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Figure 9.1  Generic structure of amides screened by NCI. 
 Table 9.5 shows the activity of our amide compounds against each of the different 
melanoma cell lines.  The set of amide compounds showed a wide range of activity 
against the different cell lines indicating that changing the amide R group has a 
significant impact on activity.  The widest range of activity was seen against the UACC-
257 cell line in which compound 13 (R = phenyl) had a growth percent of -83.0 whereas 
compound 40 (R = 3,5 dichlorophenyl) had a growth percent of 91.0.   
 
 
 
Table 9.5 
 
Compound ID LOX IMVI MALME-3M M14 MDA-MB-435 SK-MEL-2 SK-MEL-28 SK-MEL-5 UACC-257 UACC-62 Average Minimum Maximum Range
13 -90.5 -62.5 -87.3 -37.2 -33.6 -37.9 -87.0 -83.0 -51.2 -63.3 -90.5 -33.6 57.0
37 -66.7 -3.6 27.6 16.3 -35.0 69.1 14.1 41.3 44.9 12.0 -66.7 69.1 135.8
38 -68.6 -42.0 1.8 -30.0 -56.2 58.7 NT -48.2 -3.2 -23.5 -68.6 58.7 127.2
39 -32.8 18.0 27.3 40.8 NT 91.1 76.4 76.5 80.1 47.2 -32.8 91.1 123.9
40 11.1 89.4 39.7 62.9 49.5 102.1 NT 91.0 97.6 67.9 11.1 102.1 91.0
41 -69.8 -65.5 -37.0 -65.5 -79.7 -64.1 NT -89.7 -37.9 -63.6 -89.7 -37.0 52.7
42 -71.3 -69.5 -24.6 -57.7 -55.3 -30.3 NT -62.3 -19.7 -48.8 -71.3 -19.7 51.6
43 -77.0 -68.2 -47.0 -56.8 -52.3 -65.9 NT -77.7 -40.7 -60.7 -77.7 -40.7 37.0
44 -81.7 -68.7 -19.6 -56.3 -49.7 -42.2 NT -77.6 -22.0 -52.2 -81.7 -19.6 62.1
45 -67.7 -60.0 0.2 -51.1 -44.2 -41.0 NT -56.2 -40.5 -45.1 -67.7 0.2 68.0
46 -75.8 -50.7 6.3 -49.0 -51.2 54.1 NT -32.8 -47.4 -30.8 -75.8 54.1 129.8
Average -62.8 -34.8 -10.2 -25.8 -40.8 8.5 1.2 -29.0 -3.6
Minimum -90.5 -69.5 -87.3 -65.5 -79.7 -65.9 -87.0 -89.7 -51.2
Maximum 11.1 89.4 39.7 62.9 49.5 102.1 76.4 91.0 97.6
Range 101.6 158.9 127.0 128.4 129.2 168.0 163.3 180.6 148.8
NT = Not Tested
Color Growth Percent
Most Active < -50
-50 to 0
0 to 50
Least Active > 50
Melanoma Cell Lines
Figure Key
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Chapter 10: Lung Cancer 
10.1  Lung Cancer Overview 
Our compounds were screened against eight different lung cancer cell lines.  The average 
mean growth percent across the eight lung cancer cell lines was 5.2.  Table 10.1 shows 
the average mean growth percent of our compounds against each of the eight lung cancer 
cell lines screened.  Figure 3.X also shows molecular characteristics and cell line source 
information for each of the eight cell lines.  The range of biological activity against the 
different cell lines was broad as the average mean growth percent was -50.7 against the 
NCI-H522 cell line as compared to 79.9 against the NCI-H322M cell line. 
 
 
Table 10.1 
 
Table 10.2 shows the results for each compound against each lung cancer cell 
line.  As discussed in section 3.3, the stereochemistry played a key role in the activity of 
the stereoisomers of Compound 1.  (3S,8R)-1 and (3S,8S)-1 had average growth percents 
of -54.5 and -43.0 respectively against the breast cancer cell lines screened.  (3R,8S)-1 
and (3R,8R)-1 were significantly less active with average growth percents of 96.2 and 
89.5 respectively.  Lipophilicity was also shown to be important as Compound 9 (4 
carbon length chain), (3S,8R)-1 (10 carbon length chain), and 10 (16 carbon length chain) 
had average growth percents of 100.6, -54.5, and -34.3 respectively.  Substituting an 
Cell Line
Average Mean 
Growth Percent
Cancer Type Mutations/Variants166
p53 sequence codon 
change167
p53 sequence amino 
acid change167
Patient 
Age
Sex Ethnicity
NCI-H522 -50.7 Adenocarcinoma (Stage 2) TP53 deletion 191 G deletion 191 G 58 Male N/A
HOP-92 -44.2 Large cell, undifferentiated TP53, CDKN2A 175 CGC → CTC 175 R → L 62 Male N/A
NCI-H226 -8.9 Squamous cell carcinoma, mesothelioma CDKN2A 309 CCC → GCC 309 P → A N/A Male N/A
HOP-62 -2.2 Adenocarcinoma TP53, CDKN2A, KRAS insertion 212-225 insertion 212-225 60 Female N/A
NCI-H23 -1.9 Adenocarcinoma TP53, STK11, KRAS 246 ATG → ATC 246 M → I 51 Male Black
NCI-H460 22.3 Large cell, carcinoma CDKN2A, KRAS, PIK3CA, STK11 wild-type wild-type N/A Male N/A
A549/ATCC 47.1 Adenocarcinoma CDKN2A, KRAS, STK11 wild-type wild-type 58 Male Caucasian
NCI-H322M 79.9 Small cell bronchoalveolar carcinoma TP53 248 CGG → CTG 248 R → L 52 Male Caucasian
Average 5.2
N/A: Data not available
CDKN2A: Cyclin-dependent kinase inhibitor 2A
KRAS: v-Ki-ras2 Kirsten rat sarcoma viral oncogene homologue
PIK3CA: Phosphoinositide-3-kinase, catalytic, α polypeptide
STK11: Serine/threonine kinase 11/LKB1 (Peutz-Jehgers syndrome)
TP53: Tumor protein p53
Unless otherwise referenced above, cell line information was gathered from references 154-157.
Color Growth Percent
Most Active < -50
-50 to 0
0 to 50
Least Active > 50
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alcohol for the acetate at the C-3 position in (3S,8R)-1 produced little change in the 
average growth percent as Compound 16 had an average growth percent of -54.7 as 
compared to -54.5 for (3S,8R)-1.   
 
Table 10.2 
 
 
10.2  Hansch Cluster Analysis on Lung Cancer Cell Lines Data 
 
Table 10.3 shows the lung cancer testing results organized to assess the results per 
Hansch cluster analysis theory at the C-8 position.  As shown in the table, the range of 
activity is wide over the six clusters tested.  The alcohol compound (3S,8R)-1 from 
cluster 5 was the most active compound against the HOP-62, NCI-H226, NCI-H23, and 
NCI-H460 cell lines. The mesyl amide compound 12 from cluster 4b was the most active 
against the A549/ATCC and NCI-H522 cell lines.   The mesyl ester compound 15 from 
cluster 7 was the most active against the HOP-92 and NCI-H322M cell lines.   Across the 
whole set of lung cancer cell lines tested, compound (3S,8R)-1 from cluster 5 was the 
most active with an average growth percent of -54.5.  On the other end of the activity 
Compound ID A549/ATCC HOP-62 HOP-92 NCI-H226 NCI-H23 NCI-H322M NCI-H460 NCI-H522 Average Minimum Maximum Range
(3R,8S)-1 110.9 107.9 NT 82.6 103.7 87.6 101.6 78.7 96.2 78.7 110.9 32.2
(3S,8R)-1 -15.5 -93.3 -72.6 -60.5 -81.8 38.7 -54.9 -96.4 -54.5 -96.4 38.7 135.1
(3R,8R)-1 89.9 96.3 NT 75.6 105.7 96.9 101.2 60.8 89.5 60.8 105.7 44.9
(3S,8S)-1 6.9 -84.7 NT -67.5 -63.8 33.9 -35.8 -90.1 -43.0 -90.1 33.9 124.1
9 108.6 118.1 52.7 92.9 94.3 116.3 103.2 119.1 100.6 52.7 119.1 66.4
10 0.5 -88.5 -71.2 -66.6 -43.9 98.5 -18.6 -84.7 -34.3 -88.5 98.5 187.0
11 103.2 44.9 NT NT 13.1 107.0 96.3 NT 72.9 13.1 107.0 93.8
12 -37.7 -32.8 -66.2 -50.9 -71.8 6.2 -49.4 -97.2 -50.0 -97.2 6.2 103.5
13 43.3 -19.7 -61.4 -38.2 -35.7 99.6 -14.9 -79.5 -13.3 -79.5 99.6 179.1
14 50.2 -60.4 NT NT -7.1 95.4 22.9 NT 20.2 -60.4 95.4 155.8
15 -19.9 -15.5 -75.6 -42.3 -47.1 -36.5 -35.8 -87.5 -45.0 -87.5 -15.5 71.9
16 -44.6 -72.9 -71.5 -26.3 -66.0 -5.3 -55.9 -94.9 -54.7 -94.9 -5.3 89.6
37 92.6 59.8 -29.5 -12.1 9.6 112.2 51.4 -78.0 25.7 -78.0 112.2 190.1
38 71.7 5.1 -54.2 NT -2.9 93.6 31.1 -94.3 7.2 -94.3 93.6 187.9
39 80.5 105.6 45.7 6.9 30.3 103.6 70.1 -24.4 52.3 -24.4 105.6 130.0
40 101.6 107.4 86.2 NT 44.9 104.4 98.9 -34.0 72.8 -34.0 107.4 141.5
41 25.5 -77.2 NT NT -16.9 84.8 2.2 -95.7 -12.9 -95.7 84.8 180.5
42 38.0 -40.5 -78.3 NT -16.2 94.1 7.4 -75.3 -10.1 -78.3 94.1 172.3
43 10.5 -43.0 -78.0 NT -27.1 82.1 -14.6 -90.1 -22.9 -90.1 82.1 172.1
44 18.3 -47.3 -79.4 NT -0.6 87.2 -25.9 -84.9 -18.9 -84.9 87.2 172.0
45 40.0 -54.5 -75.2 NT -26.3 97.0 5.1 -93.2 -15.3 -93.2 97.0 190.2
46 82.0 11.0 NT NT -16.8 97.8 27.1 -96.8 17.4 -96.8 97.8 194.6
47 72.1 -80.9 -78.3 NT -18.7 109.6 22.0 -74.3 -6.9 -80.9 109.6 190.5
48 102.4 103.1 NT NT 95.5 112.4 99.5 98.2 101.8 95.5 112.4 17.0
Average 47.1 -2.2 -44.2 -8.9 -1.9 79.9 22.3 -50.7
Minimum -44.6 -93.3 -79.4 -67.5 -81.8 -36.5 -55.9 -97.2
Maximum 110.9 118.1 86.2 92.9 105.7 116.3 103.2 119.1
Range 155.5 211.4 165.5 160.4 187.5 152.8 159.1 216.3
NT = Not Tested
Color Growth Percent
Most Active < -50
-50 to 0
0 to 50
Least Active > 50
Lung Cancer Cell Line
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spectrum, the isothiocyanate compound 48 from cluster 6 was the least active compound 
against all of the lung cancer cell lines which it was screened against.   
 
Table 10.3 
 
Table 10.4 
 
10.3  SAR Analysis of Amide Compounds against Lung Cancer Cell Lines 
 
Eleven of the compounds we had tested by NCI have an acetate at the C-3 position and 
different amide functionalities with aromatic or heteroaromatic groups directly connected 
to the amide carbonyl group in the C-8 position as shown in Figure 10.1. 
 
Figure 10.1  Generic structure of amides screened by NCI. 
 Table 10.5 shows the activity of our amide compounds against each of the 
different lung cancer cell lines.  The set of amide compounds showed a wide range of 
activity against the different cell lines indicating that changing the amide R group has a 
significant impact on activity.  The only cell line in which the R group appeared to have 
Compound ID Cluster A549/ATCC HOP-62 HOP-92 NCI-H226 NCI-H23 NCI-H322M NCI-H460 NCI-H522 Average Minimum Maximum Range
(3S,8R)-1 5 -15.5 -93.3 -72.6 -60.5 -81.8 38.7 -54.9 -96.4 -54.5 -96.4 38.7 135.1
11 5 103.2 44.9 NT NT 13.1 107.0 96.3 NT 72.9 13.1 107.0 93.8
12 4b -37.7 -32.8 -66.2 -50.9 -71.8 6.2 -49.4 -97.2 -50.0 -97.2 6.2 103.5
13 8 43.3 -19.7 -61.4 -38.2 -35.7 99.6 -14.9 -79.5 -13.3 -79.5 99.6 179.1
14 9 50.2 -60.4 NT NT -7.1 95.4 22.9 NT 20.2 -60.4 95.4 155.8
15 7 -19.9 -15.5 -75.6 -42.3 -47.1 -36.5 -35.8 -87.5 -45.0 -87.5 -15.5 71.9
48 6 102.4 103.1 NT NT 95.5 112.4 99.5 98.2 101.8 95.5 112.4 17.0
Average 32.3 -10.5 -69.0 -48.0 -19.3 60.4 9.1 -52.5
Minimum -37.7 -93.3 -75.6 -60.5 -81.8 -36.5 -54.9 -97.2
Maximum 103.2 103.1 -61.4 -38.2 95.5 112.4 99.5 98.2
Range 141.0 196.4 14.2 22.3 177.2 148.9 154.4 195.4
NT = Not Tested
Lung Cancer Cell Line
A549/ATCC 4b -NHSO2Me 12 -37.7
HOP-62 5 -OH (3S,8R )-1 -93.3
HOP-92 7 -OSO2Me 15 -75.6
NCI-H226 5 -OH (3S,8R )-1 -60.5
NCI-H23 5 -OH (3S,8R )-1 -81.8
NCI-H322M 7 -OSO2Me 15 -36.5
NCI-H460 5 -OH (3S,8R )-1 -54.9
NCI-H522 4b -NHSO2Me 12 -97.2
Cell Line
Most Active 
Cluster
C-8 Substituent Compound ID Growth Percent
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little effect on activity was the NCI-H322M cell line against which there was negligible 
activity across all of the amide compounds with an average mean growth percent of 96.0.  
On the other end of the activity spectrum, the average mean growth percent was -76.9 
against the NCI-H522 cell line.  It would be interesting to evaluate the cellular 
differences between the NCI-H322 and NCI-H522 cell lines as it could help elucidate a 
possible mechanism of action for this class of compounds. The widest range of activity 
was seen against the HOP-92 cell line in which furan compound 44 had a growth percent 
of -79.4 whereas m-bromo compound 40 had a growth percent of 86.2. 
 
Table 10.5 
 
 
Compound ID A549/ATCC HOP-62 HOP-92 NCI-H226 NCI-H23 NCI-H322M NCI-H460 NCI-H522 Average Minimum Maximum Range
13 43.3 -19.7 -61.4 -38.2 -35.7 99.6 -14.9 -79.5 -13.3 -79.5 99.6 179.1
37 92.6 59.8 -29.5 -12.1 9.6 112.2 51.4 -78.0 25.7 -78.0 112.2 190.1
38 71.7 5.1 -54.2 NT -2.9 93.6 31.1 -94.3 7.2 -94.3 93.6 187.9
39 80.5 105.6 45.7 6.9 30.3 103.6 70.1 -24.4 52.3 -24.4 105.6 130.0
40 101.6 107.4 86.2 NT 44.9 104.4 98.9 -34.0 72.8 -34.0 107.4 141.5
41 25.5 -77.2 NT NT -16.9 84.8 2.2 -95.7 -12.9 -95.7 84.8 180.5
42 38.0 -40.5 -78.3 NT -16.2 94.1 7.4 -75.3 -10.1 -78.3 94.1 172.3
43 10.5 -43.0 -78.0 NT -27.1 82.1 -14.6 -90.1 -22.9 -90.1 82.1 172.1
44 18.3 -47.3 -79.4 NT -0.6 87.2 -25.9 -84.9 -18.9 -84.9 87.2 172.0
45 40.0 -54.5 -75.2 NT -26.3 97.0 5.1 -93.2 -15.3 -93.2 97.0 190.2
46 82.0 11.0 NT NT -16.8 97.8 27.1 -96.8 17.4 -96.8 97.8 194.6
Average 54.9 0.6 -36.0 -14.5 -5.2 96.0 21.6 -76.9
Minimum 10.5 -77.2 -79.4 -38.2 -35.7 82.1 -25.9 -96.8
Maximum 101.6 107.4 86.2 6.9 44.9 112.2 98.9 -24.4
Range 91.0 184.7 165.5 45.1 80.7 30.1 124.8 72.5
NT = Not Tested
Lung Cancer Cell Lines
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Chapter 11: Leukemia 
11.1  Leukemia Overview 
Our compounds were screened against six different leukemia cell lines.  The average 
mean growth percent across the six leukemia cell lines was 20.4.  Table 11.1 shows the 
average mean growth percent of our compounds against each of the leukemia cell lines 
screened.  Figure 3.X also shows molecular characteristics and cell line source 
information for each cell line.  Compared to the other cancer types, our compounds on 
average had a very narrow range of activity against the different leukemia cell lines with 
the most active average mean growth percent of 14.7 and the least active average mean 
growth percent of 25.3 against the MOLT-4 and K-562 cell lines respectively. 
 
 
Table 11.1 
Table 11.2 shows the results for each compound against each leukemia cell line.  
As discussed in section 3.3, the stereochemistry played a key role in the activity of the 
stereoisomers of Compound 1.  (3S,8R)-1 and (3S,8S)-1 had average growth percents of -
7.5 and -12.5 respectively against the colon cancer cell lines screened.  (3R,8S)-1 and 
(3R,8R)-1 were significantly less active with average growth percents of 89.1 and 69.1 
respectively.  Lipophilicity was also shown to be important as Compound 9 (4 carbon 
length chain), (3S,8R)-1 (10 carbon length chain), and 10 (16 carbon length chain) had 
Cell Line
Average Mean 
Growth Percent
Cancer Type Mutations/Variants166
p53 sequence 
codon change167
p53 sequence amino 
acid change167
Patient 
Age
Sex Ethnicity
MOLT-4 14.7 Acute Lymphoblastic Leukemia (ALL) TP53, CDKN2A, NRAS, PTEN, STK11 wild-type wild-type 19 Male N/A
RPMI-8226 17.3 Plasmacytoma; myeloma TP53, KRAS, EGFR 285 GAG → AAG 285 E → L 61 Male N/A
CCRF-CEM 18.7 Acute Lymphoblastic Leukemia (ALL) TP53, CDKN2A, KRAS, PTEN, FLT3 248 CGG → CAG 248 R → Q 4 Female Caucasian
HL-60(TB) 21.2 Acute Promyelocytic Leukemia TP53, CDKN2A, NRAS 248 CGG → CTG 248 R → L 36 Female Caucasian
SR 25.3 Large Cell Immunoblastic Lymphoma CDKN2A wild-type wild-type 11 Male Caucasian
K-562 25.3 Chronic Myelogenous Leukemia (CML) TP53, CDKN2A, PDGFRA N/A N/A 53 Female N/A
Average 20.4
N/A: Data not available
CDKN2A: Cyclin-dependent kinase inhibitor 2A
EGFR: Epidermal growth factor receptor
FLT3: fms-related tyrosine kinase 3
KRAS: v-Ki-ras2 Kirsten rat sarcoma viral oncogene homologue
NRAS: Neuroblastoma RAS viral (v-ras) oncogene homologue
PDGFRA: Platelet-derived growth factor receptor, α polypeptide
PTEN: Phosphatase and tensin homologue
STK11: Serine/threonine kinase 11/LKB1 (Peutz-Jehgers syndrome)
TP53: Tumor protein p53
Unless otherwise referenced above, cell line information was gathered from references 154-157.
Color Growth Percent
Most Active < -50
-50 to 0
0 to 50
Least Active > 50
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average growth percents of 108.2, -7.5, and -10.4 respectively.  Substituting an alcohol 
for the acetate at the C-3 position in (3S,8R)-1 produced a significant change in the 
average growth percent as Compound 16 had an average growth percent of -29.2 as 
compared to -7.5 for (3S,8R)-1.   
 
 
 
Table 11.2 
 
11.2  Hansch Cluster Analysis on Leukemia Cell Lines Data 
Table 11.3 shows the leukemia testing results organized to assess the results per Hansch 
cluster analysis theory at the C-8 position.  As shown in the table, the range of activity is 
wide over the six clusters tested.  The mesyl amide compound 12 from cluster 4b was the 
most active compound against CCRF-CEM, K-562, MOLT-4, and SR cell lines. The 
phenyl amide compound 13 from cluster 8 was the most active against the HL-60(TB) 
cell line.  The alcohol compound (3S,8R)-1 from cluster 5 was the most active against the 
Compound ID CCRF-CEM HL-60(TB) K-562 MOLT-4 RPMI-8226 SR Average Minimum Maximum Range
(3R,8S )-1 95.1 84.0 98.3 82.9 87.0 87.1 89.1 82.9 98.3 15.4
(3S,8R )-1 1.4 -13.8 7.7 -3.4 -25.4 -11.6 -7.5 -25.4 7.7 33.1
(3R,8R )-1 63.1 82.8 76.8 57.8 71.2 62.9 69.1 57.8 82.8 25.0
(3S,8S )-1 -9.7 -26.5 1.4 -11.4 -14.9 -14.0 -12.5 -26.5 1.4 27.9
9 111.8 108.6 103.5 103.1 111.0 111.3 108.2 103.1 111.8 8.7
10 3.3 -32.8 3.9 -3.3 1.1 -34.9 -10.4 -34.9 3.9 38.8
11 8.6 68.7 9.9 12.8 5.7 22.3 21.3 5.7 68.7 63.0
12 -20.4 -12.1 2.0 -19.6 -19.2 -26.9 -16.0 -26.9 2.0 28.9
13 4.5 -31.7 10.0 -0.4 -12.6 NT -6.0 -31.7 10.0 41.7
14 10.4 19.7 15.2 17.8 3.9 20.1 14.5 3.9 20.1 16.2
15 1.5 -7.3 5.1 5.8 -14.9 NT -2.0 -14.9 5.8 20.8
16 -27.5 -65.3 -7.9 -11.8 -33.6 NT -29.2 -65.3 -7.9 57.4
37 NT 44.1 34.4 9.6 34.2 40.9 32.6 9.6 44.1 34.5
38 14.2 17.5 19.2 7.4 NT 22.0 16.0 7.4 22.0 14.6
39 NT 78.9 45.5 10.9 49.3 63.9 49.7 10.9 78.9 68.1
40 24.9 81.0 57.7 9.9 NT 57.6 46.2 9.9 81.0 71.1
41 2.8 -4.5 2.9 4.3 NT 7.8 2.7 -4.5 7.8 12.3
42 NT 1.7 3.8 3.6 NT 5.1 3.6 1.7 5.1 3.4
43 5.7 -1.2 1.8 -0.3 NT 7.7 2.7 -1.2 7.7 9.0
44 5.8 -5.7 4.9 3.9 NT 13.0 4.4 -5.7 13.0 18.6
45 8.5 4.0 9.7 5.8 NT 19.4 9.5 4.0 19.4 15.4
46 7.7 34.2 10.5 3.7 NT 10.1 13.2 3.7 34.2 30.4
47 NT 1.5 1.3 0.3 NT 1.2 1.1 0.3 1.5 1.3
48 62.8 82.9 90.4 64.0 NT 65.9 73.2 62.8 90.4 27.6
Average 18.7 21.2 25.3 14.7 17.3 25.3
Minimum -27.5 -65.3 -7.9 -19.6 -33.6 -34.9
Maximum 111.8 108.6 103.5 103.1 111.0 111.3
Range 139.3 173.9 111.3 122.7 144.7 146.1
NT = Not Tested
Color Growth Percent
Most Active < -50
-50 to 0
0 to 50
Least Active > 50
Leukemia Cell Line
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RPMI-8226 cell line.   Across the whole set of leukemia cell lines tested, compound 12 
from cluster 4b was the most active with an average growth percent of -16.0.  On the 
other end of the activity spectrum, the isothiocyanate compound 48 from cluster 6 was 
the least active compound against all of the leukemia cell lines which it was screened 
against.   
 
 
Table 11.3 
 
Table 11.4 
 
11.3  SAR Analysis of Amide Compounds against Leukemia Cell Lines 
 
Eleven of the compounds we had tested by NCI have an acetate at the C-3 position and 
different amide functionalities with aromatic or heteroaromatic groups directly connected 
to the amide carbonyl group in the C-8 position as shown in Figure 11.1. 
 
Figure 11.1  Generic structure of amides screened by NCI. 
Compound ID Cluster CCRF-CEM HL-60(TB) K-562 MOLT-4 RPMI-8226 SR Average Minimum Maximum Range
(3S,8R )-1 5 1.4 -13.8 7.7 -3.4 -25.4 -11.6 -7.5 -25.4 7.7 33.1
11 5 8.6 68.7 9.9 12.8 5.7 22.3 21.3 5.7 68.7 63.0
12 4b -20.4 -12.1 2.0 -19.6 -19.2 -26.9 -16.0 -26.9 2.0 28.9
13 8 4.5 -31.7 10.0 -0.4 -12.6 NT -6.0 -31.7 10.0 41.7
14 9 10.4 19.7 15.2 17.8 3.9 20.1 14.5 3.9 20.1 16.2
15 7 1.5 -7.3 5.1 5.8 -14.9 NT -2.0 -14.9 5.8 20.8
48 6 62.8 82.9 90.4 64.0 NT 65.9 73.2 62.8 90.4 27.6
Average 9.8 15.2 20.0 11.0 -10.4 14.0
Minimum -20.4 -31.7 2.0 -19.6 -25.4 -26.9
Maximum 62.8 82.9 90.4 64.0 5.7 65.9
Range 83.2 114.6 88.4 83.5 31.1 92.8
NT = Not Tested
Leukemia Cell Line
CCRF-CEM 4b -NHSO2Me 12 -20.4
HL-60(TB) 8 -NHCOPh 13 -31.7
K-562 4b -NHSO2Me 12 2.0
MOLT-4 4b -NHSO2Me 12 -19.6
RPMI-8226 5 -OH (3S,8R )-1 -25.4
SR 4b -NHSO2Me 12 -26.9
Cell Line
Most Active 
Cluster
C-8 Substituent Compound ID Growth Percent
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 Table 11.5 shows the activity of our amide compounds against each of the 
different leukemia cell lines. The widest range of activity was seen against the HL-
60(TB) cell line in which compound 13 (R = phenyl) had a growth percent of -31.7 
whereas compound 40 (R = 3,5 dichlorophenyl) had a growth percent of 81.0.  On the 
other hand, the R group appeared to have little influence on the anticancer activity against 
the CCRF-CEM and MOLT-4 cell lines.  The range of activity against the CCRF-CEM 
and MOLT-4 cell lines was very narrow with range values of 22.1 and 11.2 respectively.   
 
 
Table 11.5 
Compound ID CCRF-CEM HL-60(TB) K-562 MOLT-4 RPMI-8226 SR Average Minimum Maximum Range
13 4.5 -31.7 10.0 -0.4 -12.6 NT -6.0 -31.7 10.0 41.7
37 NT 44.1 34.4 9.6 34.2 40.9 32.6 9.6 44.1 34.5
38 14.2 17.5 19.2 7.4 NT 22.0 16.0 7.4 22.0 14.6
39 NT 78.9 45.5 10.9 49.3 63.9 49.7 10.9 78.9 68.1
40 24.9 81.0 57.7 9.9 NT 57.6 46.2 9.9 81.0 71.1
41 2.8 -4.5 2.9 4.3 NT 7.8 2.7 -4.5 7.8 12.3
42 NT 1.7 3.8 3.6 NT 5.1 3.6 1.7 5.1 3.4
43 5.7 -1.2 1.8 -0.3 NT 7.7 2.7 -1.2 7.7 9.0
44 5.8 -5.7 4.9 3.9 NT 13.0 4.4 -5.7 13.0 18.6
45 8.5 4.0 9.7 5.8 NT 19.4 9.5 4.0 19.4 15.4
46 7.7 34.2 10.5 3.7 NT 10.1 13.2 3.7 34.2 30.4
Average 9.3 19.8 18.2 5.3 23.6 24.8
Minimum 2.8 -31.7 1.8 -0.4 -12.6 5.1
Maximum 24.9 81.0 57.7 10.9 49.3 63.9
Range 22.1 112.7 55.9 11.2 62.0 58.8
NT = Not Tested
Color Growth Percent
Most Active < -50
-50 to 0
0 to 50
Least Active > 50
Leukemia Cell Lines
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Chapter 12: Colon Cancer 
12.1 Colon Cancer Overview 
Our compounds were screened against seven different colon cancer cell lines.  The 
average mean growth percent across the seven colon cancer cell lines was 0.9.  Table 
12.1 shows the average mean growth percent of our compounds against each of the seven 
colon cancer cell lines screened.  Table 12.1 also shows molecular characteristics and cell 
line source information for each of the seven cell lines.  
 
 
Table 12.1 
 
Table 12.2 shows the results for each compound against each colon cancer cell 
line.  As discussed in section 3.3, the stereochemistry played a key role in the activity of 
the stereoisomers of Compound 1.  (3S,8R)-1 and (3S,8S)-1 had average growth percents 
of -74.1 and -59.1 respectively against the colon cancer cell lines screened.  (3R,8S)-1 
and (3R,8R)-1 were significantly less active with average growth percents of 104.9 and 
92.9 respectively.  Lipophilicity was also shown to be important as Compound 9 (4 
carbon length chain), (3S,8R)-1 (10 carbon length chain), and 10 (16 carbon length chain) 
had average growth percents of 104.2, -74.1, and -75.4 respectively.  Substituting an 
alcohol for the acetate at the C-3 position in (3S,8R)-1 produced little change in the 
Cell Line
Average Mean 
Growth Percent
Cancer Type Mutations/Variants166 p53 sequence codon change167
p53 sequence amino 
acid change167
Patient 
Age
Sex Ethnicity
HCC-2998 -20.7 Adenocarcinoma TP53, APC, RB1 213 CGA → TGA 175 R → STOP N/A N/A N/A
HCT-116 -19.1 Colorectal carcinoma CDKN2A, CTNNB1, KRAS, PIK3CA, BRCA2 wild-type wild-type N/A Male N/A
COLO 205 -11.9 Dukes' type D, colorectal adenocarcinoma TP53, APC, BRAF, SMAD4 266 GGA → GAA 175 G → E 70 Male Caucasian
SW-620 -7.6 Dukes' type C, colorectal adenocarcinoma TP53, APC, KRAS 273 CGT → CAT 273 R → H 51 Male Caucasian
HCT-15 9.2 Dukes' type C, colorectal adenocarcinoma TP53, APC, KRAS, PIK3CA, BRCA2 wild-type or 153 CCC → GCC wild-type or 153 P → A N/A Male N/A
KM12 17.2 Adenocarcinoma, Grade III TP53, APC, PTEN, BRCA2 179 CAT → CGT 179 H → R N/A N/A N/A
HT29 38.9 Colorectal adenocarcinoma TP53, APC, BRAF, PIK3CA, SMAD4 273 CGT → CAT 273 R → H 44 Female Caucasian
Average 0.9
N/A: Data not available
APC: Adenomatous polyposis coli
BRAF: v-raf murine sarcoma viral oncogene homologue B1
BRCA2: Familial breast/ovarian cancer gene 2
CDKN2A: Cyclin-dependent kinase inhibitor 2A
CTNNB1: Catenin (cadherin associated protein) β1
KRAS: v-Ki-ras2 Kirsten rat sarcoma viral oncogene homologue
PIK3CA: Phosphoinositide-3-kinase, catalytic, α polypeptide
PTEN: Phosphatase and tensin homologue
RB1: Retinoblastoma 1
SMAD4: SMAD, mothers against DPP homologue 4 (MADH4)
TP53: Tumor protein p53
Unless otherwise referenced above, cell line information was gathered from references 154-157.
Color Growth Percent
Most Active < -50
-50 to 0
0 to 50
Least Active > 50
Figure Key
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average growth percent as Compound 16 had an average growth percent of -72.7 as 
compared to -74.1 for (3S,8R)-1.   
 
 
Table 12.2 
 
12.2  Hansch Cluster Analysis on Colon Cancer Cell Lines Data 
 
Table 12.3 shows the colon cancer testing results organized to assess the results per 
Hansch cluster analysis theory at the C-8 position.  As shown in the table, the range of 
activity is wide over the six clusters tested.  The mesyl amide compound 12 from cluster 
4b was the most active compound against five (HCC-2998, HCT-15, HT29, KM12, and 
SW-620) of the seven cell lines tested.  The alcohol compound (3S,8R)-1 from cluster 5 
was the most active against the COLO 205 cell line and the phenyl amide compound 13 
was the most active against the HCT-116 cell line.   Across the whole set of colon cancer 
cell lines tested, compound 12 from cluster 4b was the most active with an average 
growth percent of -82.4.  On the other end of the activity spectrum, the isothiocyanate 
compound 48 from cluster 6 was the least active compound against all of the colon 
cancer cell screened.   
Compound ID COLO 205 HCC-2998 HCT-116 HCT-15 HT29 KM12 SW-620 Average Minimum Maximum Range
(3R,8S )-1 120.7 106.8 97.5 86.3 101.3 110.4 111.1 104.9 86.3 120.7 34.4
(3S,8R )-1 -92.5 -90.7 -82.5 -71.5 -27.7 -79.4 -74.1 -74.1 -92.5 -27.7 64.8
(3R,8R )-1 117.8 102.6 69.6 78.2 89.7 99.1 93.4 92.9 69.6 117.8 48.2
(3S,8S )-1 -84.4 -87.2 -73.7 -29.4 -25.3 -62.9 -50.4 -59.1 -87.2 -25.3 61.9
9 121.6 93.5 92.1 107.2 109.5 104.9 100.8 104.2 92.1 121.6 29.5
10 -97.2 -91.4 -95.3 -70.8 -27.0 -80.0 -66.0 -75.4 -97.2 -27.0 70.3
11 76.5 110.5 -19.7 6.7 85.8 30.1 4.3 42.0 -19.7 110.5 130.2
12 -86.9 -96.4 -97.2 -80.2 -56.9 -82.3 -76.7 -82.4 -97.2 -56.9 40.3
13 -31.0 -89.3 -100.0 -25.0 47.0 15.0 -35.6 -31.3 -100.0 47.0 147.0
14 -74.4 -8.6 0.8 10.5 35.5 4.3 4.2 -3.9 -74.4 35.5 109.9
15 -63.9 -92.4 -100.0 -58.2 -13.1 -47.5 -68.9 -63.4 -100.0 -13.1 86.9
16 -57.6 -91.1 -100.0 -70.5 -20.0 -86.1 -83.6 -72.7 -100.0 -20.0 80.0
37 95.4 29.5 8.8 25.2 90.3 90.0 19.2 51.2 8.8 95.4 86.6
38 -16.3 -43.8 8.1 25.6 93.3 57.2 3.4 18.2 -43.8 93.3 137.1
39 110.7 45.8 21.1 48.0 102.7 101.5 36.8 66.7 21.1 110.7 89.6
40 89.9 93.3 40.4 92.3 105.7 105.8 49.0 82.3 40.4 105.8 65.4
41 -87.3 -86.0 -36.1 0.1 -31.8 -28.5 -57.9 -46.8 -87.3 0.1 87.3
42 -79.1 -85.4 -73.4 1.4 22.3 1.0 -28.2 -34.5 -85.4 22.3 107.6
43 -88.4 -62.6 -53.5 -0.7 -27.1 -29.3 -58.9 -45.8 -88.4 -0.7 87.8
44 -83.7 -85.3 -37.8 1.6 2.5 -21.5 -63.1 -41.0 -85.3 2.5 87.8
45 -80.7 -84.0 4.6 15.0 27.6 24.6 -20.8 -16.3 -84.0 27.6 111.6
46 -17.1 -32.0 8.4 21.5 85.3 66.6 -13.6 17.0 -32.0 85.3 117.3
47 -78.4 -65.9 -37.2 10.7 56.2 NT -11.3 -21.0 -78.4 56.2 134.7
48 99.8 113.1 96.8 97.9 108.5 101.6 105.0 103.2 96.8 113.1 16.3
Average -11.9 -20.7 -19.1 9.2 38.9 17.2 -7.6
Minimum -97.2 -96.4 -100.0 -80.2 -56.9 -86.1 -83.6
Maximum 121.6 113.1 97.5 107.2 109.5 110.4 111.1
Range 218.8 209.6 197.5 187.5 166.4 196.5 194.7
NT = Not Tested
Colon Cancer Cell Lines
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Table 12.4 
 
12.3  SAR Analysis of Amide Compounds against Colon Cancer Cell Lines 
 
Eleven of the compounds we had tested by NCI have an acetate at the C-3 position and 
different amide functionalities with aromatic or heteroaromatic groups directly connected 
to the amide carbonyl group in the C-8 position as shown in Figure 12.1. 
 
Figure 12.1  Generic structure of amides screened by NCI. 
 Table 12.5 shows the activity of our amide compounds against each of the 
different colon cancer cell lines.  The set of amide compounds showed a wide range of 
activity against the different cell lines indicating that changing the amide R group has a 
significant impact on activity.  The widest range of activity was seen against the COLO 
Compound ID Cluster COLO 205 HCC-2998 HCT-116 HCT-15 HT29 KM12 SW-620 Average Minimum Maximum Range
(3S,8R )-1 5 -92.5 -90.7 -82.5 -71.5 -27.7 -79.4 -74.1 -74.1 -92.5 -27.7 64.8
11 5 76.5 110.5 -19.7 6.7 85.8 30.1 4.3 42.0 -19.7 110.5 130.2
12 4b -86.9 -96.4 -97.2 -80.2 -56.9 -82.3 -76.7 -82.4 -97.2 -56.9 40.3
13 8 -31.0 -89.3 -100.0 -25.0 47.0 15.0 -35.6 -31.3 -100.0 47.0 147.0
14 9 -74.4 -8.6 0.8 10.5 35.5 4.3 4.2 -3.9 -74.4 35.5 109.9
15 7 -63.9 -92.4 -100.0 -58.2 -13.1 -47.5 -68.9 -63.4 -100.0 -13.1 86.9
48 6 99.8 113.1 96.8 97.9 108.5 101.6 105.0 103.2 96.8 113.1 16.3
Average -24.6 -22.0 -43.1 -17.1 25.6 -8.3 -20.2
Minimum -92.5 -96.4 -100.0 -80.2 -56.9 -82.3 -76.7
Maximum 99.8 113.1 96.8 97.9 108.5 101.6 105.0
Range 192.2 209.6 196.8 178.1 165.4 183.9 181.6
NT = Not Tested
Color Growth Percent
Most Active < -50
-50 to 0
0 to 50
Least Active > 50
Colon Cancer Cell Lines
Figure Key
COLO 205 5 -OH (3S,8R )-1 -92.5
HCC-2998 4b -NHSO2Me 12 -96.4
HCT-116 8 -NHCOPh 13 -100.0
HCT-15 4b -NHSO2Me 12 -80.2
HT29 4b -NHSO2Me 12 -56.9
KM12 4b -NHSO2Me 12 -82.3
SW-620 4b -NHSO2Me 12 -76.7
Cell Line
Most Active 
Cluster
C-8 Substituent Compound ID Growth Percent
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205 cell line in which pyrazine compound 43 had a growth percent of -88.4 whereas m-
trifluoromethyl compound 39 had a growth percent of 110.7. 
 
 
Table 12.5 
Compound ID COLO 205 HCC-2998 HCT-116 HCT-15 HT29 KM12 SW-620 Average Minimum Maximum Range
13 -31.0 -89.3 -100.0 -25.0 47.0 15.0 -35.6 -31.3 -100.0 47.0 147.0
37 95.4 29.5 8.8 25.2 90.3 90.0 19.2 51.2 8.8 95.4 86.6
38 -16.3 -43.8 8.1 25.6 93.3 57.2 3.4 18.2 -43.8 93.3 137.1
39 110.7 45.8 21.1 48.0 102.7 101.5 36.8 66.7 21.1 110.7 89.6
40 89.9 93.3 40.4 92.3 105.7 105.8 49.0 82.3 40.4 105.8 65.4
41 -87.3 -86.0 -36.1 0.1 -31.8 -28.5 -57.9 -46.8 -87.3 0.1 87.3
42 -79.1 -85.4 -73.4 1.4 22.3 1.0 -28.2 -34.5 -85.4 22.3 107.6
43 -88.4 -62.6 -53.5 -0.7 -27.1 -29.3 -58.9 -45.8 -88.4 -0.7 87.8
44 -83.7 -85.3 -37.8 1.6 2.5 -21.5 -63.1 -41.0 -85.3 2.5 87.8
45 -80.7 -84.0 4.6 15.0 27.6 24.6 -20.8 -16.3 -84.0 27.6 111.6
46 -17.1 -32.0 8.4 21.5 85.3 66.6 -13.6 17.0 -32.0 85.3 117.3
Average -17.0 -36.3 -19.0 18.6 47.1 34.8 -15.4
Minimum -88.4 -89.3 -100.0 -25.0 -31.8 -29.3 -63.1
Maximum 110.7 93.3 40.4 92.3 105.7 105.8 49.0
Range 199.2 182.7 140.4 117.3 137.5 135.1 112.1
Color Growth Percent
Most Active < -50
-50 to 0
0 to 50
Least Active > 50
Colon Cancer Cell Lines
Figure Key
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Table 12.6 
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Table 12.7 
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Table 12.8 
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Chapter 13: Experimentals 
 
 (3S,8S)-8-hydroxyheptadeca-1-en-4,6-diyn-3-yl acetate (3S,8S)-1 
Copper (I) chloride (0.008 g, 0.08 mmol) was added to a stirred 30 % solution (1.65 mL) 
of n-butylamine in distilled water at 0 °C which resulted in a deep blue solution.  A few 
crystals of NH2OH.HCl were added until solution was colorless.  A solution of (S)-3 
(0.101 g, 0.55 mmol) in CH2Cl2 (0.82 mL) was added under argon atmosphere which 
resulted in yellow reaction mixture.  After 10 minutes, a solution of (S)-2 (0.153 g, 0.75 
mmol) in CH2Cl2 (1.0 mL) was added dropwise over 5 minutes.  A few crystals of 
NH2OH.HCl were added as necessary whenever solution turned blue or green.  After 1 
hour, reaction was quenched with water, extracted 3 times with CH2Cl2, dried over 
Na2SO4, and concentrated under reduced pressure.  Immediate purification by flash 
chromatography on silica gel (hexanes – 15% EtOAc/hexanes) afforded (3S,8S)-1 (0.135 
g, 80.2%, yellow oil).  TLC Rf = 0.414 (25% EtOAc/hexanes); [α]D
17 = -29.1° (c = 0.6, 
CHCl3/0.75% ethanol); 
1H NMR (500 MHz, CHLOROFORM-d) δ 5.83 - 5.95 (m, 2H), 
5.52 - 5.59 (dd, J = 1.22, 16.63 Hz, 1H), 5.33 - 5.39 (dd, J = 1.10, 10.03 Hz, 1H), 4.43 
(m, 1H), 2.11 (s, 3H), 1.91 (d, J = 4.40 Hz, 1H), 1.66 - 1.77 (m, 2H), 1.44 (quint, J = 7.58 
Hz, 2H), 1.22 - 1.35 (m, 12H), 0.85 - 0.91 (t, J = 6.97 Hz, 3H); 13C NMR (125 MHz, 
CHLOROFORM-d) δ 169.5, 131.9, 119.7, 81.3, 74.3, 70.8, 68.6, 64.4, 62.8, 37.4, 31.8, 
29.5, 29.4, 29.3, 29.2, 25.0, 22.7, 20.9, 14.1; IR (ATR) 3413, 2925, 2855, 2258, 2157, 
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1748, 1371, 1220, 1015 cm-1; HRMS (ESI-TOF) [M + H]+ calcd. for C19H29O3 305.2117, 
found 305.2138. 
 
 
 (3R,8R)-8-hydroxyheptadeca-1-en-4,6-diyn-3-yl acetate (3R,8R)-1 
Copper (I) chloride (0.008 g, 0.08 mmol) was added to a stirred 30 % solution (1.65 mL) 
of n-butylamine in distilled water at 0 °C which resulted in a deep blue solution.  A few 
crystals of NH2OH.HCl were added until solution was colorless.  A solution of (R)-3 
(0.098 g, 0.54 mmol) in CH2Cl2 (0.82 mL) was added under argon atmosphere which 
resulted in yellow reaction mixture.  After 10 minutes, a solution of (R)-2 (0.230 g, 1.1 
mmol) in CH2Cl2 (1.0 mL) was added dropwise over 3.5 minutes.  A few crystals of 
NH2OH.HCl were added as necessary whenever solution turned blue or green.  After 1 
hour, reaction was quenched with water, extracted 3 times with CH2Cl2, dried over 
Na2SO4, and concentrated under reduced pressure.  Immediate purification by flash 
chromatography on silica gel (hexanes – 15% EtOAc/hexanes) afforded (3R,8R)-1 (0.088 
g, 53.9%, yellow oil).  [α]D
18 = +31.7° (c = 0.9, CHCl3/0.75% ethanol); 
1H NMR (500 
MHz, CHLOROFORM-d)  5.83 - 5.94 (m, 2H), 5.52 - 5.59 (m, 1H), 5.33 - 5.38 (m, 
1H), 4.43 (m, 1H), 2.10 - 2.13 (d, J = 0.49 Hz, 3H), 1.92 (d, J = 4.16 Hz, 1H), 1.65 - 1.78 
(m, 2H), 1.40 - 1.48 (m, 2H), 1.22 - 1.35 (m, 12H), 0.88 (t, J = 6.97 Hz, 3H); 13C NMR 
(125 MHz, CHLOROFORM-d)  169.5, 131.9, 119.7, 81.3, 74.3, 70.8, 68.5, 64.4, 62.8, 
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37.4, 31.9, 29.5, 29.5, 29.3, 29.2, 25.0, 22.7, 20.9, 14.1; IR (ATR) 3440, 2924, 2855, 
2256, 2157, 1748, 1371, 1219, 1015 cm-1; HRMS (ESI-TOF) [M + H]+ calcd. for 
C19H29O3 305.2117, found 305.2132. 
 
 
 (3R,8S)-8-hydroxyheptadeca-1-en-4,6-diyn-3-yl acetate (3R,8S)-1 
Copper (I) chloride (0.007 g, 0.07 mmol) was added to a stirred 30 % solution (1.65 mL) 
of n-butylamine in distilled water at 0 °C which resulted in a deep blue solution.  A few 
crystals of NH2OH.HCl were added until solution was colorless.  A solution of (S)-3 
(0.107 g, 0.59 mmol) in CH2Cl2 (0.82 mL) was added under argon atmosphere which 
resulted in yellow reaction mixture.  After 10 minutes, a solution of (R)-2 (0.147 g, 0.72 
mmol) in CH2Cl2 (1.0 mL) was added dropwise over 5 minutes.  A few crystals of 
NH2OH.HCl were added as necessary whenever solution turned blue or green.  After 1 
hour, reaction was quenched with water, extracted 3 times with CH2Cl2, dried over 
Na2SO4, and concentrated under reduced pressure.  Immediate purification by flash 
chromatography on silica gel (hexanes – 15% EtOAc/hexanes) afforded (3R,8S)-1 (0.128 
g, 71.5%, yellow oil).  TLC Rf = 0.414 (25% EtOAc/hexanes); [α]D
17 = +44.6° (c = 1.2, 
CHCl3/0.75% ethanol); 
1H NMR (500 MHz, CHLOROFORM-d)  5.83 - 5.95 (m, 2H), 
5.55 (d, J = 16.63 Hz, 1H), 5.36 (d, J = 9.78 Hz, 1H), 4.43 (m, 1H), 2.08 - 2.15 (s, 3H), 
1.93 (d, J = 4.65 Hz, 1H), 1.65 - 1.78 (m, 2H), 1.39 - 1.48 (m, 2H), 1.19 - 1.36 (m, 12H), 
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0.88 (t, J = 6.85 Hz, 3H); 13C NMR (125 MHz, CHLOROFORM-d)  169.5, 131.9, 
119.7, 81.3, 74.3, 70.8, 68.5, 64.4, 62.8, 37.4, 31.8, 29.5, 29.4, 29.3, 29.2, 25.0, 22.7, 
20.9, 14.1; IR (ATR) 3432, 2924, 2855, 2257, 2157, 1748, 1371, 1219, 1015 cm-1; 
HRMS (ESI-TOF) [M + H]+ calcd. for C19H29O3 305.2117, found 305.2167. 
 
 
 (3S,8R)-8-hydroxyheptadeca-1-en-4,6-diyn-3-yl acetate (3S,8R)-1 
Copper (I) chloride (0.015 g, 0.15 mmol) was added to a stirred 30 % solution (3.3 mL) 
of n-butylamine in distilled water at 0 °C which resulted in a deep blue solution.  A few 
crystals of NH2OH.HCl were added until solution was colorless.  A solution of (R)-3 
(0.202 g, 1.10 mmol) in CH2Cl2 (1.7 mL) was added under argon atmosphere which 
resulted in yellow reaction mixture.  After 10 minutes, a solution of (S)-2 (0.277 g, 1.36 
mmol) in CH2Cl2 (2.0 mL) was added dropwise over 5 minutes.  A few crystals of 
NH2OH.HCl were added as necessary whenever solution turned blue or green.  After 45 
minutes, reaction was quenched with water, extracted 3 times with CH2Cl2, dried over 
Na2SO4, and concentrated under reduced pressure.  Immediate purification by flash 
chromatography on silica gel (hexanes – 15% EtOAc/hexanes) afforded (3S,8R)-1 (0.225 
g, 66.7%, yellow oil).  TLC Rf = 0.429 (25% EtOAc/hexanes); [α]D
17 = -46.0° (c = 0.7, 
CHCl3/0.75% ethanol); 
1H NMR (500 MHz, CHLOROFORM-d)  5.81 - 5.97 (m, 2H), 
5.51 - 5.61 (m, 1H), 5.31 - 5.41 (m, 1H), 4.43 (t, J = 6.60 Hz, 1H), 2.08 - 2.19 (s, 3H), 
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1.80 – 1.96 (br. s., 1H), 1.72 (m, 2H), 1.39 - 1.53 (m, 2H), 1.18 - 1.37 (m, 12H), 0.84 - 
0.97 (t, J = 6.90 Hz, 3H); 13C NMR (125 MHz, CHLOROFORM-d)  169.5, 131.9, 
119.7, 81.3, 74.3, 70.8, 68.6, 64.4, 62.8, 37.4, 31.9, 29.5, 29.5, 29.3, 29.2, 25.0, 22.7, 
20.9, 14.1; IR (ATR) 3413, 2926, 2855, 2257, 2158, 1749, 1371, 1219, 1014 cm-1; 
HRMS (ESI-TOF) [M + H]+ calcd. for C19H29O3 305.2117, found 305.2106. 
 
 
 
 (R)-5-bromopent-1-en-4-yn-3-yl acetate (R)-2 
To a solution of (R)-5 (6.4 g, 32.4 mmol) in acetonitrile (135 mL) was added N-
bromosuccinimide (7.0 g, 39.5 mmol) followed by AgF (5.3 g, 42.0 mmol).  The reaction 
flask was then wrapped in aluminum foil to block out light.  After 48 hours, reaction 
mixture was filtered through fine-fritted funnel and rinsed through with Et2O.  Filtrate 
was diluted with Et2O, washed with H20, dried over Na2SO4, and concentrated under 
reduced pressure.  Purification by flash chromatography on silica gel (Hexanes – 10% 
EtOAc/Hexanes) afforded (R)-2 (3.6 g, 54.1%, yellow oil). 
Rf = 0.462 (15% EtOAc/hexanes); [α]D
21 = +30.5° (c = 1.6, CHCl3); 
1H NMR (500 MHz, 
CHLOROFORM-d)  5.84 - 5.94 (m, 2H), 5.51 - 5.58 (m, 1H), 5.35 (d, J = 9.05 Hz, 1H), 
2.12 (s, 3H); 13C NMR (125 MHz, CHLOROFORM-d)  169.5, 132.3, 119.4, 75.4, 64.8, 
47.9, 20.9; IR (ATR) 2217, 1742, 1371, 1220 cm-1; MS (EI) [M]+202 
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 (S)-5-bromopent-1-en-4-yn-3-yl acetate (S)-2 
To a solution of (S)-6 (4.7 g, 29.2 mmol) in Et2O (360 mL) was added DMAP (0.37 g, 
3.0 mmol) followed by acetic anhydride (4.4 mL, 46.6 mmol).  After stirring for 2 hours 
at ambient temperature, reaction was quenched with water, extracted with Et2O, washed 
with water and brine, and dried over Na2SO4.  Purification by flash chromatography on 
silica gel (Hexanes – 10% EtOAc/Hexanes) afforded (S)-2 (3.6 g, 81.5%, light yellow 
oil).  Rf = 0.462 (15% EtOAc/hexanes); [α]D
21 = -28.2° (c = 1.8, CHCl3);  
1H NMR (500 
MHz, CHLOROFORM-d)  5.82 - 5.92 (m, 2H), 5.50 - 5.57 (m, 1H), 5.34 (d, J = 8.80 
Hz, 1H), 2.09 - 2.12 (s, 3H); 13C NMR (125 MHz, CHLOROFORM-d)  169.5, 132.2, 
119.3, 75.4, 64.8, 47.8, 20.9; IR (ATR) 2217, 1742, 1371, 1220 cm-1; MS (EI) [M]+202 
 
 
 (R)-dodec-1-yn-3-ol (R)-3 
To a solution of (R)-8 (3.3 g, 11.1 mmol) in methanol (225 mL) was added K2CO3 (3.1 g, 
22.3 mmol).  Solution was stirred at ambient temperature under argon atmosphere.  After 
22 hours, reaction was quenched with saturated NH4Cl, extracted three times with 
CH2Cl2, dried over Na2SO4, and concentrated under reduced pressure.  Concentrate was 
purified by loading on to a 2-inch pad of silica gel and eluting with 25% EtOAc/Hexanes 
which afforded (R)-3 (2.0 g, 100%, clear oil).  Rf = 0.259 (15% EtOAc/hexanes); [α]D
23 = 
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+2.9° (c = 10.4, CHCl3); 
1H NMR (500 MHz, CHLOROFORM-d)  4.35 (m., 1H), 2.43 - 
2.47 (d, J = 2.20 Hz, 1H), 2.34 - 2.40 (br. s., 1H), 1.64 - 1.76 (m, 2H), 1.39 - 1.49 (m, 
2H), 1.20 - 1.35 (m, 12H), 0.83 - 0.90 (t, J = 6.97 Hz, 3H); 13C NMR (125 MHz, 
CHLOROFORM-d)  85.1, 72.7, 62.2, 37.6, 31.8, 29.5, 29.3, 29.2, 25.0, 22.6, 14.1; IR 
(ATR) 3382. 3311. 2923, 2854, 1466 cm-1; MS (EI) [M – 1]+ 181.   
 
 
 
 
 (S)-dodec-1-yn-3-ol (S)-3 
To a solution of (S)-7 (2.0 g, 7.9 mmol) in methanol (160 mL) was added K2CO3 (4.4 g, 
31.7 mmol).  Solution was stirred at ambient temperature under argon atmosphere.  After 
3 hours and 25 minutes, reaction was quenched with saturated NH4Cl, extracted three 
times with CH2Cl2, dried over Na2SO4, and concentrated under reduced pressure.  
Purification by flash chromatography on silica gel (Hexanes – 15% EtOAc/Hexanes) 
afforded (S)-3 (1.3 g, 91.8%, clear oil).  Rf = 0.190 (15% EtOAc/hexanes); [α]D
21 = -3.4° 
(c = 11.9, CHCl3); 
1H NMR (500 MHz, CHLOROFORM-d)  4.33 - 4.41 (m, 1H), 2.46 
(d, J = 1.96 Hz, 1H), 2.09 (d, J = 5.38 Hz, 1H), 1.65 - 1.78 (m, 2H), 1.40 - 1.51 (m, 2H), 
1.20 - 1.36 (m, 12H), 0.88 (t, J = 6.85 Hz, 3H); 13C NMR (125 MHz, CHLOROFORM-d) 
 85.0, 72.8, 62.3, 37.6, 31.9, 29.5, 29.3, 29.2, 25.0, 22.6, 14.1; IR (ATR) 3382, 3311, 
2924, 2854, 1466 cm-1; MS(EI) [M – 1]+ 181.   
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 (S)-5-(trimethylsilyl)pent-1-en-4-yn-3-ol (S)-4; (R)-5-(trimethylsilyl)pent-1-en-4-yn-3-yl 
acetate (R)-5 
To a solution of (trimethylsilyl)acetylene (7.81 g, 11.0 mL, 79.5 mmol) in dry Et2O (95 mL) at -78 
°C was added dropwise a solution of n-butyllithium (2.25 M in hexanes, 31 mL, 69.8 
mmol) over 30 minutes under an Ar atmosphere.  The reaction mixture was then stirred 
for 30 minutes before a solution of acrolein (3.7 g, 4.4 mL, 65.9 mmol) in Et2O (5 mL) 
was added dropwise over 10 minutes.  The resulting mixture was allowed to gradually 
warm to ambient temperature.  After stirring for 20 hours, the mixture was quenched by 
slow addition of saturated NH4Cl.  The mixture was extracted with Et2O, washed with 
H20 and brine, dried over Na2SO4, and concentrated to near dryness.  The resultant 
yellow oil (±4) was used directly in the next reaction without further purification. 
 
The yellow oil (±4) was dissolved in dry hexanes (302 ml) followed by the addition of 
ground, activated 4-Å molecular sieves (3.11 g) and lipase (Pseudomonas fluorescens, 
Amano Lipase AK, 1.89 g).  To the well-stirred suspension was added vinyl acetate (29.0 
mL, 314.6 mmol) over 10 minutes.  The suspension was stirred under an Ar atmosphere 
for 24 hours and then filtered through a pad of Celite and concentrated.  The resulting 
yellow oil was purified by silica gel chromatography (3-25% EtOAc/hexanes) to give 
(S)-4 (5.0 g, 48.7%, clear oil, ee 96.8) and (R)-5 (5.8 g, 45.2%, clear oil, ee 96.0). 
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Data for ±4: Rf = 0.167 (15% EtOAc/hexanes); 1H NMR (500 MHz, CHLOROFORM-d) 
 5.93 - 6.02 (m, 1H), 5.44 - 5.51 (d, J = 16.87 Hz, 1H), 5.21 - 5.26 (d, J = 10.27 Hz, 
1H), 4.88 (m, 1H), 1.99 (d, J = 5.62 Hz, 1H), 0.15 - 0.22 (m, 9H); 13C NMR (125 MHz, 
CHLOROFORM-d)  136.6, 116.6, 103.9, 91.2, 63.6, -0.2; IR (ATR) 3354, 2961, 2175, 
1250, 839 cm-1; HRMS (ESI-TOF) [M + H]+ calcd. for C8H15OSi 155.0892, found 
155.0878. 
 
Data for (S)-4: Rf = 0.167 (15% EtOAc/hexanes); [α]D
22 = +29.4° (c =1.4 , CHCl3); 
1H 
NMR (500 MHz, CHLOROFORM-d)  5.97 (ddd, J = 5.38, 10.15, 17.00 Hz, 1H), 5.48 
(dt, J = 1.28, 17.00 Hz, 1H), 5.24 (dt, J = 1.25, 10.21 Hz, 1H), 4.88 (m, 1H), 1.96 (br. s., 
1H), 0.18 - 0.20 (s, 9H); 13C NMR (125 MHz, CHLOROFORM-d)  136.6, 116.6, 103.9, 
91.2, 63.6, -0.2; IR (ATR) 3359, 2961, 2175, 1250, 839 cm-1; HRMS (ESI-TOF) [M + 
H]+ calcd. for C8H15OSi 155.0892, found 155.0874. 
 
Data for (R)-5: Rf = 0.449 (15% EtOAc/hexanes); [α]D
22 = +27.4° (c =7.7 , CHCl3); 1H 
NMR (500 MHz, CHLOROFORM-d)  5.82 - 5.90 (m, 2H), 5.51 - 5.56 (m, 1H), 5.28 - 
5.32 (m, 1H), 2.09 (s, 3H), 0.16 - 0.19 (s, 9H); 13C NMR (125 MHz, CHLOROFORM-d) 
 169.4, 132.7, 118.9, 100.0, 92.2, 64.5, 21.0, -0.3; IR (ATR) 2962, 2182, 1745, 1223, 
840 cm-1; HRMS (ESI-TOF) [M + H]+ calcd. for C10H17O2Si 191.0998, found 191.0988. 
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(S)-5-bromopent-1-en-4-yn-3-ol (S)-6 
 
To a solution of (S)-4 (1.9 g, 12.2 mmol) in acetone (42 mL) was added N-
bromosuccinimide (3.4 g, 19.4 mmol) and AgNO3 (0.43 g, 2.5 mmol).  Reaction mixture 
was stirred for 4 hours under Ar atmosphere at ambient temperature.  Reaction mixture 
was then chilled to 0°C, quenched with H20, extracted with Et2O, washed with H20 and 
brine, dried over Na2SO4, and concentrated under reduced pressure.  Purification by flash 
chromatography on silica gel (Hexanes – 10% EtOAc/Hexanes) afforded (S)-6 (1.95 g, 
99.7%, yellow oil).  Rf = 0.207 (15% EtOAc/hexanes); [α]D
23 = +22.8° (c = 10.5, CHCl3); 
1H NMR (500 MHz, CHLOROFORM-d)  5.89 - 6.03 (m, 1H), 5.43 - 5.54 (m, 1H), 5.21 
- 5.32 (m, 1H), 4.86 - 4.97 (m, 1H), 2.02 (br. s., 1H); C13 NMR; IR (ATR) 3376, 2213, 
2181, 1709, 1651, 1404, 1254, 983 cm-1;  HRMS (ESI-TOF) [M]+ calcd. for C5H5BrO 
159.9524, found 159.9558. 
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 (S)-1-(trimethylsilyl)dodec-1-yn-3-ol (S)-7; (R)-1-(trimethylsilyl)dodec-1-yn-3-yl 
acetate (R)-8 
To a solution of (trimethylsilyl)acetylene (15.62 g, 22.0 mL, 155.6 mmol) in dry Et2O (185 mL) at -
78 °C was added dropwise a solution of n-butyllithium (2.3 M in hexanes, 61 mL, 140.3 
mmol) over 1 hour via syringe pump under an Ar atmosphere.  The reaction mixture was 
then stirred for 10 minutes before a solution of decanal (20.75 g, 25.0 mL, 127.5 mmol) 
in Et2O (15 mL) was added dropwise over 40 minutes via syringe pump.  The resulting 
mixture was allowed to gradually warm to ambient temperature.  After stirring for 17 
hours, the mixture was quenched by slow addition of saturated NH4Cl (36 mL) followed 
by H20 (18 mL).  The mixture was extracted with Et2O, washed with H20 and brine, dried 
over Na2SO4, and concentrated to near dryness.  The resultant yellow oil (±7) was used 
directly in the next reaction without further purification. 
 
The yellow oil (±7) was dissolved in dry hexanes (500 ml) followed by the addition of 
ground, activated 4-Å molecular sieves (8.31 g) and lipase (Pseudomonas fluorescens, 
Amano Lipase AK, 4.89 g).  To the well-stirred suspension was added vinyl acetate (48.0 
mL, 520.8 mmol) over 10 minutes.  The suspension was stirred under an Ar atmosphere 
for 25 hours and 10 minutes and then filtered through a pad of Celite and concentrated.  
The resulting yellow oil was purified by silica gel chromatography (2-15% 
EtOAc/hexanes) to give (S)-7 (11.1 g, 34.3%, yellow oil, ee 94.2) and (R)-8 (16.9 g, 
44.7%, yellow oil, ee 100.0). 
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Data for ±7: Rf = 0.365 (15% EtOAc/hexanes); 1H NMR (500 MHz, CHLOROFORM-d) 
 4.35 (t, J = 6.60 Hz, 1H), 1.62 - 1.75 (m, 2H), 1.40 - 1.50 (m, 2H), 1.23 - 1.37 (m, 
12H), 0.85 - 0.92 (t, J = 6.85 Hz, 3H), 0.14 - 0.21 (s, 9H); 13C NMR (125 MHz, 
CHLOROFORM-d)  106.9, 89.3, 62.9, 37.7, 31.9, 29.5, 29.3, 29.2, 25.1, 22.7, 14.1, -
0.1; IR (ATR): 3328, 2957, 2924, 2854, 2172, 1467, 1250, 841, 760 cm-1; MS(EI) [M – 
1]+ 253 
 
Data for (S)-7: Rf = 0.365 (15% EtOAc/hexanes); [α]D
18 = +0.4° (c =5.1, CHCl3);  1H 
NMR (500 MHz, CHLOROFORM-d)  4.35 (q, J = 6.19 Hz, 1H), 1.82 (d, J = 5.38 Hz, 
1H), 1.63 - 1.75 (m, 2H), 1.40 – 1.50 (m, 2H), 1.23 - 1.36 (m, 12H), 0.85 – 0.93 (t, J = 
6.72 Hz, 3H), 0.13 - 0.23 (s, 9H); 13C NMR (125 MHz, CHLOROFORM-d)  106.9, 
89.3, 62.9, 37.7, 31.9, 29.5, 29.3, 29.2, 25.1, 22.7, 14.1, -0.1; IR (ATR): 3330, 2957, 
2924, 2855, 2173, 1467, 1250, 840, 760 cm-1; MS(EI) [M – 1]+ 253  
 
 
Data for (R)-8: Rf = 0.538 (15% EtOAc/hexanes); [α]D
22 = +32.1° (c =1.7, CHCl3); 1H 
NMR (500 MHz, CHLOROFORM-d)  5.38 (t, J = 6.72 Hz, 1H), 2.08 (d, J = 0.73 Hz, 
3H), 1.68 - 1.80 (m, 2H), 1.37 – 1.46 (m, 2H), 1.21 - 1.36 (m, 12H), 0.84 - 0.93 (t, J = 
6.85 Hz, 3H), 0.10 - 0.26 (d, J = 0.73 Hz, 9H); 13C NMR (125 MHz, CHLOROFORM-d) 
 169.9, 102.8, 90.2, 64.4, 34.8, 31.9, 29.4, 29.4, 29.3, 29.0, 24.9, 22.7, 21.1, 14.1, -0.2; 
IR (ATR): 2956, 2926, 2855, 2180, 1746, 1467, 1371, 1250, 1230, 1089, 842, 760 cm-1; 
HRMS (ESI-TOF) [M + H]+ calcd. for C17H33O2Si 297.2250, found 297.2244. 
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JH-4-198, TJL-2-064 
(3S,8R)-8-hydroxyundeca-1-en-4,6-diyn-3-yl acetate (3S,8R)-9 
 
Copper (I) chloride (0.015 g, 0.15 mmol) was added to a stirred 30 % solution (2.5 mL) 
of n-butylamine in distilled water at 0 °C which resulted in a deep blue solution.  A few 
crystals of NH2OH.HCl were added until solution was colorless.  A solution of (R)-17 
(0.081 g, 0.82 mmol) in CH2Cl2 (1.4 mL) was added under argon atmosphere which 
resulted in yellow reaction mixture.  After 10 minutes, a solution of (S)-2 (0.247 g, 1.21 
mmol) in CH2Cl2 (2.0 mL) was added dropwise over 5 minutes.  A few crystals of 
NH2OH.HCl were added as necessary whenever solution turned blue or green.  After 1 
hour and 40 minutes, reaction was quenched with water, extracted 3 times with CH2Cl2, 
dried over Na2SO4, and concentrated under reduced pressure.  Immediate purification by 
flash chromatography on silica gel (hexanes – 15% EtOAc/hexanes) afforded (3S,8R)-9 
(0.083 g, 45.9%, yellow oil).  TLC Rf = 0.292 (25% EtOAc/hexanes); [α]D
21 = -55.2° 
(CHCl3);  
1H NMR (500 MHz, CHLOROFORM-d)  5.83 - 5.94 (m, 2H), 5.52 - 5.59 (m, 
1H), 5.33 - 5.39 (m, 1H), 4.45 (q, J = 6.25 Hz, 1H), 2.11 (s, 3H), 1.94 (d, J = 5.26 Hz, 
1H), 1.71 (m, 2H), 1.44 - 1.53 (m, 2H), 0.95 (t, J = 7.40 Hz, 3H); 13C NMR (125 MHz, 
CHLOROFORM-d)  169.5, 131.9, 119.7, 81.3, 74.3, 70.8, 68.6, 64.4, 62.6, 39.4, 20.9, 
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18.3, 13.6; IR (ATR) 3420, 2961, 2935, 2875, 2256, 2158, 1746, 1371, 1219, 1016, 974 
cm-1; MS(EI) [M – 1]+ 219. 
 
 
 (3S,8R)-8-hydroxytricosa-1-en-4,6-diyn-3-yl acetate (3S,8R)-10 
Copper (I) chloride (0.004 g, 0.04 mmol) was added to a stirred 30 % solution (0.9 mL) 
of n-butylamine in distilled water at 0 °C which resulted in a deep blue solution.  A few 
crystals of NH2OH.HCl were added until solution was colorless.  A solution of (R)-18 
(0.074 g, 0.28 mmol) in CH2Cl2 (0.45 mL) was added under argon atmosphere which 
resulted in yellow reaction mixture.  After 10 minutes, a solution of (S)-2 (0.069 g, 0.34 
mmol) in CH2Cl2 (0.54 mL) was added dropwise over 5 minutes.  A few crystals of 
NH2OH.HCl were added as necessary whenever solution turned blue or green.  After 25 
minutes, reaction was quenched with water, extracted 3 times with CH2Cl2, dried over 
Na2SO4, and concentrated under reduced pressure.  Immediate purification by flash 
chromatography on silica gel afforded (3S,8R)-10 (0.058 g, 53.9%, light orange solid).  
TLC Rf = 0.353 (25% EtOAc/hexanes); [α]D
22 = -39.7° (c = 1.3, CHCl3); 
1H NMR (500 
MHz, CHLOROFORM-d)  5.82 - 5.95 (m, 2H), 5.52 - 5.58 (m, 1H), 5.33 - 5.38 (m, 
1H), 4.42 (t, J = 6.72 Hz, 1H), 2.10 - 2.13 (s, 3H), 1.95 – 2.05 (br.s., 1H), 1.66 - 1.77 (m, 
2H), 1.43 (m, 2H), 1.21 - 1.35 (m, 24H), 0.86 - 0.90 (t, J = 6.97 Hz, 3H); 13C NMR (125 
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MHz, CHLOROFORM-d)  169.5, 131.9, 119.7, 81.3, 74.3, 70.8, 68.5, 64.4, 62.8, 37.4, 
31.9, 29.7, 29.7, 29.6, 29.6, 29.5, 29.5, 29.3, 29.2, 25.0, 22.7, 20.9, 14.1; IR (ATR) 3355, 
2915, 2849, 2258, 2158, 1746, 1223, 1017 cm-1; MS(EI) [M – 1]+ 387. 
 
 
 (3S,8R)-8-aminoheptadeca-1-en-4,6-diyn-3-yl acetate (3S,8R)-11 
Copper (I) chloride (0.075 g, 0.75 mmol) was added to a stirred 30 % solution (14.5 mL) 
of n-butylamine in distilled water at 0 °C which resulted in a deep blue solution.  A few 
crystals of NH2OH.HCl were added until solution was colorless.  A solution of (R)-19 
(0.877 g, 4.83 mmol) in CH2Cl2 (7.3 mL) was added under argon atmosphere which 
resulted in yellow reaction mixture.  After 10 minutes, a solution of (S)-2 (1.330 g, 6.55 
mmol) in CH2Cl2 (9.5 mL) was added dropwise over 12 minutes.  A few crystals of 
NH2OH.HCl were added as necessary whenever solution turned blue or green.  After 20 
minutes, GC/MS showed that there still remained some (R)-19.  After 1 hour of stirring, 
added a second solution of (S)-2 (0.160 g, 0.79 mmol) in CH2Cl2 (2.0 mL).  Fifteen 
minutes after the second solution of was (S)-2 added, reaction was quenched with water, 
extracted 3 times with CH2Cl2, dried over Na2SO4, and concentrated under reduced 
pressure.  Immediate purification by flash chromatography on silica gel (hexanes – 50% 
EtOAc/hexanes) afforded (3S,8R)-11 (0.976 g, 66.5%, red, orange oil).  TLC Rf = 0.286 
(60% EtOAc/hexanes); [α]D
18 = +22.5° (c = 0.18, CHCl3); 
1H NMR (500 MHz, 
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CHLOROFORM-d)  5.84 - 5.94 (m, 2H), 5.55 (d, J = 16.14 Hz, 1H), 5.35 (d, J = 9.54 
Hz, 1H), 3.60 (t, J = 6.85 Hz, 1H), 2.11 (s, 3H), 1.38 - 1.67 (m, 6H), 1.22 - 1.34 (m, 
12H), 0.89 (t, J = 6.72 Hz, 3H); 13C NMR (125 MHz, CHLOROFORM-d)  169.5, 
132.1, 119.6, 84.5, 73.0, 71.3, 66.3, 64.5, 44.0, 37.4, 31.8, 29.5, 29.4, 29.3, 29.2, 25.9, 
22.6, 20.9, 14.1; IR (ATR) 3297, 2924, 2854, 2254, 1746, 1220 cm-1; HRMS (ESI-TOF) 
[M + H]+ calcd. for C19H30NO2 304.2277, found 304.2265. 
 
 
4-087 
(3S,8R)-8-(methylsulfonamido)heptadeca-1-en-4,6-diyn-3-yl acetate (3S,8R)-12 
To a solution of (3S,8R)-11 (0.056 g, 0.19 mmol) in CH2Cl2 (1.4 mL) at 0°C under Ar 
atmosphere was added triethylamine (0.06 mL, 0.43 mmol) followed by methanesulfonyl 
chloride (0.02 mL, 0.26 mmol).  After 1 hour and 50 minutes, reaction was quenched 
with water, extracted three times with CH2Cl2, dried over Na2SO4, and concentrated 
under reduced pressure.  Purification by flash chromatography on silica gel (hexanes – 
25% EtOAc/hexanes) afforded (3S,8R)-12 (0.047 g, 66.7%) as a light brown oil.  TLC Rf 
= 0.413 (40% EtOAc/hexanes); [α]D
23 = +29.6° (c = 2.37, CHCl3); 
1H NMR (500 MHz, 
CHLOROFORM-d)  5.80 - 5.94 (m, 2H), 5.50 - 5.59 (m, 1H), 5.32 - 5.41 (m, 1H), 4.67 
(d, J = 9.11 Hz, 1H), 4.25 (m, 1H), 3.03 - 3.13 (s, 3H), 2.06 - 2.16 (s, 3H), 1.71 - 1.77 (m, 
2H), 1.42 - 1.50 (m, 2H), 1.24 - 1.33 (m, 12H), 0.86 - 0.91 (t, J = 7.02 Hz, 3H); 13C NMR 
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(125 MHz, CHLOROFORM-d)  169.4, 131.7, 119.8, 78.9, 74.6, 70.3, 68.5, 64.3, 46.0, 
41.6, 36.2, 31.8, 29.4, 29.3, 29.2, 28.8, 25.4, 22.6, 20.8, 14.1; IR (ATR) 3286, 2927, 
2856, 2258, 1747, 1326, 1220, 1155 cm-1; HRMS (ESI-TOF) [M + H]+ calcd. for 
C20H32NO4S 382.2052, found 383.2072. 
 
 
4-053, 4-037 
(3S,8R)-8-benzamidoheptadeca-1-en-4,6-diyn-3-yl acetate (3S,8R)-13  
To a solution of (3S,8R)-11 (0.046 g, 0.15 mmol) in CH2Cl2 (1.6 mL) at 0°C under Ar 
was added benzoic anhydride (0.047 g, 0.21 mmol) followed by triethylamine (0.03 mL, 
0.22 mmol).  Reaction mixture was stirred for 15 minutes at 0°C and then allowed to 
warm to ambient temperature.  After 1 hour and 15 minutes, reaction mixture was 
quenched with water, extracted three times with CH2Cl2, dried over Na2SO4, and 
concentrated under reduced pressure.  Purification by flash chromatography on silica gel 
(hexanes – 15% EtOAc/hexanes) afforded (3S,8R)-13 (0.031 g, 51.2%) as a beige oil.  
TLC Rf = 0.340 (25% EtOAc/hexanes); [α]D
17 = -2.9° (c = 0.66, CHCl3); 
1H NMR (500 
MHz, CHLOROFORM-d)  7.76 - 7.80 (m, 2H), 7.51 - 7.55 (m, 1H), 7.43 - 7.47 (m, 
2H), 6.30 (d, J = 8.56 Hz, 1H), 5.82 - 5.93 (m, 2H), 5.52 - 5.58 (m, 1H), 5.33 - 5.38 (m, 
1H), 5.01 - 5.09 (q, J = 7.42 Hz, 1H), 2.10 - 2.13 (s, 3H), 1.73 - 1.83 (m, 2H), 1.44 - 1.52 
(m, 2H), 1.23 - 1.37 (m, 12H), 0.86 - 0.91 (t, J = 6.97 Hz, 3H); 13C NMR (125 MHz, 
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CHLOROFORM-d)  169.5, 166.3, 133.7, 131.9, 131.8, 128.6, 127.0, 119.7, 79.9, 73.4, 
71.0, 67.0, 64.4, 42.3, 35.7, 31.8, 29.5, 29.4, 29.2, 29.1, 25.6, 22.7, 20.9, 14.1; IR (ATR) 
3307, 2925, 2855, 2258, 1747, 1638, 1527, 1219 cm-1; HRMS (ESI-TOF) [M + H]+ 
calcd. for C26H34NO3 408.2539, found 408.2538. 
 
 
(3S,8R)-8-(butylamino)heptadeca-1-en-4,6-diyn-3-yl acetate (3S,8R)-14 
 
To a solution of (3S,8R)-11 (0.239 g, 0.79 mmol) in methanol (4.1 mL) under argon 
atmosphere was added butyraldehyde (0.11 mL, 1.2 mmol).  Reaction mixture was stirred 
at ambient temperature for 20 minutes and then chilled to 0°C at which time NaBH4 was 
added (0.028 g, 0.73 mmol).  Reaction mixture was stirred for 1 hour and 20 minutes and 
then diluted with EtOAc, washed with saturated NaHCO3, dried over Na2SO4, and 
concentrated under reduced pressure.  Purification by flash chromatography on silica gel 
(hexanes – 10% EtOAc/hexanes) afforded (3S,8R)-14 (0.151 g, 53.4%) as a yellow oil.  
TLC Rf = 0.350 (25% EtOAc/hexanes); 
1H NMR (500 MHz, CHLOROFORM-d)  5.85 - 
5.95 (m, 2H), 5.53 - 5.58 (m, 1H), 5.33 - 5.37 (m, 1H), 3.41 (dd, J = 5.75, 8.19 Hz, 1H), 
2.84 (ddd, J = 5.99, 8.38, 11.07 Hz, 1H), 2.56 (ddd, J = 5.87, 8.31, 11.00 Hz, 1H), 2.11 - 
2.12 (s, 3H), 1.54 - 1.69 (m, 2H), 1.20 - 1.52 (m, 19H), 0.93 (t, J = 7.21 Hz, 3H), 0.86 - 
0.90 (t, J = 6.97, 3H); 13C NMR (125 MHz, CHLOROFORM-d)  169.5, 132.1, 119.6, 
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83.5, 72.3, 71.4, 67.0, 64.6, 50.8, 47.3, 35.8, 32.2, 31.9, 29.5, 29.5, 29.3, 29.3, 26.0, 22.7, 
20.9, 20.5, 14.1, 14.0; IR (ATR) 2925, 2855, 2252, 1748, 1218 cm-1; HRMS (ESI-TOF) 
[M + H]+ calcd. for C23H38NO2 360.2903, found 360.2878. 
 
 
(3S,8R)-8-((methylsulfonyl)oxy)heptadeca-1-en-4,6-diyn-3-yl acetate (3S,8R)-15 
 
To a solution of (3S,8R)-1 (0.027 g, 0.09 mmol) in CH2Cl2 (0.3 mL) at 0°C under Ar 
atmosphere was added triethylamine (0.02 mL, 0.14 mmol) followed by methanesulfonyl 
chloride (0.01 mL, 0.13 mmol).  After 1 hour, reaction was quenched with water, 
extracted three times with CH2Cl2, dried over Na2SO4, and concentrated under reduced 
pressure.  Purification by flash chromatography on silica gel afforded (3S,8R)-15 (0.021 
mg, 62.4%) as a beige oil.  TLC Rf = 0.355 (25% EtOAc/hexanes); [α]D
21 = +35.6° (c = 
2.0, CHCl3); 
1H NMR (500 MHz, CHLOROFORM-d)  5.84 - 5.93 (m, 2H), 5.52 - 5.57 
(m, 1H), 5.36 - 5.40 (m, 1H), 5.22 (t, J = 6.60 Hz, 1H), 3.10 - 3.13 (s, 3H), 2.11 - 2.13 (s, 
3H), 1.84 - 1.96 (m, 2H), 1.48 (m, 2H), 1.23 - 1.36 (m, 12H), 0.86 - 0.91 (t, J = 6.97 Hz, 
3H); 13C NMR (125 MHz, CHLOROFORM-d)  169.4, 131.5, 120.0, 76.5, 75.1, 72.0, 
71.5, 69.8, 64.2, 39.2, 35.5, 31.8, 29.4, 29.3, 29.2, 28.8, 24.6, 22.6, 20.8, 14.1; HRMS 
(ESI-TOF) [M + Na]+ calcd. for C20H30NaO5S 405.1712, found 405.1708. 
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(3S,8R)-heptadeca-1-en-4,6-diyne-3,8-diol (3S,8R)-16 
 
Copper (I) chloride (0.011 g, 0.11 mmol) was added to a stirred 30 % solution (1.6 mL) 
of n-butylamine in distilled water at 0 °C which resulted in a deep blue solution.  A few 
crystals of NH2OH.HCl were added until solution was colorless.  A solution of (R)-3 
(0.105 g, 0.58 mmol) in CH2Cl2 (0.9 mL) was added under argon atmosphere which 
resulted in yellow reaction mixture.  After 10 minutes, a solution of (S)-6 (0.155 g, 0.96 
mmol) in CH2Cl2 (1.4 mL) was added dropwise over 5 minutes.  A few crystals of 
NH2OH.HCl were added as necessary whenever solution turned blue or green.  After 55 
minutes, reaction was quenched with water, extracted three times with CH2Cl2, dried over 
Na2SO4, and concentrated under reduced pressure.  Immediate purification by flash 
chromatography on silica gel (15% EtOAc/hexanes) afforded (3S,8R)-16 (0.046 g, 
30.4%) as a reddish-brown oil. TLC Rf = 0.429 (40% EtOAc/hexanes); [α]D
22 = +22.3° (c 
= 1.3, CHCl3); 
1H NMR (500 MHz, CHLOROFORM-d)  5.95 (ddd, J = 5.38, 10.15, 
17.00 Hz, 1H), 5.44 - 5.53 (d, J = 17.12 Hz , 1H), 5.23 - 5.30 (d, J = 10.03 Hz, 1H), 4.95 
(d, J = 4.65 Hz, 1H), 4.44 (t, J = 6.48 Hz, 1H), 2.21 (br. s., 1H), 2.05 (br. s., 1H), 1.66 - 
1.79 (m, 2H), 1.40 - 1.50 (m, 2H), 1.21 - 1.37 (m, 12H), 0.89 (t, J = 6.97 Hz, 3H); 13C 
NMR (125 MHz, CHLOROFORM-d)  135.8, 117.3, 81.1, 77.8, 70.3, 68.7, 63.5, 62.8, 
37.4, 31.9, 29.5, 29.5, 29.3, 29.2, 25.0, 22.7, 14.1; IR (ATR) 3350, 2916, 2850, 1020 cm-
1; HRMS (ESI-TOF) [M + H]+ calcd. for C17H27NO2 263.2011, found 263.2044. 
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 (R)-hex-1-yn-3-ol (R)-17 
To a solution of (R)-74 (0.34 g, 1.6 mmol) in methanol (40 mL) was added K2CO3 (0.53 
g, 3.8 mmol).  Solution was stirred at ambient temperature under argon atmosphere.  
After 22.75 hours, reaction was quenched with saturated NH4Cl, extracted three times 
with CH2Cl2, dried over Na2SO4, and concentrated under reduced pressure which 
afforded (R)-17 (0.13 g, 84.9%, light yellow oil, ee 100.0).  (R)-17 was in the synthesis 
of (3S,8R)-19 without further purification.   
[α]D
18 = +5.5° (c = 0.2, CHCl3); 
1H NMR (500 MHz, CHLOROFORM-d)  4.39 (t, J = 
5.87 Hz, 1H), 2.47 (d, J = 2.20 Hz, 1H), 1.91 (br. s., 1H), 1.65 - 1.77 (m, 2H), 1.45 - 1.55 
(m, 2H), 0.93 - 0.99 (t, J = 7.34 Hz, 3H); 13C NMR (125 MHz, CHLOROFORM-d)  
85.0, 72.8, 62.1, 39.7, 18.3, 13.7; IR (ATR) 3313, 2959, 2928, 1466 cm-1; MS(EI) [M – 
1]+ 97.   
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 (R)-octadec-1-yn-3-ol (R)-18 
To a solution of (R)-77 (0.147 g, 0.39 mmol) in methanol (8.0 mL) was added K2CO3 
(0.108 g, 0.78 mmol).  Solution was stirred at ambient temperature under argon 
atmosphere.  After 15 hours and 50 minutes, reaction was quenched with saturated 
NH4Cl, extracted three times with CH2Cl2, dried over Na2SO4, and concentrated under 
reduced pressure which afforded (R)-18 (quantitative yield, yellow solid, ee 100.0).  (R)-
18 was in the synthesis of (3S,8R)-10 without further purification.  [α]D
17 = +1.5° (c = 1.4, 
CHCl3); 
1H NMR (500 MHz, CHLOROFORM-d)  4.38 (m, 1H), 2.47 (d, J = 2.20 Hz, 
1H), 1.82 (br. s., 1H), 1.66 - 1.77 (m, 2H), 1.42 - 1.52 (m, 2H), 1.20-1.39 (m, 24H), 0.89 
(t, J = 6.97 Hz, 3H); 13C NMR (125 MHz, CHLOROFORM-d)  85.0, 72.8, 62.3, 37.6, 
31.9, 29.7, 29.7, 29.7, 29.6, 29.5, 29.5, 29.4, 29.2, 25.0, 22.7, 14.1; IR (ATR) 3292, 3279, 
2914, 2848, 2117, 1470 cm-1 
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 (R)-dodec-1-yn-3-amine (R)-19 
To a solution of (R)-79 (4.1 g, 10.7 mmol) in 200 proof ethanol (107 mL) was added 85% 
hydrazine monohydrate in H20 (0.66 mL).  Solution was heated to reflux under Ar 
atmosphere.  After 3 hours and 25 minutes, added more 85% hydrazine monohydrate in 
H20 (0.2 mL) as GC/MS showed that starting material remained at 2 hours and 55 
minutes. Thirty minutes later, reaction was cooled to ambient temperature.  Reaction pH 
was adjusted to pH~3 with 3M HCl.  It was then filtered through a Celite pad and rinsed 
through with methanol.  Filtrate pH was adjusted to pH~13 with 1M NaOH, diluted with 
H2O, and stirred for 1 hour at ambient temperature.  Reaction mixture was then extracted 
with Et2O, washed with saturated NaHCO3, and dried over Na2SO4.  Extract was 
concentrated under reduced pressure at 0°C followed by purification by silica gel 
chromatography (Hexanes – 60% EtOAc/Hexanes) to give (R)-19 (1.8 g, 88.9%, light 
yellow oil).  TLC Rf = 0.174 (60% EtOAc/hexanes); [α]D
21 = -5.9° (c =11.0 , CHCl3); 
1H 
NMR (500 MHz, CHLOROFORM-d)  3.55 (t, J = 6.36 Hz, 1H), 2.24 - 2.32 (m, 1H), 
2.17 (br. s., 2H), 1.52 - 1.67 (m, 2H), 1.44 (m, 2H), 1.18 - 1.36 (m, 12H), 0.87 (t, J = 6.85 
Hz, 3H); 13C NMR (125 MHz, CHLOROFORM-d)  87.5, 70.4, 43.3, 37.8, 31.9, 29.5, 
29.3, 29.3, 29.3, 25.9, 22.6, 14.1; IR (ATR) 3311, 2923, 2854 cm-1; HRMS (ESI-TOF) 
[M + H]+ calcd. for C11H24N 182.1909, found 182.1903. 
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 (R)-N-(dodec-1-yn-3-yl)benzamide (R)-20 
To a solution of (R)-19 (0.134 g, 0.74 mmol) in CH2Cl2 (6.9 mL) at 0°C under Ar was 
added benzoic anhydride (0.209 g, 0.92 mmol) followed by triethylamine (0.15 mL, 1.1 
mmol).  Reaction mixture was stirred for 15 minutes at 0°C and then allowed to warm to 
ambient temperature.  After 1 hour and 10 minutes, reaction mixture was quenched with 
water, extracted three times with CH2Cl2, washed two times with saturated NaHCO3, 
dried over Na2SO4, and concentrated under reduced pressure.  Purification by flash 
chromatography on silica gel (hexanes – 10% EtOAc/hexanes) afforded (R)-20 (0.116 g, 
55.1%) as a white solid. 
TLC Rf = 0.420 (25% EtOAc/hexanes); [α]D
21 = +21.7° (c = 1.4, CHCl3); 
1H NMR (500 
MHz, CHLOROFORM-d)  7.77 - 7.81 (m, 2H), 7.49 - 7.54 (m, 1H), 7.41 - 7.46 (m, 
2H), 6.35 (d, J = 8.07 Hz, 1H), 4.96 (ddt, J = 2.45, 6.17, 8.04 Hz, 1H), 2.30 - 2.32 (d, J = 
2.45 Hz, 1H), 1.72 - 1.84 (m, 2H), 1.45 - 1.54 (m, 2H), 1.22 - 1.38 (m, 12H), 0.85 - 0.91 
(t, J = 6.97 Hz, 3H); 13C NMR (125 MHz, CHLOROFORM-d)  166.3, 134.0, 131.7, 
128.6, 127.0, 83.3, 71.3, 41.8, 35.8, 31.8, 29.5, 29.5, 29.2, 29.1, 25.6, 22.6, 14.1; IR 
(ATR) 3311, 3282, 2917, 2849, 2361, 1641, 1528 cm-1. 
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N-((3S,8R)-3-hydroxyheptadeca-1-en-4,6-diyn-8-yl)benzamide (3S,8R)-21 
Copper (I) chloride (0.004 g, 0.038 mmol) was added to a stirred 30 % solution (0.9 mL) 
of n-butylamine in distilled water at 0 °C which resulted in a deep blue solution.  A few 
crystals of NH2OH.HCl were added until solution was colorless.  A solution of (R)-20 
(0.086 g, 0.30 mmol) in CH2Cl2 (0.5 mL) was added under argon atmosphere which 
resulted in yellow reaction mixture.  After 10 minutes, a solution of (S)-6 (0.081 g, 0.50 
mmol) in CH2Cl2 (0.7 mL) was added dropwise over 5 minutes.  A few crystals of 
NH2OH.HCl were added as necessary whenever solution turned blue or green.  After 45 
minutes, analysis of the reaction mixture by GC/MS showed that there was still some R-
XX present.  At 1 hour and 15 minutes, added additional (S)-6 (0.036 g, 0.22 mmol) in 
CH2Cl2 (0.5 mL).  Reaction was stirred an additional 15 minutes and then quenched with 
water, extracted 3 times with CH2Cl2, dried over Na2SO4, and concentrated under 
reduced pressure.  Immediate purification by flash chromatography on silica gel 
(Hexanes - 25% EtOAc/hexanes) afforded (3S,8R)-21 (0.105 g, 95.3%) as a beige oil. 
TLC Rf = 0.192 (25% EtOAc/hexanes); [α]D
18 = +50.9° (c = 1.0, CHCl3); 
1H NMR (500 
MHz, CHLOROFORM-d)  7.76 - 7.80 (m, 2H), 7.49 - 7.54 (m, 1H), 7.41 - 7.46 (t, J = 
7.76 Hz, 2H), 6.43 (d, J = 8.39 Hz, 1H), 5.94 (ddd, J = 5.34, 10.17, 17.04 Hz, 1H), 5.44 - 
5.50 (m, 1H), 5.25 (dd, J = 0.76, 10.17 Hz, 1H), 5.05 (q, J = 7.38 Hz, 1H), 4.92 - 4.96 (m, 
1H), 2.55 (br. s., 1H), 1.73 - 1.84 (m, 2H), 1.43 - 1.51 (m, 2H), 1.22 - 1.37 (m, 12H), 0.88 
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(t, J = 6.99 Hz, 3H); 13C NMR (125 MHz, CHLOROFORM-d)  166.4, 135.8, 133.7, 
131.8, 128.6, 127.0, 117.2, 79.6, 77.0, 70.3, 67.2, 63.4, 42.4, 35.7, 31.8, 29.5, 29.4, 29.2, 
29.1, 25.7, 22.6, 14.1; IR (ATR) 3275, 2922, 2854, 1633, 1524 cm-1; HRMS (ESI-TOF) 
[M + H]+ calcd. for C24H32NO2 366.2433, found 366.2436. 
 
 
 (R)-N-butyldodec-1-yn-3-amine (R)-22 
To a solution of (R)-19 (0.162 g, 0.89 mmol) in methanol (4.1 mL) under argon 
atmosphere was added butyraldehyde (0.11 mL, 1.2 mmol).  Reaction mixture was stirred 
at ambient temperature for 20 minutes and then chilled to 0°C at which time NaBH4 was 
added (0.035 g, 0.91 mmol).  Reaction mixture was stirred for 1 hour and then diluted 
with EtOAc, washed with saturated NaHCO3, dried over Na2SO4, and concentrated under 
reduced pressure to yield (R)-22 (0.188 g, 88.9%) as a clear oil.  TLC Rf = 0.566 (40% 
EtOAc/hexanes); [α]D
18 = +15.1° (c = 1.7, CHCl3); 
1H NMR (500 MHz, 
CHLOROFORM-d)  3.36 (t, J = 6.86 Hz, 1H), 2.82 - 2.91 (m, 1H), 2.54 - 2.63 (m, 1H), 
2.27 (s, 1H), 1.20 - 1.68 (m, 21H), 0.85 - 0.98 (m, 6H); 13C NMR (125 MHz, 
CHLOROFORM-d)  85.8, 71.1, 50.1, 47.2, 35.9, 32.1, 31.9, 29.5, 29.5, 29.4, 29.3, 26.0, 
22.7, 20.5, 14.1, 14.0; IR (ATR) 3659, 3248, 2925, 1686, 1525, 1253 cm-1. 
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 (3S,8R)-8-(butylamino)heptadeca-1-en-4,6-diyn-3-ol (3S,8R)-23 
Copper (I) chloride (0.006 g, 0.06 mmol) was added to a stirred 30 % solution (1.1 mL) 
of n-butylamine in distilled water at 0 °C which resulted in a deep blue solution.  A few 
crystals of NH2OH.HCl were added until solution was colorless.  A solution of (R)-22 
(0.087 g, 0.37 mmol) in CH2Cl2 (0.55 mL) was added under argon atmosphere which 
resulted in yellow reaction mixture.  After 10 minutes, a solution of (S)-6 (0.118 g, 0.73 
mmol) in CH2Cl2 (1.1 mL) was added dropwise over 5 minutes.  A few crystals of 
NH2OH.HCl were added as necessary whenever solution turned blue or green.  After 45 
minutes, reaction was quenched with water, extracted 3 times with CH2Cl2, dried over 
Na2SO4, and concentrated under reduced pressure.  Immediate purification by flash 
chromatography on silica gel (hexanes – 15% EtOAc/hexanes) afforded (3S,8R)-23 
(0.063 g, 53.9%, tan solid).  TLC Rf = 0.473 (40% EtOAc/hexanes); [α]D
21 = +59.7° (c = 
1.0, CHCl3); 
1H NMR (500 MHz, CHLOROFORM-d)  5.95 (ddd, J = 5.38, 10.15, 17.00 
Hz, 1H), 5.46 (td, J = 1.01, 17.30 Hz, 1H), 5.22 - 5.27 (td, J = 1.10, 10.03 Hz, 1H), 4.92 
(d, J = 5.38 Hz, 1H), 3.42 (dd, J = 5.62, 8.31 Hz, 1H), 2.83 (ddd, J = 6.24, 8.62, 11.07 
Hz, 1H), 2.56 (ddd, J = 5.62, 8.50, 11.07 Hz, 1H), 1.74 – 2.20 (br. s., 1H), 1.20 - 1.69 (m, 
21H), 0.90 – 0.94 (t, J=7.21 Hz, 3 H), 0.85 – 0.89 (t, J=6.97 Hz, 3 H); 13C NMR (125 
MHz, CHLOROFORM-d)  136.2, 117.0, 82.9, 76.1, 70.7, 67.3, 63.4, 50.8, 47.2, 35.7, 
32.0, 31.9, 29.5, 29.5, 29.3, 29.3, 26.0, 22.7, 20.5, 14.1, 14.0; IR (ATR) 3676, 3249, 
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2922, 2853, 2682, 1028 cm-1; HRMS (ESI-TOF) [M + H]+ calcd. for C21H36NO 
318.2797, found 318.2787. 
 
 
 (3S,8R)-8-(4-chlorobenzamido)heptadeca-1-en-4,6-diyn-3-yl acetate (3S,8R)-24 
To a solution of (3S,8R)-11 (0.056 g, 0.19 mmol) in CH2Cl2 (1.8 mL) at 0°C under Ar 
atmosphere was added triethylamine (0.04 mL, 0.29 mmol) followed by a solution of 4-
chlorobenzoyl chloride (0.05 g, 0.29 mmol) in CH2Cl2 (1 mL).  Reaction mixture was 
stirred at 0°C for 3 hours and 15 minutes. Reaction was then quenched with water, 
extracted three times with CH2Cl2, washed with saturated NaHCO3, dried over Na2SO4, 
and concentrated under reduced pressure.  Purification by flash chromatography on silica 
gel (hexanes – 15% EtOAc/hexanes) afforded (3S,8R)-24 (0.028 g, 34.4%) as a yellow 
oil.  TLC Rf = 0.260 (15% EtOAc/hexanes); [α]D
18 = -19.9° (c = 0.9, CHCl3); 
1H NMR 
(500 MHz, CHLOROFORM-d)  7.70 - 7.75 (m, 2H), 7.39 - 7.44 (m, 2H), 6.39 (d, J = 
8.56 Hz, 1H), 5.81 - 5.92 (m, 2H), 5.50 - 5.58 (m, 1H), 5.31 - 5.39 (m, 1H), 5.01 (q, J = 
7.50 Hz, 1H), 2.09 - 2.12 (s, 3H), 1.72 - 1.82 (m, 2H), 1.41 - 1.51 (m, 2H), 1.22 - 1.36 
(m, 12H), 0.85 - 0.91 (t, J = 6.97 Hz, 3H); 13C NMR (125 MHz, CHLOROFORM-d)  
169.5, 165.3, 138.1, 132.1, 131.8, 128.9, 128.5, 119.8, 79.7, 73.5, 70.9, 67.1, 64.4, 42.5, 
35.6, 31.8, 29.5, 29.4, 29.2, 29.1, 25.7, 22.6, 20.9, 14.1; IR (ATR) 3301, 2925, 2855, 
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2259, 1748, 1638, 1532, 1486, 1220 cm-1; HRMS (ESI-TOF) [M + H]+ calcd. for 
C26H33ClNO3 442.2149, found 442.2096. 
 
 
 (3S,8R)-8-(3,4-dichlorobenzamido)heptadeca-1-en-4,6-diyn-3-yl acetate (3S,8R)-25 
 
To a solution of (3S,8R)-11 (0.060 g, 0.20 mmol) in CH2Cl2 (2.0 mL) at 0°C under Ar 
atmosphere was added triethylamine (0.03 mL, 0.24 mmol) followed by a solution of 3,4-
dichlorobenzoyl chloride (0.051 g, 0.25 mmol) in CH2Cl2 (1 mL).  Reaction mixture was 
stirred at 0°C for 1.5 hours. Reaction was then quenched with water, extracted three times 
with CH2Cl2, washed with saturated NaHCO3, dried over Na2SO4, and concentrated 
under reduced pressure.  Purification by flash chromatography on silica gel (hexanes – 
15% EtOAc/hexanes) afforded (3S,8R)-25 (0.039 g, 41.1%) as a yellow oil.  TLC Rf = 
0.231 (15% EtOAc/hexanes); [α]D
22 = -19.9° (c = 1.0, CHCl3); 
1H NMR (500 MHz, 
CHLOROFORM-d)  7.90 (d, J = 2.20 Hz, 1H), 7.63 (dd, J = 2.08, 8.44 Hz, 1H), 7.51 
(d, J = 8.56 Hz, 1H), 6.60 (d, J = 8.31 Hz, 1H), 5.82 - 5.91 (m, 2H), 5.50 - 5.57 (m, 1H), 
5.32 - 5.37 (m, 1H), 4.99 (t, J = 7.50 Hz, 1H), 2.10 - 2.13 (s, 3H), 1.72 - 1.82 (m, 2H), 
1.40 - 1.50 (m, 2H), 1.23 - 1.34 (m, 12H), 0.85 - 0.90 (t, J = 6.97 Hz, 3H); 13C NMR (125 
MHz, CHLOROFORM-d)  169.6, 164.2, 136.2, 133.5, 133.1, 131.8, 130.6, 129.3, 
126.3, 119.8, 79.4, 73.6, 70.9, 67.2, 64.5, 42.6, 35.5, 31.8, 29.5, 29.4, 29.2, 29.0, 25.7, 
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22.6, 20.9, 14.1; IR (ATR) 3253, 2923, 2855, 1744, 1636, 1535, 1226 cm-1; HRMS (ESI-
TOF) [M + H]+ calcd. for C26H32Cl2NO3 476.1759, found 476.1770. 
 
 
 (3S,8R)-8-(4-methylbenzamido)heptadeca-1-en-4,6-diyn-3-yl acetate (3S,8R)-26 
To a solution of (3S,8R)-11 (0.032 g, 0.10 mmol) in CH2Cl2 (1.0 mL) at 0°C under Ar 
atmosphere was added triethylamine (0.06 mL, 0.43 mmol) followed by a solution of p-
toluoyl chloride (0.02 mL, 0.15 mmol) in CH2Cl2 (1.0 mL).  Reaction mixture was stirred 
at 0°C for 45 minutes. Reaction was then quenched with water, extracted three times with 
CH2Cl2, dried over Na2SO4, and concentrated under reduced pressure.  Purification by 
flash chromatography on silica gel (hexanes – 15% EtOAc/hexanes) afforded (3S,8R)-26 
but it was contaminated with p-toluic acid per GC/MS analysis.  Diluted product with 
ether, washed four times with saturated NaHCO3, washed once with brine, dried over 
Na2SO4, and concentrated under reduced pressure which afforded purified (3S,8R)-26 
(0.030 g, 67.7%, yellow oil).   TLC Rf = 0.538 (25% EtOAc/hexanes); [α]D
21 = -12.5° (c = 
0.8, CHCl3); 
1H NMR (500 MHz, CHLOROFORM-d)  7.67 (d, J = 8.31 Hz, 2H), 7.22 - 
7.26 (m, 2H), 6.27 (d, J = 8.31 Hz, 1H), 5.83 - 5.93 (m, 2H), 5.52 - 5.58 (m, 1H), 5.33 - 
5.38 (m, 1H), 5.01 - 5.08 (q, J = 7.50 Hz, 1H), 2.40 (s, 3H), 2.10 - 2.14 (s, 3H), 1.72 - 
1.82 (m, 2H), 1.43 - 1.52 (m, 2H), 1.22 - 1.36 (m, 12H), 0.88 (t, J = 6.97 Hz, 3H); 13C 
NMR (125 MHz, CHLOROFORM-d)  169.5, 166.2, 142.3, 131.9, 130.9, 129.2, 127.0, 
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119.7, 80.1, 73.3, 71.0, 66.9, 64.4, 42.3, 35.7, 31.8, 29.5, 29.4, 29.2, 29.1, 25.6, 22.6, 
21.5, 20.9, 14.1; IR (ATR) 3670, 3268, 2920, 2853, 2259, 1744, 1632, 1530, 1504, 1219 
cm-1; HRMS (ESI-TOF) [M + H]+ calcd. for C27H36NO3 422.2695, found 422.2672. 
 
 
 (3S,8R)-8-(4-methoxybenzamido)heptadeca-1-en-4,6-diyn-3-yl acetate (3S,8R)-27 
To a solution of (3S,8R)-11 (0.045 g, 0.15 mmol) in CH2Cl2 (2.0 mL) at 0°C under Ar 
atmosphere was added triethylamine (0.06 mL, 0.43 mmol) followed by a solution of 4-
methoxybenzoyl chloride (0.043 g, 0.25 mmol) in CH2Cl2 (1 mL).  Reaction mixture was 
stirred at 0°C for 1 hour and 50 minutes. Reaction was then quenched with water, 
extracted three times with CH2Cl2, washed with saturated NaHCO3, dried over Na2SO4, 
and concentrated under reduced pressure.  Purification by flash chromatography on silica 
gel (hexanes – 15% EtOAc/hexanes) afforded (3S,8R)-27 (0.014 g, 21.8%) as a yellow 
oil.  [α]D
18 = -19.7° (c = 0.3, CHCl3); 
1H NMR (500 MHz, CHLOROFORM-d)  7.70 - 
7.77 (m, 2H), 6.90 - 6.97 (m, 2H), 6.18 (d, J = 8.48 Hz, 1H), 5.83 - 5.93 (m, 2H), 5.52 - 
5.58 (m, 1H), 5.33 - 5.38 (m, 1H), 5.04 (q, J = 7.40 Hz, 1H), 3.86 (s, 3H), 2.10 - 2.13 (s, 
3H), 1.71 - 1.83 (m, 2H), 1.42 - 1.52 (m, 2H), 1.19 - 1.38 (m, 12H), 0.85 - 0.92 (t, J = 
6.98 Hz, 3H); 13C NMR (125 MHz, CHLOROFORM-d)  169.4, 165.8, 162.4, 132.0, 
128.8, 126.1, 119.7, 113.8, 80.2, 73.4, 71.0, 66.9, 64.4, 55.4, 42.3, 35.8, 31.8, 29.5, 29.4, 
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29.2, 29.1, 25.7, 22.6, 20.9, 14.1; IR (ATR) 3277, 2924, 2854, 2263, 1733, 1628, 1506, 
1242 cm-1; HRMS (ESI-TOF) [M + H]+ calcd. for C27H36NO4 438.2644, found 438.2611. 
 
 
 
 (3S,8R)-8-benzamido-11-cyclohexylundeca-1-en-4,6-diyn-3-yl acetate (3S,8R)-28 
To a solution (3S,8R)-35 (0.047 g, 0.15 mmol) in CH2Cl2 (1.7 mL) at 0°C under Ar was 
added benzoic anhydride (0.045 g, 0.20 mmol) followed by triethylamine (0.03 mL, 0.22 
mmol).  Reaction mixture was stirred for 15 minutes at 0°C and then allowed to warm to 
ambient temperature.  After 1 hour and 30 minutes, reaction mixture was quenched with 
water, extracted three times with CH2Cl2, washed with saturated NaHCO3, dried over 
Na2SO4, and concentrated under reduced pressure.  Purification by flash chromatography 
on silica gel (hexanes – 15% EtOAc/hexanes) afforded (3S,8R)-28 (0.050 g, 79.6%) as a 
yellow oil 
Rf = 0.400 (25% EtOAc/hexanes); [α]D
18 = -4.3° (c = 0.6, CHCl3); 
1H NMR (500 MHz, 
CHLOROFORM-d) δ 7.78 (d, J = 7.34 Hz, 2H), 7.52 (t, J = 7.34 Hz, 1H), 7.44 (t, J = 
7.46 Hz, 2H), 6.41 (d, J = 8.31 Hz, 1H), 5.82 - 5.93 (m, 2H), 5.51 - 5.59 (d, J = 16.14 Hz, 
1H), 5.35 (d, J = 9.29 Hz, 1H), 5.04 (q, J = 7.42 Hz, 1H), 2.11 (s, 3H), 1.60 - 1.82 (m, 
7H), 1.43 - 1.53 (m, 2H), 1.09 - 1.27 (m, 6H), 0.80 - 0.93 (m, 2H) 13C NMR (125 MHz, 
CHLOROFORM-d) δ 169.5, 166.3, 133.7, 131.8, 131.8, 128.6, 127.0, 119.7, 80.0, 73.3, 
71.0, 66.9, 64.4, 42.3, 37.4, 36.8, 35.9, 33.3, 33.2, 26.6, 26.3, 23.0, 20.9; IR (ATR) 3300, 
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2922, 2851, 2257, 1747, 1639, 1527, 1219 cm-1; HRMS (ESI-TOF) [M + H]+ calcd. for 
C26H32NO3 406.2382, found 406.2365. 
  
 
4-cyclohexylbutan-1-ol 29 
To a solution of cyclohexanebutyric acid (2.508 g, 14.7 mmol) in Et2O (58 mL) at 0°C 
under Ar was added lithium aluminum hydride (1.250 g, 32.9 mmol) in two portions.  
Reaction mixture was stirred for two hours at 0°C and then quenched with H2O (1.3 mL).  
After stirring 20 minutes, added 4M NaOH (1.3 mL).  After stirring 30 minutes, added 
H20 (5.2 mL).  After stirring 1 hour, filtered through Celite, dried over Na2SO4, and 
concentrated under reduced pressure which afforded 29 (1.391 g, 60.4%) as a light 
yellow oil.  29 used without further purification in the synthesis of 30.  TLC Rf = 0.259 
(25% EtOAc/hexanes); 1H NMR (500 MHz, CHLOROFORM-d) δ 3.60 - 3.65 (t, J = 
7.34 Hz, 2H), 1.59 - 1.73 (m, 6H), 1.49 - 1.57 (m, 2H), 1.30 - 1.38 (m, 2H), 1.11 - 1.26 
(m, 6H), 0.80 - 0.92 (m, 2H); 13C NMR (125 MHz, CHLOROFORM-d)  63.0, 37.6, 
37.2, 33.3, 33.0, 26.7, 26.4, 23.0; IR(ATR) 3340, 2920, 2850, 1448 cm-1.  
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4-cyclohexylbutanal 30 
A solution of oxalyl chloride (0.88 mL, 10.3 mmol) in CH2Cl2 (72 mL) was chilled to -
78°C.  Added solution of DMSO (1.3 mL) in CH2Cl2 (7.2 mL) was added over three 
minutes and stirred for two more minutes.  Next, a solution of 29 (1.34 g, 8.6 mmol) in 
CH2Cl2 (7.2 mL) was added over three minutes.  Reaction mixture stirred for 40 minutes 
at -78°C.  Added triethylamine (6.0 mL) over three minutes and allowed reaction to warm 
to RT.  After 2 hours and 40 minutes, quenched with H20 and adjusted to pH ~ 4 with 1M 
HCl.  Extracted with CH2Cl2, washed with H2O, washed with brine, dried over Na2SO4, 
and concentrated under reduced pressure.  Ran resultant yellow oil through thin pad of 
silica gel with 25% EtOAc/hexanes which afforded 30 (1.26 g, 95.0%) as a clear oil.  
TLC Rf = 0.593 (25% EtOAc/hexanes); 
1H NMR (500 MHz, CHLOROFORM-d)  9.74 - 
9.76 (t, J = 1.88 Hz, 1H), 2.37 - 2.42 (dt, J = 1.95, 7.50 Hz, 2H), 1.59 - 1.73 (m, 7H), 
1.14 - 1.26 (m, 6H), 0.80 - 0.92 (m, 2H); 13C NMR (125 MHz, CHLOROFORM-d)  
202.9, 44.1, 37.4, 36.9, 33.1, 26.6, 26.3, 19.4; IR (ATR) 2920, 2850, 1728, 1711, 1448 
cm-1. 
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 (S)-6-cyclohexyl-1-(trimethylsilyl)hex-1-yn-3-ol (S)-31; (R)-6-cyclohexyl-1-
(trimethylsilyl)hex-1-yn-3-yl acetate (R)-32 
 
To a solution of (trimethylsilyl)acetylene (1.5 mL, 10.8 mmol) in dry Et2O (13 mL) at -78 
°C was added dropwise a solution of n-butyllithium (2.25 M in hexanes, 4.2 mL, 9.4 
mmol) over five minutes under an Ar atmosphere.  The reaction mixture was then stirred 
for 50 minutes before a solution of 30 (1.26 g, 8.1 mmol) in Et2O (8 mL) was added 
dropwise over five minutes.  Stirred at -78 °C for 10 minutes and then allowed to warm 
to ambient temperature.  After stirring for 2 hours, the mixture was quenched by slow 
addition of saturated NH4Cl.  The mixture was extracted with Et2O, washed with H20 and 
brine, dried over Na2SO4, and concentrated under reduced pressure which afforded ±31 
(2.04 g, 99.5%) as a yellow oil.  The resultant yellow oil (±31) was used directly in the 
next reaction without further purification. 
 
 ±31 (2.00 g, 7.9 mmol) was dissolved in dry hexanes (31 ml) followed by the addition of 
ground, activated 4-Å molecular sieves (0.52 g) and lipase (Pseudomonas fluorescens, 
Amano Lipase AK, 0.30 g).  To the well-stirred suspension was added vinyl acetate (3.0 
mL, 32.5 mmol) over 3 minutes.  The suspension was stirred under an Ar atmosphere for 
24 hours and then filtered through a pad of Celite and concentrated under reduced 
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pressure.  The resulting yellow oil was purified by silica gel chromatography (hexanes-
15% EtOAc/hexanes) to give (S)-31 (0.66 g, 33.3%, yellow oil) and (R)-32 (0.78 g, 
33.3%, yellow oil). 
 
Data for ±31 racemic:  TLC Rf = 0.371 (15% EtOAc/hexanes); 
1H NMR (500 MHz, 
CHLOROFORM-d)  4.35 (t, J = 6.60 Hz, 1H), 1.82 (br. s., 1H), 1.61 - 1.75 (m, 7H), 
1.39 - 1.50 (m, 2H), 1.16 - 1.28 (m, 6H), 0.82 – 0.93 (m, 2H), 0.18 (s, 9H); 13C NMR 
(125 MHz, CHLOROFORM-d)  106.9, 89.3, 62.9, 37.9, 37.4, 36.9, 33.3, 33.3, 26.7, 
26.4, 22.3, -0.1; IR (ATR) 3684, 3361, 2922, 2852, 2174, 1250, 840 cm-1. 
 
Data for (S)-31:  TLC Rf = 0.371 (15% EtOAc/hexanes); [α]D
18 = +3.6° (c = 1.1, CHCl3); 
IR (ATR) 3676, 3314, 2921, 2852, 2171, 1249, 840 cm-1; HRMS (ESI-TOF) [M + H]+ 
calcd. for C15H29OSi 253.1988, found 253.1983. 
 
 
Data for (R)-32: TLC Rf = 0.567 (15% EtOAc/hexanes); [α]D
21 = +69.7° (c = 1.4, CHCl3); 
IR (ATR) 2922, 2852, 2182, 1747, 1230, 841 cm-1. 
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(R)-2-(6-cyclohexyl-1-(trimethylsilyl)hex-1-yn-3-yl)isoindoline-1,3-dione (R)-33 
 
To a solution of (S)-31 (0.447 g, 1.8 mmol) in THF (14 mL) was added phthalimide 
(0.374 g, 2.5 mmol) followed by triphenylphosphine (0.665 g, 2.5 mmol).  The reaction 
mixture was then chilled to 0°C followed by the dropwise addition of DIAD (0.67 mL, 
3.2 mmol) and stirred at 0°C under Ar atmosphere.  After 3 hours, reaction mixture was 
concentrated under reduced pressure, diluted with Et2O, and chilled to 0°C.  Slowly 
added hexanes until precipitate formed.  Precipitate was filtered off through Celite and 
the filtrate was concentrated under reduced pressure.  The resultant yellow oil was 
purified by silica gel chromatography (Hexanes – 5% EtOAc/Hexanes) to afford (R)-33 
(0.643 g, 95,3%, yellow crystals).  TLC Rf = 0.415 (15% EtOAc/hexanes); [α]D
18 = -2.4° 
(c = 1.0, CHCl3); IR (ATR) 2920, 2855, 2173, 1709, 1385 cm
-1; HRMS (ESI-TOF) [M + 
H]+ calcd. for C23H32NO2Si 382.2202, found 382.2209. 
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 (R)-6-cyclohexylhex-1-yn-3-amine (R)-34 
To a solution of (R)-33 (0.620 g, 1.6 mmol) in 200 proof ethanol (18 mL) was added 85% 
hydrazine monohydrate in H20 (0.10 mL).  Solution was heated to reflux under Ar 
atmosphere.  After four hours, reaction was cooled to ambient temperature.  Reaction pH 
was adjusted to pH~3 with 1M HCl.  It was then filtered through a Celite pad and rinsed 
through with methanol.  Filtrate pH was adjusted to pH~13 with 1M NaOH and stirred 
for 50 minutes at ambient temperature.  Reaction mixture was then diluted with H20, 
extracted with Et2O, washed with saturated NaHCO3, and dried over Na2SO4.  Extract 
was concentrated under reduced pressure at 0°C.  After concentration, it was observed 
that there was still H20 in the concentrate.  Diluted concentrate with Et2O, washed with 
brine, dried over Na2SO4, and concentrated under reduced pressure at 0°C.  The resultant 
yellow oil was purified by flash chromatography on silica gel (Hexanes – 60% 
EtOAc/Hexanes) to give (R)-34 (0.174 g, 59.7%, light yellow oil).  TLC Rf = 0.189 (60% 
EtOAc/hexanes); [α]D
18 = -4.9° (c = 0.5, CHCl3); IR (ATR) 3309, 2921, 2851 cm
-1; 
HRMS (ESI-TOF) [M + H]+ calcd. for C12H22N 180.1752, found 180.1749. 
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 (3S,8R)-8-amino-11-cyclohexylundeca-1-en-4,6-diyn-3-yl acetate (3S,8R)-35 
Copper (I) chloride (0.0099 g, 0.10 mmol) was added to a stirred 30 % solution (1.7 mL) 
of n-butylamine in distilled water at 0 °C which resulted in a deep blue solution.  A few 
crystals of NH2OH.HCl were added until solution was colorless.  A solution of (R)-34 
(0.0918 g, 0.51 mmol) in CH2Cl2 (1.0 mL) was added under argon atmosphere which 
resulted in yellow reaction mixture.  After 10 minutes, a solution of (S)-2 (0.20 g, 0.99 
mmol) in CH2Cl2 (1.0 mL) was added dropwise over 5 minutes.  A few crystals of 
NH2OH.HCl were added as necessary whenever solution turned blue or green.  After 20 
minutes, reaction was quenched with water, extracted 3 times with CH2Cl2, dried over 
Na2SO4, and concentrated under reduced pressure.  Immediate purification by flash 
chromatography on silica gel (hexanes – 50% EtOAc/hexanes) afforded (3S,8R)-35 
(0.109 g, 70.6%, red-orange oil). 
[α]D
18 = +6.2° (c = 1.3, CHCl3); 
1H NMR (500 MHz, CHLOROFORM-d) δ 5.83 - 5.94 
(m, 2H), 5.50 - 5.58 (dd, J = 1.50, 16.46 Hz, 1H), 5.31 - 5.37 (dd, J = 1.38, 9.60 Hz, 1H), 
3.55 - 3.62 (t, J = 6.73 Hz, 1H), 2.09 - 2.11 (s, 3H), 1.50 - 1.74 (m, 9H), 1.35 - 1.49 (m, 
2H), 1.07 - 1.27 (m, 6H), 0.80 - 0.92 (m, 2H); 13C NMR (125 MHz, CHLOROFORM-d) 
δ 169.5, 132.1, 119.5, 84.6, 73.0, 71.3, 66.2, 64.5, 44.0, 37.7, 37.4, 37.0, 33.3, 33.3, 26.6, 
26.3, 23.1, 20.9; IR (ATR) 2921, 2851, 2254, 1746, 1219 cm-1. 
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 (3S,8R)-8-aminoheptadeca-1-en-4,6-diyn-3-ol (3S,8R)-36 
Copper (I) chloride (0.008 g, 0.08 mmol) was added to a stirred 30 % solution (1.65 mL) 
of n-butylamine in distilled water at 0 °C which resulted in a deep blue solution.  A few 
crystals of NH2OH.HCl were added until solution was colorless.  A solution of (R)-19 
(0.106 g, 0.58 mmol) in CH2Cl2 (0.8 mL) was added under argon atmosphere which 
resulted in yellow reaction mixture.  After 10 minutes, a solution of (S)-6 (0.180 g, 1.11 
mmol) in CH2Cl2 (1.7 mL) was added dropwise over 5 minutes.  A few crystals of 
NH2OH.HCl were added as necessary whenever solution turned blue or green.  After 45 
minutes, reaction was quenched with water, extracted 3 times with CH2Cl2, dried over 
Na2SO4, and concentrated under reduced pressure.  Immediate purification by flash 
chromatography on silica gel (hexanes – 50% EtOAc/hexanes) afforded (3S,8R)-36 
(0.068 g, 44.6%, brown oil).  TLC Rf = 0.097 (60% EtOAc/hexanes); [α]D
21 = +37.0° (c = 
1.4, CHCl3); IR (ATR) 3675, 3345, 2988, 2901, 1066.  
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 (3S,8R)-8-(3-bromobenzamido)heptadeca-1-en-4,6-diyn-3-yl acetate (3S,8R)-37 
To a solution of (3S,8R)-11 (0.060 g, 0.20 mmol) in CH2Cl2 (1.0 mL) at 0°C under Ar 
atmosphere was added triethylamine (0.04 mL, 0.29 mmol) followed by a solution of 3-
bromobenzoyl chloride (0.03 mL, 0.23 mmol) in CH2Cl2 (1 mL).  Reaction mixture was 
stirred at 0°C for 1 hour and 10 minutes. Reaction was then quenched with saturated 
NH4Cl, diluted with Et20, extracted three times with Et2O, washed with water, saturated 
NaHCO3, and brine, dried over Na2SO4, and concentrated under reduced pressure.  
Purification by flash chromatography on silica gel (hexanes – 15% EtOAc/hexanes) 
afforded (3S,8R)-37 (0.051 g, 53.2%) as a yellow-orange oil. 
TLC Rf = 0.491 (25% EtOAc/hexanes); [α]D
18 = -11.6° (c = 2.3, CHCl3);  
1H NMR (500 
MHz, CHLOROFORM-d)  7.93 (s, 1H), 7.71 (d, J = 7.58 Hz, 1H), 7.62 - 7.66 (m, 1H), 
7.31 (t, J = 7.83 Hz, 1H), 6.51 (d, J = 8.31 Hz, 1H), 5.83 - 5.92 (m, 2H), 5.51 - 5.58 (m, 
1H), 5.32 - 5.38 (m, 1H), 5.01 (q, J = 7.34 Hz, 1H), 2.11 (s, 3H), 1.73 - 1.82 (m, 2H), 
1.42 - 1.51 (m, 2H), 1.22 - 1.35 (m, 12H), 0.88 (t, J = 6.85 Hz, 3H) 13C NMR (125 MHz, 
CHLOROFORM-d)  169.6, 165.0, 135.7, 134.7, 131.8, 130.2, 130.2, 125.7, 122.7, 
119.8, 79.6, 73.5, 70.9, 67.2, 64.5, 42.5, 35.6, 31.8, 29.5, 29.4, 29.2, 29.0, 25.6, 22.6, 
20.9, 14.1; IR (ATR) 3246, 2920, 2852, 1745, 1634, 1530, 1218 cm-1; HRMS (ESI-TOF) 
[M + H]+ calcd. for C26H33BrNO3 486.1644, found 486.1675. 
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 (3S,8R)-8-(3-methylbenzamido)heptadeca-1-en-4,6-diyn-3-yl acetate (3S,8R)-38 
To a solution of (3S,8R)-11 (0.059 g, 0.20 mmol) in CH2Cl2 (1.0 mL) at 0°C under Ar 
atmosphere was added triethylamine (0.04 mL, 0.29 mmol) followed by a solution of m-
toluoylbenzoyl chloride (0.03 mL, 0.23 mmol) in CH2Cl2 (1 mL).  Reaction mixture was 
stirred at 0°C for 1 hour and 40 minutes. Reaction was then quenched with saturated 
NH4Cl, diluted with Et20, extracted three times with Et2O, washed with water, saturated 
NaHCO3, and brine, dried over Na2SO4, and concentrated under reduced pressure.  
Purification by flash chromatography on silica gel (hexanes – 15% EtOAc/hexanes) 
afforded (3S,8R)-38 but was contaminated with m-toluoylcarboxylic acid.  Product was 
diluted with Et2O, washed ten times with saturated NaHCO3,  washed twice with brine, 
dried over Na2SO4, and concentrated under reduced pressure to afford (3S,8R)-38 (0.035 
g, 42.7%) as a yellow solid.  TLC Rf = 0.358 (25% EtOAc/hexanes); [α]D
18 = -6.8° (c = 
1.9, CHCl3);  
1H NMR (500 MHz, CHLOROFORM-d)  7.59 (s, 1H), 7.55 (t, J = 3.30 
Hz, 1H), 7.32 (d, J = 5.14 Hz, 2H), 6.33 (d, J = 8.31 Hz, 1H), 5.83 - 5.92 (m, 2H), 5.52 - 
5.59 (d, J = 15.65 Hz, 1H), 5.33 - 5.38 (d, J = 9.05 Hz, 1H), 5.04 (q, J = 7.34 Hz, 1H), 
2.40 (s, 3H), 2.11 (s, 3H), 1.73 - 1.82 (m, 2H), 1.43 - 1.52 (m, 2H), 1.22 - 1.36 (m, 12H), 
0.88 (t, J = 6.97 Hz, 3H); 13C NMR (125 MHz, CHLOROFORM-d)  169.5, 166.5, 
138.5, 133.7, 132.5, 131.9, 128.5, 127.7, 124.0, 119.7, 80.0, 73.3, 71.0, 66.9, 64.4, 42.3, 
35.7, 31.8, 29.5, 29.4, 29.2, 29.1, 25.6, 22.6, 21.3, 20.9, 14.1; IR (ATR) 3258, 2920, 
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2852, 1742, 1637, 1529, 1218 cm-1; HRMS (ESI-TOF) [M + H]+ calcd. for C27H36NO3 
422.2695, found 422.2714. 
 
 
 (3S,8R)-8-(3-(trifluoromethyl)benzamido)heptadeca-1-en-4,6-diyn-3-yl acetate 
(3S,8R)-39 
To a suspension of 3-(trifluoromethyl)benzoic acid (0.045 g, 0.24 mmol) in CH2Cl2 (1.0 
mL) at 0°C under Ar was added DCC (0.051 g, 0.25 mmol).  Then a solution of (3S,8R)-
11 (0.060 g, 0.20 mmol) in CH2Cl2 (1.0 mL) was added followed by addition of DMAP 
(5.8 mg, 0.047 mmol).  After 1 hour and 20 minutes, reaction was quenched with 
saturated NH4Cl, diluted with Et20, extracted three times with Et2O, washed with water, 
saturated NaHCO3, and brine, dried over Na2SO4, and concentrated under reduced 
pressure.  .  Purification by flash chromatography on silica gel (hexanes – 20% 
EtOAc/hexanes) afforded (3S,8R)-39 (0.058 g, 62.2%) as a yellow oil. 
TLC Rf = 0.481 (20% EtOAc/hexanes); [α]D
18 = -8.2° (c = 0.5, CHCl3); 
1H NMR (500 
MHz, CHLOROFORM-d)  8.06 (s, 1H), 7.99 (d, J = 7.83 Hz, 1H), 7.77 (d, J = 7.58 Hz, 
1H), 7.54 - 7.61 (t, J = 7.83 Hz, 1H), 6.69 (d, J = 8.31 Hz, 1H), 5.81 - 5.92 (m, 2H), 5.49 
- 5.59 (m, 1H), 5.31 - 5.39 (m, 1H), 5.03 (q, J = 7.34 Hz, 1H), 2.11 (s, 3H), 1.74 - 1.85 
(m, 2H), 1.42 - 1.53 (m, 2H), 1.20 - 1.37 (m, 12H), 0.88 (t, J = 6.85 Hz, 3H); 13C NMR 
(125 MHz, CHLOROFORM-d)  169.6, 165.0, 134.5, 131.8, 130.4, 129.2, 128.4, 128.3, 
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124.1, 124.1, 119.8, 79.5, 73.5, 70.9, 67.2, 64.5, 42.6, 35.6, 31.8, 29.5, 29.4, 29.2, 29.0, 
25.7, 22.6, 20.9, 14.1; IR (ATR) 3245, 2921, 2853, 1749, 1640, 1534, 1124 cm-1; HRMS 
(ESI-TOF) [M + H]+ calcd. for C27H33F3NO3 476.2413, found 476.2429. 
 
 
 (3S,8R)-8-(3,5-dichlorobenzamido)heptadeca-1-en-4,6-diyn-3-yl acetate (3S,8R)-40 
To a suspension of 3,5-dichlorobenzoic acid (0.044 g, 0.23 mmol) in CH2Cl2 (1.0 mL) at 
0°C under Ar was added DCC (0.048 g, 0.23 mmol).  Then a solution of (3S,8R)-11 
(0.061 g, 0.20 mmol) in CH2Cl2 (1.0 mL) was added followed by addition of DMAP (3.7 
mg, 0.030 mmol).  After 2 hours and 40 minutes, reaction was quenched with saturated 
NH4Cl, diluted with Et20, extracted three times with Et2O, washed two times with water, 
washed 5 times with 1M NaOH, washed 2 times with brine, dried over Na2SO4, and 
concentrated under reduced pressure.  Purification by flash chromatography on silica gel 
(hexanes – 10% EtOAc/hexanes) afforded (3S,8R)-40 (0.037 g, 39.1%) as a yellow oil.  
TLC Rf = 0.448 (15% EtOAc/hexanes); [α]D
18 = -14.9° (c = 0.9, CHCl3); 
1H NMR (500 
MHz, CHLOROFORM-d)  7.67 (d, J = 1.71 Hz, 2H), 7.49 - 7.51 (m, 1H), 6.53 (d, J = 
8.31 Hz, 1H), 5.83 - 5.92 (m, 2H), 5.52 - 5.58 (m, 1H), 5.33 - 5.38 (m, 1H), 4.99 (q, J = 
7.50 Hz, 1H), 2.12 (s, 3H), 1.72 - 1.82 (m, 2H), 1.42 - 1.52 (m, 2H), 1.22 - 1.36 (m, 12H), 
0.88 (t, J = 6.97 Hz, 3H); 13C NMR (125 MHz, CHLOROFORM-d)  169.6, 163.9, 
136.6, 135.5, 131.7, 131.6, 125.7, 119.8, 79.3, 73.6, 70.9, 67.4, 64.5, 42.7, 35.5, 31.8, 
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29.5, 29.4, 29.2, 29.0, 25.6, 22.6, 20.9, 14.1; IR (ATR) 3255, 2924, 2855, 1746, 1637, 
1567, 1531, 1220 cm-1; HRMS (ESI-TOF) [M + H]+ calcd. for C26H32Cl2NO3 476.1759, 
found 476.1803. 
 
 
 (3S,8R)-8-(5-methylisoxazole-3-carboxamido)heptadeca-1-en-4,6-diyn-3-yl acetate 
(3S,8R)-41 
To a suspension of 5-methylisoxazole-3-carboxylic acid (0.052 g, 0.41 mmol) in CH2Cl2 
(1.6 mL) at 0°C under Ar was added DCC (0.062 g, 0.30 mmol).  Then a solution of 
(3S,8R)-11 (0.080 g, 0.26 mmol) in CH2Cl2 (1.0 mL) was added followed by addition of 
DMAP (5.5 mg, 0.045 mmol).  After 17 hours, reaction was quenched with saturated 
NH4Cl, extracted with CH2Cl2, washed with water and brine, dried over Na2SO4, and 
concentrated under reduced pressure.  .  Purification by flash chromatography on silica 
gel (hexanes – 15% EtOAc/hexanes) afforded (3S,8R)-41 (23.1 mg, 21.2%) as a yellow 
oil.  TLC Rf = 0.295 (25% EtOAc/hexanes); [α]D
18 = +31.8° (c = 0.25, CHCl3); 
1H NMR 
(500 MHz, CHLOROFORM-d) δ 6.93 (d, J = 8.56 Hz, 1H), 6.44 (d, J = 0.98 Hz, 1H), 
5.82 - 5.92 (m, 2H), 5.51 - 5.58 (m, 1H), 5.32 - 5.38 (m, 1H), 4.96 (q, J = 7.58 Hz, 1H), 
2.47 - 2.51 (d, J = 0.73 Hz, 3H), 2.09 - 2.13 (s, 3H), 1.73 - 1.80 (q, J = 7.58 Hz, 2H), 1.42 
- 1.50 (m, 2H), 1.22 - 1.35 (m, 12H), 0.85 - 0.90 (t, J = 7.09 Hz, 3H); 13C NMR (125 
MHz, CHLOROFORM-D) δ 171.4, 169.4, 158.2, 158.0, 131.9, 119.7, 101.4, 79.1, 73.5, 
70.9, 67.2, 64.4, 41.8, 35.4, 31.8, 29.4, 29.4, 29.2, 29.0, 25.5, 22.6, 20.9, 14.1, 12.3; IR 
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(ATR) 3315, 2921, 2853, 1746, 1657, 1535, 1218 cm-1; HRMS (ESI-TOF) [M + H]+ 
calcd. for C24H33N2O4 413.2440, found 413.2477. 
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(3S,8R)-8-(picolinamido)heptadeca-1-en-4,6-diyn-3-yl acetate (3S,8R)-42 
To a suspension of pyridine-2-carboxylic acid (0.031 g, 0.25 mmol) in CH2Cl2 (1.0 mL) 
at 0°C under Ar was added DCC (0.054 g, 0.26 mmol).  Then a solution of (3S,8R)-11 
(0.060 g, 0.20 mmol) in CH2Cl2 (1.0 mL) was added followed by addition of DMAP (3.9 
mg, 0.032 mmol).  After 2 hours and 10 minutes, reaction was quenched with saturated 
NH4Cl, diluted with Et20, extracted three times with Et2O, washed with water, saturated 
NaHCO3, and brine, dried over Na2SO4, and concentrated under reduced pressure.  
Purification by flash chromatography on silica gel (hexanes – 20% EtOAc/hexanes) 
afforded (3S,8R)-42 (0.061 g, 75.5%) as a yellow oil. 
TLC Rf = 0.357 (25% EtOAc/hexanes); [α]D
18 = +1.9° (c = 0.8, CHCl3); 
1H NMR (500 
MHz, CHLOROFORM-d)  8.56 (d, J = 4.65 Hz, 1H), 8.15 - 8.23 (t, J = 8.32 Hz, 2H), 
7.81 - 7.89 (apparent dt, J = 1.47, 7.75 Hz, 1H), 7.41 - 7.48 (m, 1H), 5.81 - 5.94 (m, 2H), 
5.53 (d, J = 16.14 Hz, 1H), 5.33 (d, J = 9.29 Hz, 1H), 4.96 - 5.05 (q, J = 7.50 Hz, 1H), 
2.09 (s, 3H), 1.76 - 1.85 (q, J = 7.50 Hz, 2H), 1.44 - 1.53 (m, 2H), 1.20 - 1.37 (m, 12H), 
0.87 (t, J = 6.85 Hz, 3H); 13C NMR (125 MHz, CHLOROFORM-d)  169.4, 163.2, 
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149.2, 148.1, 137.3, 131.9, 126.4, 122.4, 119.7, 79.9, 73.1, 71.1, 66.7, 64.4, 41.8, 35.6, 
31.8, 29.4, 29.4, 29.2, 29.0, 25.6, 22.6, 20.8, 14.1; IR (ATR) 3381, 2924, 2856, 2261, 
1747, 1678, 1508, 1220 cm-1; HRMS (ESI-TOF) [M + H]+ calcd. for C25H33N2O3 
409.2491, found 409.2517. 
 
 
 (3S,8R)-8-(pyrazine-2-carboxamido)heptadeca-1-en-4,6-diyn-3-yl acetate (3S,8R)-43 
To a suspension of pyrazinecarboxylic acid (0.033 g, 0.27 mmol) in CH2Cl2 (1.0 mL) at 
0°C under Ar was added DCC (0.053 g, 0.26 mmol).  Then a solution of (3S,8R)-11 
(0.062 g, 0.20 mmol) in CH2Cl2 (1.0 mL) was added followed by addition of DMAP (5.2 
mg, 0.043 mmol).  After 1 hour and 30 minutes, reaction was quenched with saturated 
NH4Cl, diluted with Et20, extracted three times with Et2O, washed with water, saturated 
NaHCO3, and brine, dried over Na2SO4, and concentrated under reduced pressure.  
Purification by flash chromatography on silica gel (hexanes – 25% EtOAc/hexanes) 
afforded (3S,8R)-43 (0.057 g, 68.1%) as a yellow oil.  TLC Rf = 0.226 (25% 
EtOAc/hexanes); [α]D
18 = 0.0° (c = 1.1, CHCl3); 
1H NMR (500 MHz, CHLOROFORM-d) 
 9.39 (s, 1H), 8.75 - 8.79 (s, 1H), 8.54 (s, 1H), 7.94 (d, J = 8.56 Hz, 1H), 5.81 - 5.92 (m, 
2H), 5.53 (d, J = 15.65 Hz, 1H), 5.33 (d, J = 9.05 Hz, 1H), 4.97 - 5.06 (q, J = 7.50 Hz, 
1H), 2.09 (s, 3H), 1.76 - 1.85 (q, J = 7.58 Hz, 2H), 1.42 - 1.52 (m, 2H), 1.19 - 1.36 (m, 
12H), 0.86 (t, J = 6.72 Hz, 3H); 13C NMR (125 MHz, CHLOROFORM-d)  169.4, 
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161.9, 147.5, 144.5, 143.8, 142.5, 131.8, 119.7, 79.3, 73.4, 70.8, 67.0, 64.3, 41.8, 35.5, 
31.8, 29.4, 29.3, 29.2, 29.0, 25.6, 22.6, 20.8, 14.1; IR (ATR) 3325, 2924, 2856, 2260, 
1746, 1675, 1513, 1220, 1012 cm-1; HRMS (ESI-TOF) [M + H]+ calcd. for C24H32N3O3 
410.2444, found 410.2467. 
 
 
 (3S,8R)-8-(furan-2-carboxamido)heptadeca-1-en-4,6-diyn-3-yl acetate (3S,8R)-44 
To a solution of (3S,8R)-11 (0.060 g, 0.20 mmol) in CH2Cl2 (1.0 mL) at 0°C under Ar 
atmosphere was added triethylamine (0.04 mL, 0.29 mmol) followed by a solution of 2-
furoyl chloride (0.02 mL, 0.21 mmol) in CH2Cl2 (1 mL).  Reaction mixture was stirred at 
0°C for 1 hour and 5 minutes. Reaction was then quenched with saturated NH4Cl, diluted 
with Et20, extracted three times with Et2O, washed with water, saturated NaHCO3, and 
brine, dried over Na2SO4, and concentrated under reduced pressure.  Purification by flash 
chromatography on silica gel (hexanes – 15% EtOAc/hexanes) afforded (3S,8R)-44 but it 
was contaminated with furan-2-carboxylic anhydride.  Product was diluted with Et2O and 
washed 10 times with saturated NaHCO3.  However, it was still contaminated with furan-
2-carboxylic anhydride.  It was again diluted in Et2O and stirred rapidly with 6M NaOH 
(aq.).  It was then extracted three times with Et2O, washed with water, saturated 
NaHCO3, and brine, dried over Na2SO4, and concentrated under reduced pressure to 
afford (3S,8R)-44 (0.042 g, 53.5%) as a yellow oil.  TLC Rf = 0.224 (25% 
EtOAc/hexanes); [α]D
18 = -14.0° (c = 0.5, CHCl3); 
1H NMR (500 MHz, CHLOROFORM-
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d)  7.43 - 7.47 (m, 1H), 7.14 (d, J = 3.42 Hz, 1H), 6.47 - 6.54 (m, 2H), 5.82 - 5.93 (m, 
2H), 5.51 - 5.58 (d, J = 15.65 Hz, 1H), 5.35 (d, J = 9.05 Hz, 1H), 4.95 - 5.03 (q, J = 7.50 
Hz, 1H), 2.10 (s, 3H), 1.76 (q, J = 7.58 Hz, 2H), 1.42 - 1.51 (m, 2H), 1.21 - 1.35 (m, 
12H), 0.88 (t, J = 6.85 Hz, 3H); 13C NMR (125 MHz, CHLOROFORM-d)  169.5, 157.1, 
147.3, 144.1, 131.9, 119.7, 114.9, 112.3, 79.7, 73.4, 70.9, 67.0, 64.4, 41.5, 35.6, 31.8, 
29.5, 29.4, 29.2, 29.0, 25.6, 22.6, 20.9, 14.1; IR (ATR) 3305, 2925, 2855, 1748, 1652, 
1521, 1221 cm-1; HRMS (ESI-TOF) [M + H]+ calcd. for C24H32NO4 398.2331, found 
398.2358. 
 
 
 (3S,8R)-8-(2-chlorobenzamido)heptadeca-1-en-4,6-diyn-3-yl acetate (3S,8R)-45 
To a solution of (3S,8R)-11 (0.060 g, 0.20 mmol) in CH2Cl2 (2.0 mL) at 0°C under Ar 
atmosphere was added triethylamine (0.04 mL, 0.29 mmol) followed by a solution of 2-
chlorobenzoyl chloride (0.03 mL, 0.24 mmol) in CH2Cl2 (1 mL).  Reaction mixture was 
stirred at 0°C for 4 hours and 30 minutes. Reaction was then quenched with saturated 
NH4Cl, diluted with Et20, extracted three times with Et2O, washed with water, saturated 
NaHCO3, and brine, dried over Na2SO4, and concentrated under reduced pressure.  
Purification by flash chromatography on silica gel (hexanes – 15% EtOAc/hexanes) 
afforded (3S,8R)-45 but was contaminated per NMR.  Product was diluted in Et2O, 
washed ten times with saturated NaHCO3, washed two times with brine, dried over 
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Na2SO4 and concentrated under reduced pressure to afford (3S,8R)-45 (0.043 g, 49.5%) 
as a yellow oil.  TLC Rf = 0.327 (25% EtOAc/hexanes); [α]D
18 = -7.3° (c = 0.5, CHCl3); 
1H NMR (500 MHz, CHLOROFORM-d)  7.66 (dd, J = 1.34, 7.46 Hz, 1H), 7.31 - 7.42 
(m, 3H), 6.44 (d, J = 8.31 Hz, 1H), 5.83 - 5.92 (m, 2H), 5.51 - 5.58 (d, J = 15.65 Hz, 1H), 
5.35 (d, J = 8.80 Hz, 1H), 5.01 - 5.07 (q, J = 7.42 Hz, 1H), 2.10 (s, 3H), 1.76 - 1.84 (m, 
2H), 1.49 (quin, J = 7.40 Hz, 2H), 1.22 - 1.38 (m, 12H), 0.88 (t, J = 6.97 Hz, 3H); 13C 
NMR (125 MHz, CHLOROFORM-d)  169.4, 165.2, 134.2, 131.9, 131.6, 130.6, 130.3, 
130.2, 127.1, 119.7, 79.5, 73.4, 70.9, 67.1, 64.4, 42.4, 35.5, 31.8, 29.4, 29.4, 29.2, 29.0, 
25.6, 22.6, 20.9, 14.1; IR (ATR) 3256, 2924, 2854, 1742, 1644, 1525, 1222 cm-1; HRMS 
(ESI-TOF) [M + H]+ calcd. for C26H33ClNO3 442.2149, found 442.2179. 
 
 
 (3S,8R)-8-(4-fluorobenzamido)heptadeca-1-en-4,6-diyn-3-yl acetate (3S,8R)-46 
To a solution of (3S,8R)-11 (0.059 g, 0.20 mmol) in CH2Cl2 (2.0 mL) at 0°C under Ar 
atmosphere was added triethylamine (0.04 mL, 0.29 mmol) followed by a solution of 4-
fluorobenzoyl chloride (0.03 mL, 0.25 mmol) in CH2Cl2 (1 mL).  Reaction mixture was 
stirred at 0°C for 1 hour and 40 minutes. Reaction mixture was then quenched with water, 
extracted three times with CH2Cl2, washed with water and saturated NaHCO3, dried over 
Na2SO4, and concentrated under reduced pressure.  Purification by flash chromatography 
on silica gel (hexanes – 10% EtOAc/hexanes) afforded (3S,8R)-46 but was contaminated 
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with 4-fluorobenzoic acid.  Product was diluted with Et2O, washed five times with 
saturated NaHCO3, dried over Na2SO4, and concentrated under reduced pressure to afford 
(3S,8R)-46 (0.057 g, 68.6%, light yellow oil). 
TLC Rf = 0.194 (15% EtOAc/hexanes); [α]D
18 = -4.4° (c = 1.3, CHCl3); 
1H NMR (500 
MHz, CHLOROFORM-d)  7.81 (dd, J = 5.26, 8.68 Hz, 2H), 7.11 (t, J = 8.56 Hz, 2H), 
6.48 (d, J = 8.31 Hz, 1H), 5.82 - 5.92 (m, 2H), 5.50 - 5.58 (m, 1H), 5.32 - 5.38 (m, 1H), 
5.01 (q, J = 7.50 Hz, 1H), 2.11 (s, 3H), 1.70 - 1.82 (m, 2H), 1.41 - 1.51 (m, 2H), 1.21 - 
1.35 (m, 12H), 0.88 (t, J = 6.97 Hz, 3H); 13C NMR (125 MHz, CHLOROFORM-d)  
169.5, 165.8, 165.3, 163.8, 131.8, 129.9, 129.9, 129.5, 129.4, 119.7, 115.7, 115.5, 79.8, 
73.4, 70.9, 67.0, 64.4, 42.4, 35.6, 31.8, 29.5, 29.4, 29.2, 29.0, 25.7, 22.6, 20.9, 14.1; IR 
(ATR) 3290, 2926, 2855, 2259, 1748, 1639, 1501, 1221 cm-1; HRMS (ESI-TOF) [M + 
H]+ calcd. for C26H33FNO3 426.2444, found 426.2455.   
 
 
 (3S,8R)-8-(4-(benzyloxy)butanamido)heptadeca-1-en-4,6-diyn-3-yl acetate (3S,8R)-
47 
To a suspension of 4-benzyloxybutyric acid (0.069 g, 0.36 mmol) in CH2Cl2 (1.0 mL) at 
0°C under Ar was added DCC (0.052 g, 0.25 mmol).  Then a solution of (3S,8R)-11 
(0.060 g, 0.20 mmol) in CH2Cl2 (1.0 mL) was added followed by addition of DMAP (4.3 
mg, 0.035 mmol).  After 3 hours, reaction was quenched with saturated NH4Cl, diluted 
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with Et20, extracted three times with Et2O, washed two times with water, washed 5 times 
with saturated NaHCO3, washed 2 times with brine, dried over Na2SO4, and concentrated 
under reduced pressure.  Purification by flash chromatography on silica gel (hexanes – 
25% EtOAc/hexanes) afforded (3S,8R)-47 (0.067 g, 70.9%) as a yellow oil.  TLC Rf = 
0.164 (25% EtOAc/hexanes); [α]D
18 = +20.0° (c = 1.8, CHCl3); 
1H NMR (500 MHz, 
CHLOROFORM-d)  7.28 - 7.39 (m, 5H), 6.06 (d, J = 8.56 Hz, 1H), 5.82 - 5.93 (m, 2H), 
5.51 - 5.59 (d, J = 15.65 Hz, 1H), 5.35 (d, J = 9.05 Hz, 1H), 4.79 (q, J = 7.34 Hz, 1H), 
4.47 - 4.55 (m, 2H), 3.53 (t, J = 5.87 Hz, 2H), 2.31 (t, J = 7.09 Hz, 2H), 2.10 (s, 3H), 1.94 
(quin, J = 6.48 Hz, 2H), 1.52 - 1.60 (m, 2H), 1.36 (br. s., 2H), 1.22 - 1.34 (m, 12H), 0.88 
(t, J = 6.97 Hz, 3H); 13C NMR (125 MHz, CHLOROFORM-d)  171.7, 169.4, 138.1, 
131.9, 128.4, 127.7, 127.7, 119.7, 80.3, 73.1, 73.0, 71.0, 69.3, 66.5, 64.4, 41.5, 35.4, 33.4, 
31.8, 29.4, 29.4, 29.2, 29.0, 25.5, 25.5, 22.6, 20.8, 14.1; IR (ATR) 3286, 2924, 2855, 
2258, 1748, 1646, 1533, 1219 cm-1; HRMS (ESI-TOF) [M + H]+ calcd. for C30H42NO4 
480.3114, found 480.3120. 
 
 (3S,8R)-8-isothiocyanatoheptadeca-1-en-4,6-diyn-3-yl acetate (3S,8R)-48 
To a solution of (3S,8R)-11 (0.072 g, 0.24 mmol) in CH2Cl2 (0.9 mL) was added 
saturated aqueous NaHCO3 (0.9 mL).  Reaction was then cooled to 0°C under Ar 
atmosphere and thiophosgene 0.035 mL, 0.46 mmol) was added.  Reaction mixture was 
stirred at 0°C for 1 hour and 20 minutes. Reaction was then diluted with CH2Cl2 and 
 202 
saturated aqueous NaHCO3, extracted three times with CH2Cl2, washed with brine, dried 
over Na2SO4, and concentrated under reduced pressure.  Purification by flash 
chromatography on silica gel (hexanes – 5% EtOAc/hexanes) afforded (3S,8R)-48 (0.029 
g, 35.3%) as a light brown oil.  TLC Rf = 0.304 (10% EtOAc/hexanes); [α]D
18 = -17.0° (c 
= 0.31, CHCl3); 
1H NMR (500 MHz, CHLOROFORM-d)  5.84 - 5.94 (m, 2H), 5.56 (d, 
J = 16.14 Hz, 1H), 5.38 (d, J = 9.29 Hz, 1H), 4.48 (t, J = 6.60 Hz, 1H), 2.12 (s, 3H), 1.82 
- 1.90 (m, 2H), 1.44 - 1.54 (m, 2H), 1.23 - 1.36 (m, 12H), 0.89 (t, J = 6.97 Hz, 3H); 13C 
NMR (125 MHz, CHLOROFORM-d)  169.4, 137.8, 131.6, 119.9, 75.5, 75.1, 70.3, 
68.6, 64.3, 49.4, 36.7, 31.8, 29.4, 29.3, 29.2, 28.7, 25.4, 22.6, 20.8, 14.1; IR (ATR) 2926, 
2855, 2039, 1748, 1218 cm-1; HRMS (ESI-TOF) [M + H]+ calcd. for C20H28NO2S 
346.1841, found 346.1871. 
 
 
ethyl ((3S,8R)-3-hydroxyheptadeca-1-en-4,6-diyn-8-yl)carbamate (3S,8R)-49 
Copper (I) chloride (0.007 g, 0.07 mmol) was added to a stirred 30 % solution (1.0 mL) 
of n-butylamine in distilled water at 0 °C which resulted in a deep blue solution.  A few 
crystals of NH2OH.HCl were added until solution was colorless.  A solution of (R)-57 
(0.084 g, 0.33 mmol) in CH2Cl2 (0.5 mL) was added under argon atmosphere which 
resulted in yellow reaction mixture.  After 10 minutes, a solution of (S)-6 (0.067 g, 0.42 
mmol) in CH2Cl2 (0.6 mL) was added dropwise over 5 minutes.  A few crystals of 
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NH2OH.HCl were added as necessary whenever solution turned blue or green.  After 16 
minutes, analysis of the reaction mixture by GC/MS showed that there was still some 
(R)-57 present.  At 50 minutes, added additional (S)-6 (0.043 g, 0.27 mmol) in CH2Cl2 
(0.5 mL).  Reaction was stirred an additional 1 hour and then quenched with water, 
extracted 3 times with CH2Cl2, dried over Na2SO4, and concentrated under reduced 
pressure..  Immediate purification by flash chromatography on silica gel (hexanes – 10% 
EtOAc/hexanes) afforded (3S,8R)-49 (0.065 g, 58.4%, brown-orange solid).  TLC Rf = 
0.192 (25% EtOAc/hexanes); [α]D
21 = +67.3° (c = 1.0, CHCl3); 1H NMR (500 MHz, 
CHLOROFORM-d)  5.95 (ddd, J = 5.38, 10.27, 17.12 Hz, 1H), 5.48 (dt, J = 1.10, 17.12 
Hz, 1H), 5.26 (dt, J = 1.01, 10.21 Hz, 1H), 4.94 (t, J = 5.75 Hz, 1H), 4.83 (d, J = 7.83 Hz, 
1H), 4.54 (d, J = 7.34 Hz, 1H), 4.13 (m, 2H), 2.16 (d, J = 5.62 Hz, 1H), 1.63 - 1.70 (m, 
2H), 1.38 - 1.46 (m, 2H), 1.22 - 1.34 (m, 15H), 0.85 - 0.92 (t, J = 6.97 Hz, 3H); 13C NMR 
(125 MHz, CHLOROFORM-d)  155.5, 135.8, 117.2, 79.9, 76.8, 70.4, 66.9, 63.4, 61.3, 
43.7, 35.8, 31.8, 29.5, 29.4, 29.2, 29.0, 25.5, 22.7, 14.5, 14.1; IR (ATR) 3299, 2923, 
2854, 1686, 1530, 1255 cm-1; HRMS (ESI-TOF) [M + H]+ calcd. for C20H32NO3 
334.2382, found 334.2372. 
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N-((3S,8R)-3-hydroxyheptadeca-1-en-4,6-diyn-8-yl)acetamide (3S,8R)-50 
Copper (I) chloride (0.007 g, 0.07 mmol) was added to a stirred 30 % solution (1.0 mL) 
of n-butylamine in distilled water at 0 °C which resulted in a deep blue solution.  A few 
crystals of NH2OH.HCl were added until solution was colorless.  A solution of (R)-58 
(0.074 g, 0.33 mmol) in CH2Cl2 (0.5 mL) was added under argon atmosphere which 
resulted in yellow reaction mixture.  After 10 minutes, a solution of (S)-6 (0.109 g, 0.68 
mmol) in CH2Cl2 (1.0 mL) was added dropwise over 5 minutes.  A few crystals of 
NH2OH.HCl were added as necessary whenever solution turned blue or green.  After 45 
minutes, reaction was quenched with water, extracted 3 times with CH2Cl2, dried over 
Na2SO4, and concentrated under reduced pressure.  Immediate purification by flash 
chromatography on silica gel (hexanes – 40% EtOAc/hexanes) afforded (3S,8R)-50 
(0.093 g, 92.5%, brown oil).  TLC Rf = 0.118 (40% EtOAc/hexanes); [α]D
21 = +133.7° (c 
= 0.9, CHCl3); 
1H NMR (500 MHz, CHLOROFORM-d)  5.94 (ddd, J = 5.38, 10.15, 
17.00 Hz, 1H), 5.78 (d, J = 8.31 Hz, 1H), 5.44 - 5.51 (d, J = 16.87 Hz, 1H), 5.26 (d, J = 
10.27 Hz, 1H), 4.93 (d, J = 4.89 Hz, 1H), 4.82 (q, J = 7.50 Hz, 1H), 2.44 (br. s., 1H), 2.00 
(s, 3H), 1.62 - 1.70 (m, 2H), 1.37 - 1.45 (m, 2H), 1.22 - 1.35 (m, 12H), 0.86 - 0.91 (t, J = 
6.85 Hz, 3H); 13C NMR (125 MHz, CHLOROFORM-d)  169.1, 135.9, 117.2, 79.7, 
76.9, 70.3, 66.9, 63.4, 41.9, 35.6, 31.8, 29.5, 29.4, 29.3, 29.1, 25.6, 23.2, 22.7, 14.1; IR 
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(ATR) 3255, 2917, 2851, 1650, 1542 cm-1; HRMS (ESI-TOF) [M + H]+ calcd. for 
C19H30NO2 304.2277, found 304.2281. 
 
 
 (3S,8R)-8-(ethylamino)heptadeca-1-en-4,6-diyn-3-ol (3S,8R)-51 
Copper (I) chloride (0.007 g, 0.07 mmol) was added to a stirred 30 % solution (1.2 mL) 
of n-butylamine in distilled water at 0 °C which resulted in a deep blue solution.  A few 
crystals of NH2OH.HCl were added until solution was colorless.  A solution of (R)-59 
(0.077 g, 0.37 mmol) in CH2Cl2 (0.6 mL) was added under argon atmosphere which 
resulted in yellow reaction mixture.  After 10 minutes, a solution of (S)-6 (0.110 g, 0.68 
mmol) in CH2Cl2 (1.0 mL) was added dropwise over 5 minutes.  A few crystals of 
NH2OH.HCl were added as necessary whenever solution turned blue or green.  After 55 
minutes, reaction was quenched with water, extracted 3 times with CH2Cl2, dried over 
Na2SO4, and concentrated under reduced pressure.  Immediate purification by flash 
chromatography on silica gel (hexanes – 40% EtOAc/hexanes) afforded (3S,8R)-51 
(0.032 g, 30.0%, brown solid).  TLC Rf = 0.300 (60% EtOAc/hexanes); [α]D
20 = +55.0° (c 
= 0.5, CHCl3); 
1H NMR (500 MHz, CHLOROFORM-d)  5.96 (ddd, J = 5.50, 10.11, 
17.03 Hz, 1H), 5.48 (td, J = 1.24, 17.03 Hz, 1H), 5.26 (td, J = 1.06, 10.29 Hz, 1H), 4.92 - 
4.97 (m, 1H), 3.44 (dd, J = 5.50, 8.34 Hz, 1H), 2.92 (qd, J = 7.20, 11.05 Hz, 1H), 2.62 
(qd, J = 7.20, 11.05 Hz, 1H), 1.54 - 1.78 (m, 3H), 1.37 - 1.52 (m, 2H), 1.21 - 1.35 (m, 
12H), 1.12 (t, J = 7.27 Hz, 3H), 0.89 (t, J = 6.92 Hz, 3H); 13C NMR (125 MHz, 
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CHLOROFORM-d)  136.1, 117.1, 83.0, 76.0, 70.8, 67.3, 63.5, 50.6, 41.8, 35.7, 31.9, 
29.5, 29.5, 29.3, 29.3, 26.0, 22.7, 15.1, 14.1; IR (ATR) 3675, 3251, 2924, 2855, 2678, 
1029 cm-1; HRMS (ESI-TOF) [M + H]+ calcd. for C19H32NO 290.2484, found 290.2460. 
 
 
 
 (3S,8R)-8-methoxyheptadeca-1-en-4,6-diyn-3-ol (3S,8R)-52 
Copper (I) chloride (0.006 g, 0.06 mmol) was added to a stirred 30 % solution (1.5 mL) 
of n-butylamine in distilled water at 0 °C which resulted in a deep blue solution.  A few 
crystals of NH2OH.HCl were added until solution was colorless.  A solution of (R)-60 
(0.102 g, 0.52 mmol) in CH2Cl2 (0.75 mL) was added under argon atmosphere which 
resulted in yellow reaction mixture.  After 10 minutes, a solution of (S)-6 (0.114 g, 0.71 
mmol) in CH2Cl2 (1.1 mL) was added dropwise over 5 minutes.  A few crystals of 
NH2OH.HCl were added as necessary whenever solution turned blue or green.  After 20 
minutes, analysis of the reaction mixture by GC/MS showed that there was still some 
(R)-60 present.  At 50 minutes, added additional (S)-6 (0.075 g, 0.47 mmol) in CH2Cl2 
(0.5 mL).  Reaction was stirred an additional 1 hour and then quenched with water, 
extracted 3 times with CH2Cl2, dried over Na2SO4, and concentrated under reduced 
pressure..  Immediate purification by flash chromatography on silica gel (hexanes – 10% 
EtOAc/hexanes) afforded (3S,8R)-52 (0.089 g, 62.1%, brown oil).  TLC Rf = 0.396 (25% 
EtOAc/hexanes); [α]D
22 = +73.2° (c = 0.5, CHCl3); 
1H NMR (500 MHz, 
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CHLOROFORM-d)  5.96 (ddd, J = 5.38, 10.27, 17.12 Hz, 1H), 5.49 (ddd, J = 0.98, 
1.47, 17.12 Hz, 1H), 5.25 - 5.29 (ddd, J = 0.98, 1.47, 10.27 Hz, 1H), 4.95 (t, J = 5.75 Hz, 
1H), 4.00 (t, J = 6.48 Hz, 1H), 3.39 - 3.42 (s, 3H), 2.10 (d, J = 6.60 Hz, 1H), 1.66 - 1.78 
(m, 2H), 1.38 - 1.47 (m, 2H), 1.22 - 1.34 (m, 12H), 0.86 - 0.91 (t, J = 6.97 Hz, 3H); 13C 
NMR (125 MHz, CHLOROFORM-d)  135.8, 117.3, 79.6, 77.1, 71.7, 70.4, 69.5, 63.5, 
56.7, 35.3, 31.9, 29.5, 29.5, 29.3, 29.2, 25.1, 22.7, 14.1; IR (ATR) 3666, 3404, 2927, 
2856, 1099 cm-1; MS(EI) [M – 1]+  275. 
 
 
 (1S,6R)-6-(butylamino)-1-cyclopropylpentadeca-2,4-diyn-1-ol (1S,6R)-53 
Copper (I) chloride (0.007 g, 0.07 mmol) was added to a stirred 30 % solution (1.25 mL) 
of n-butylamine in distilled water at 0 °C which resulted in a deep blue solution.  A few 
crystals of NH2OH.HCl were added until solution was colorless.  A solution of (R)-22 
(0.104 g, 0.44 mmol) in CH2Cl2 (0.63 mL) was added under argon atmosphere which 
resulted in yellow reaction mixture.  After 10 minutes, a solution of (S)-63 (0.135 g, 0.77 
mmol) in CH2Cl2 (1.1 mL) was added dropwise over 5 minutes.  A few crystals of 
NH2OH.HCl were added as necessary whenever solution turned blue or green.  After 1 
hour and 10 minutes, reaction was quenched with water, extracted 3 times with CH2Cl2, 
dried over Na2SO4, and concentrated under reduced pressure.  Immediate purification by 
flash chromatography on silica gel (hexanes – 20% EtOAc/hexanes) afforded (1S,6R)-53 
(0.058 g, 39.9%, yellow solid).  TLC Rf = 0.345 (40% EtOAc/hexanes); [α]D
21 = +61.2° (c 
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= 2.1, CHCl3); 
1H NMR (500 MHz, CHLOROFORM-d)  4.17 (d, J = 6.85 Hz, 1H), 3.41 
(dd, J = 5.62, 8.31 Hz, 1H), 2.83 (ddd, J = 6.24, 8.62, 11.07 Hz, 1H), 2.56 (ddd, J = 5.62, 
8.50, 11.07 Hz, 1H), 1.74 – 2.19 (br.s., 1H), 1.54 - 1.71 (m, 2H), 1.20 - 1.52 (m, 20H), 
0.84 - 0.96 (m, 6H), 0.57 (m, 2H), 0.41 - 0.51 (m, 2H); 13C NMR (125 MHz, 
CHLOROFORM-d)  82.3, 76.7, 69.3, 67.4, 66.0, 50.8, 47.2, 35.7, 32.0, 31.9, 29.5, 29.5, 
29.3, 29.3, 26.0, 22.7, 20.5, 17.2, 14.1, 14.0, 3.3, 1.8; IR (ATR) 3259, 2924, 2854, 2714, 
1040 cm-1; HRMS (ESI-TOF) [M + H]+ calcd. for C22H38NO 332.2953, found 332.2935. 
 
 
 (4S,9R,E)-9-(butylamino)octadeca-2-en-5,7-diyn-4-ol (4S,9R)-54 
Copper (I) chloride (0.010 g, 0.10 mmol) was added to a stirred 30 % solution (1.25 mL) 
of n-butylamine in distilled water at 0 °C which resulted in a deep blue solution.  A few 
crystals of NH2OH.HCl were added until solution was colorless.  A solution of (R)-22 
(0.100 g, 0.42 mmol) in CH2Cl2 (0.63 mL) was added under argon atmosphere which 
resulted in yellow reaction mixture.  After 10 minutes, a solution of (S)-66 (0.133 g, 0.76 
mmol) in CH2Cl2 (1.1 mL) was added dropwise over 5 minutes.  A few crystals of 
NH2OH.HCl were added as necessary whenever solution turned blue or green.  After 3 
hours, reaction was quenched with water, extracted 3 times with CH2Cl2, dried over 
Na2SO4, and concentrated under reduced pressure.  Immediate purification by flash 
chromatography on silica gel (hexanes – 20% EtOAc/hexanes) afforded (4S,9R)-54 
(0.049 g, 35.6%, tan solid).  TLC Rf = 0.400 (40% EtOAc/hexanes); [α]D
21 = +70.4° (c = 
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2.0, CHCl3); 
1H NMR (500 MHz, CHLOROFORM-d)  5.85 - 5.95 (m, 1H), 5.56 - 5.64 
(m, 1H), 4.86 (d, J = 6.36 Hz, 1H), 3.42 (dd, J = 5.62, 8.31 Hz, 1H), 2.83 (ddd, J = 6.11, 
8.68, 11.13 Hz, 1H), 2.56 (ddd, J = 5.62, 8.74, 11.07 Hz, 1H), 1.71 - 1.76 (m, 3H), 1.21 - 
1.70 (m, 22H), 0.85 - 0.96 (m, 6H); 13C NMR (126 MHz, CHLOROFORM-d)  129.5, 
129.3, 82.6, 77.0, 70.2, 67.5, 63.0, 50.8, 47.2, 35.7, 32.0, 31.9, 29.5, 29.5, 29.3, 29.3, 
26.0, 22.6, 20.5, 17.5, 14.1, 14.0; IR (ATR) 3254, 2923, 2853, 2682, 1467 cm-1; HRMS 
(ESI-TOF) [M + H]+ calcd. for C22H38NO 332.2953, found 332.2950. 
 
 
 (1S,6R)-6-(butylamino)-1-phenylpentadeca-2,4-diyn-1-ol (1S,6R)-55 
Copper (I) chloride (0.008 g, 0.08 mmol) was added to a stirred 30 % solution (1.25 mL) 
of n-butylamine in distilled water at 0 °C which resulted in a deep blue solution.  A few 
crystals of NH2OH.HCl were added until solution was colorless.  A solution of (R)-22 
(0.101 g, 0.43 mmol) in CH2Cl2 (0.63 mL) was added under argon atmosphere which 
resulted in yellow reaction mixture.  After 10 minutes, a solution of (S)-69 (0.159 g, 0.75 
mmol) in CH2Cl2 (1.1 mL) was added dropwise over 5 minutes.  A few crystals of 
NH2OH.HCl were added as necessary whenever solution turned blue or green.  After 50 
minutes, reaction was quenched with water, extracted 3 times with CH2Cl2, dried over 
Na2SO4, and concentrated under reduced pressure.  Immediate purification by flash 
chromatography on silica gel (hexanes – 20% EtOAc/hexanes) afforded (1S,6R)-55 
(0.056 g, 35.7%, brownish yellow solid).  TLC Rf = 0.388 (40% EtOAc/hexanes); [α]D
21 = 
 210 
+22.3° (c = 2.2, CHCl3); 
1H NMR (500 MHz, CHLOROFORM-d)  7.51 - 7.55 (m, 2H), 
7.37 - 7.41 (m, 2H), 7.32 - 7.36 (m, 1H), 5.51 (s, 1H), 3.41 (dd, J = 5.50, 8.44 Hz, 1H), 
2.82 (ddd, J = 6.24, 8.74, 11.19 Hz, 1H), 2.55 (ddd, J = 5.62, 8.74, 11.07 Hz, 1H), 1.22 - 
1.70 (m, 22H), 0.86 - 0.96 (m, 6H); 13C NMR (125 MHz, CHLOROFORM-d)  140.0, 
128.6, 128.5, 126.6, 82.9, 77.2, 70.9, 67.5, 64.7, 50.8, 47.2, 35.6, 31.9, 31.9, 29.5, 29.5, 
29.3, 29.3, 26.0, 22.7, 20.4, 14.1, 14.0; IR (ATR) 3666, 3274, 2923, 2854, 2685 cm-1; 
HRMS (ESI-TOF) [M + H]+ calcd. for C25H38NO 368.2953, found 368.2932. 
 
 
 (1S,6R)-6-(butylamino)-1-(4-ethoxyphenyl)pentadeca-2,4-diyn-1-ol (1S,6R)-56 
Copper (I) chloride (0.011 g, 0.11 mmol) was added to a stirred 30 % solution (1.25 mL) 
of n-butylamine in distilled water at 0 °C which resulted in a deep blue solution.  A few 
crystals of NH2OH.HCl were added until solution was colorless.  A solution of (R)-22 
(0.105 g, 0.44 mmol) in CH2Cl2 (0.63 mL) was added under argon atmosphere which 
resulted in yellow reaction mixture.  After 10 minutes, a solution of (S)-70 (0.194 g, 0.76 
mmol) in CH2Cl2 (1.1 mL) was added dropwise over 5 minutes.  A few crystals of 
NH2OH.HCl were added as necessary whenever solution turned blue or green.  After 2 
hours and 20 minutes, reaction was quenched with water, extracted 3 times with CH2Cl2, 
dried over Na2SO4, and concentrated under reduced pressure.  Immediate purification by 
flash chromatography on silica gel (hexanes – 20% EtOAc/hexanes) afforded (1S,6R)-56 
(0.068 g, 37.3%, brownish yellow solid).  TLC Rf = 0.424 (40% EtOAc/hexanes); [α]D
21 = 
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+17.2° (c = 2.9, CHCl3); 
1H NMR (500 MHz, CHLOROFORM-d)  7.42 - 7.48 (m, 2H), 
6.88 - 6.94 (m, 2H), 5.48 (s, 1H), 4.05 (q, J = 7.09 Hz, 2H), 3.42 (dd, J = 5.75, 8.19 Hz, 
1H), 2.85 (ddd, J = 6.36, 8.31, 11.25 Hz, 1H), 2.56 (ddd, J = 5.75, 8.38, 11.07 Hz, 1H), 
1.22 - 1.70 (m, 25H), 0.86 - 0.96 (m, 6H); 13C NMR (125 MHz, CHLOROFORM-d)  
159.0, 132.2, 128.0, 114.5, 82.7, 77.5, 70.6, 67.6, 64.3, 63.4, 50.8, 47.2, 35.6, 31.9, 31.9, 
29.5, 29.5, 29.3, 29.3, 26.0, 22.6, 20.4, 14.7, 14.1, 14.0; IR (ATR) 3245, 2923, 2853, 
2675, 1511, 1245 cm-1; HRMS (ESI-TOF) [M + H]+ calcd. for C27H42NO2 412.3216, 
found 412.3232. 
 
 
 (R)-ethyl dodec-1-yn-3-ylcarbamate (R)-57 
To a solution of (R)-19 (0.119 g, 0.66 mmol) in CH2Cl2 (3.4 mL) at ambient temperature 
under Ar was added DMAP (0.008 g, 0.07 mmol), triethylamine (0.10 mL, 0.72 mmol), 
and ethyl chloroformate (0.07 ml, 0.74 mmol).  After 19 hours, reaction mixture was 
quenched with water, extracted three times with CH2Cl2, dried over Na2SO4, and 
concentrated under reduced pressure.  Purification by flash chromatography on silica gel 
(hexanes – 5% EtOAc/hexanes) afforded (R)-57 (0.110 g, 66.3%) as a white solid.  TLC 
Rf = 0.367 (15% EtOAc/hexanes); [α]D
21 = +31.5° (c = 1.3, CHCl3); 
1H NMR (500 MHz, 
CHLOROFORM-d)  4.75 - 4.86 (d, J = 6.36 Hz, 1H), 4.40 – 4.50 (d, J = 6.36 Hz, 1H), 
4.10 – 4.19 (q, J = 7.50 Hz, 2H), 2.28 (d, J = 2.45 Hz, 1H), 1.63 - 1.71 (m, 2H), 1.43 
(quin, J = 7.46 Hz, 2H), 1.21 - 1.36 (m, 15H), 0.85 - 0.92 (t, J = 6.97 Hz, 3H); 13C NMR 
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(125 MHz, CHLOROFORM-d)  155.6, 83.4, 71.0, 61.1, 43.1, 36.0, 31.9, 29.5, 29.5, 
29.3, 29.1, 25.5, 22.7, 14.6, 14.1; IR (ATR) 3315, 2919, 2851, 1680, 1530, 1254 cm-1;  
MS(EI) [M – 29 (CH2CH3)]
+ 224. 
 
 
 (R)-N-(dodec-1-yn-3-yl)acetamide (R)-58 
To a solution of (R)-19 (0.128 g, 0.70 mmol) in CH2Cl2 (3.0 mL) at 0°C under Ar was 
added triethylamine (0.23 mL, 1.65 mmol) followed by a solution of acetyl chloride (0.10 
ml, 1.4 mmol)  in CH2Cl2 (0.8 mL).  After 40 minutes, reaction mixture was quenched 
with water, extracted three times with CH2Cl2, washed with brine, dried over Na2SO4, 
and concentrated under reduced pressure.  Purification by flash chromatography on silica 
gel (hexanes – 40% EtOAc/hexanes) afforded (R)-58 (0.097 g, 61.4%) as a white solid.  
TLC Rf = 0.196 (40% EtOAc/hexanes); [α]D
21 = +38.1° (c = 1.1, CHCl3); 
1H NMR (500 
MHz, CHLOROFORM-d)  5.73 (d, J = 7.83 Hz, 1H), 4.69 - 4.76 (m, 1H), 2.24 - 2.28 
(m, 1H), 1.98 - 2.01 (s, 3H), 1.60 - 1.71 (m, 2H), 1.38 - 1.47 (m, 2H), 1.22 - 1.33 (m, 
12H), 0.88 (t, J = 6.85 Hz, 3H); 13C NMR (125 MHz, CHLOROFORM-d)  168.9, 83.3, 
71.0, 41.3, 35.7, 31.8, 29.5, 29.4, 29.3, 29.1, 25.5, 23.2, 22.6, 14.1; IR (ATR) 3294, 3271, 
2917, 2850, 1737, 1647, 1547, 1372 cm-1. 
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 (R)-N-ethyldodec-1-yn-3-amine (R)-59 
To a solution of (R)-19 (0.205 g, 1.13 mmol) in methanol (5.5 mL) under argon 
atmosphere was added acetaldehyde (0.10 mL, 1.8 mmol).  Reaction mixture was stirred 
at ambient temperature for 20 minutes and then chilled to 0°C at which time NaBH4 was 
added (0.038 g, 0.99 mmol).  Reaction mixture was stirred for 55 minutes and then 
diluted with EtOAc, washed with saturated NaHCO3, dried over Na2SO4, and 
concentrated under reduced pressure to yield  (R)-59 (0.206 g, 87.1%) as a clear oil.  TLC 
Rf = 0.379 (40% EtOAc/hexanes); [α]D
20 = +19.2° (c = 1.0, CHCl3); 
1H NMR (500 MHz, 
CHLOROFORM-d)  3.39 (ddd, J = 2.18, 5.77, 8.12 Hz, 1H), 2.94 (m, 1H), 2.65 (m, 
1H), 2.27 (d, J = 2.01 Hz, 1H), 1.54 - 1.71 (m, 2H), 1.40 - 1.53 (m, 2H), 1.21 - 1.36 (m, 
13H), 1.09 - 1.17 (t, J = 7.20 Hz, 3H), 0.88 (t, J = 7.03 Hz, 3H); 13C NMR (125 MHz, 
CHLOROFORM-d)  71.3, 49.9, 41.5, 35.8, 31.9, 29.5, 29.5, 29.4, 29.3, 25.9, 22.7, 15.0, 
14.1; IR (ATR) 3675 3311 2923, 2855 cm-1; MS(EI) [M – 1]+ 208.   
 
 
 (R)-3-methoxydodec-1-yne (R)-60 
To a suspension of NaH (60% in mineral oil, 0.088 g, 2.2 mmol) in THF at 0°C under Ar 
atmosphere was added a solution of (R)-3 (0.302 g, 1.66 mmol) in THF (1.8 mL).  After 
stirring for 45 minutes, methyl iodide (0.38 mL, 6.1 mmol) was added.  After 3 hours, 
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reaction was quenched by slow addition of saturated NH4Cl, extracted with Et2O, washed 
with water, washed with brine, dried over Na2SO4, and concentrated under reduced 
pressure at 0°C.  Purification by flash chromatography on silica gel (hexanes – 5% 
EtOAc/hexanes) afforded (R)-60 (0.291 g, 89.3%, clear oil).  TLC Rf = 0.185 (5% 
EtOAc/hexanes); [α]D
21 = +31.7° (c = 1.3, CHCl3); 
1H NMR (500 MHz, 
CHLOROFORM-d)  3.93 (dt, J = 2.08, 6.54 Hz, 1H), 3.39 - 3.44 (s, 3H), 2.44 (d, J = 
2.20 Hz, 1H), 1.64 - 1.78 (m, 2H), 1.41 - 1.49 (m, 2H), 1.22 - 1.35 (m, 12H), 0.85 - 0.92 
(t, J = 6.97 Hz, 3H); 13C NMR (125 MHz, CHLOROFORM-d)  82.8, 73.6, 71.1, 56.4, 
35.5, 31.9, 29.5, 29.3, 29.3, 25.1, 22.7, 14.1; IR (ATR) 3311, 2925, 2854, 1102 cm-1; 
MS(EI) [M – 1]+ 195. 
 
 
 (S)-1-cyclopropyl-3-(trimethylsilyl)prop-2-yn-1-ol (S)-61; (R)-1-cyclopropyl-3-
(trimethylsilyl)prop-2-yn-1-yl acetate (R)-62 
To a solution of (trimethylsilyl)acetylene (1.5 mL, 10.7 mmol) in dry Et2O (12 mL) at -78 
°C was added dropwise a solution of n-butyllithium (2.3 M in hexanes, 4.2 mL, 9.7 
mmol) over 10 minutes under an Ar atmosphere.  The reaction mixture was then stirred 
for 30 minutes before a solution of cyclopropanecarboxaldehyde (0.68 mL, 9.0 mmol) in 
Et2O (2 mL) was added dropwise over 10 minutes.  The resulting mixture was allowed to 
gradually warm to ambient temperature.  After stirring for 24 hours, the mixture was 
quenched by slow addition of saturated NH4Cl followed by H2O.  The mixture was 
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extracted with Et2O, washed with H20 and brine, dried over Na2SO4, and concentrated to 
near dryness.  The resultant light orange-yellow oil (±61) was used directly in the next 
reaction without further purification. 
 
±61 was dissolved in dry hexanes (36 ml) followed by the addition of ground, activated 
4-Å molecular sieves (0.40 g) and lipase (Pseudomonas fluorescens, Amano Lipase AK, 
0.23 g).  To the well-stirred suspension was added vinyl acetate (3.4 mL, 36.9 mmol) 
over 3 minutes.  The suspension was stirred under an Ar atmosphere for 24 hours and 
then filtered through a pad of Celite and concentrated.  The resulting yellow oil was 
purified by silica gel flash chromatography (Hexanes – 25% EtOAc/hexanes) to give (S)-
61 (0.62 g, 40.7%, light yellow oil) and (R)-62 (0.74 g, 38.9%, faint pink oil). 
 
Data for ±61:  Rf = 0.211 (15% EtOAc/hexanes); 
1H NMR (500 MHz, CHLOROFORM-
d)  4.23 (t, J = 5.75 Hz, 1H), 2.15 (d, J = 5.14 Hz, 1H), 1.18 - 1.27 (m, 1H), 0.39 - 0.58 
(m, 4H), 0.12 - 0.19 (s, 9H); 13C NMR (125 MHz, CHLOROFORM-d)  104.1, 89.6, 
65.9, 16.7, 3.1, 1.4, -0.2; IR (ATR) 3335, 2961, 2900, 2175, 1250, 840 cm-1. 
 
Data for (S)-61:  Rf = 0.211 (15% EtOAc/hexanes); [α]D
17 = +42.8° (c = 1.8, CHCl3); 
1H 
NMR (500 MHz, CHLOROFORM-d)  4.24 (t, J = 6.11 Hz, 1H), 2.02 (d, J = 6.11 Hz, 
1H), 1.18 - 1.28 (m, 1H), 0.38 - 0.60 (m, 4H), 0.11 - 0.24 (s, 9H); 13C NMR (125 MHz, 
CHLOROFORM-d)  104.1, 89.6, 65.9, 16.7, 3.2, 1.4, -0.2; IR (ATR) 3344, 2962, 2900, 
2174, 1250, 839 cm-1. 
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Data for (R)-62: Rf = 0.476 (15% EtOAc/hexanes); [α]D
17 = +42.4° (c = 2.4, CHCl3); 
1H 
NMR (500 MHz, CHLOROFORM-d)  5.31 (d, J = 6.60 Hz, 1H), 2.08 - 2.13 (s, 3H), 
1.20 - 1.29 (m, 1H), 0.43 - 0.60 (m, 4H), 0.14 - 0.19 (s, 9H); 13C NMR (125 MHz, 
CHLOROFORM-d)  170.0, 100.2, 90.5, 67.6, 21.2, 14.1, 3.4, 2.0, -0.3; IR (ATR) 2964, 
2182, 1742, 1231, 842 cm-1. 
 
 
 
4-166 
(S)-3-bromo-1-cyclopropylprop-2-yn-1-ol (S)-63 
To a solution of (S)-61 (0.57 g, 3.4 mmol) in acetone (10 mL) was added N-
bromosuccinimide (0.92 g, 5.1 mmol) followed by AgNO3 (0.12 g, 0.70 mmol).  The 
reaction was stirred for 5 hours and 20 minutes at ambient temperature under Ar 
atmosphere.  Reaction was then chilled to 0°C, quenched with H20, extracted with Et2O, 
washed with water and brine, and concentrated under reduced pressure at 0°C.  The 
resulting yellow oil was purified by silica gel flash chromatography (Hexanes-10% 
EtOAc/hexanes) to give (S)-63 (0.51 g, 85.4%, light yellow oil); Rf = 0.213 (15% 
EtOAc/hexanes); [α]D
22 = +46.2° (c = 2.4, CHCl3); 
1H NMR (500 MHz, 
CHLOROFORM-d)  4.19 (d, J = 6.60 Hz, 1H), 2.03 - 2.14 (br. s., 1H), 1.21 - 1.30 (m, 
1H), 0.52 - 0.63 (m, 2H), 0.40 - 0.52 (m, 2H); 13C NMR (125 MHz, CHLOROFORM-d) 
 79.0, 66.7, 45.2, 17.2, 3.3, 1.6; IR (ATR) 3345, 3005, 2901, 2212, 1025 cm-1. 
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 (S,E)-1-(trimethylsilyl)hex-4-en-1-yn-3-ol (S)-64; (R,E)-1-(trimethylsilyl)hex-4-en-1-
yn-3-yl acetate (R)-65 
To a solution of (trimethylsilyl)acetylene (1.5 mL, 10.7 mmol) in dry Et2O (12 mL) at -78 
°C was added dropwise a solution of n-butyllithium (2.3 M in hexanes, 4.2 mL, 9.7 
mmol) over 10 minutes under an Ar atmosphere.  The reaction mixture was then stirred 
for 30 minutes before a solution of crotonaldehyde (0.75 mL, 8.9 mmol) in Et2O (2 mL) 
was added dropwise over 10 minutes.  The resulting mixture was allowed to gradually 
warm to ambient temperature.  After stirring for 22 hours, the mixture was quenched by 
slow addition of saturated NH4Cl followed by H2O.  The mixture was extracted with 
Et2O, washed with H20 and brine, dried over Na2SO4, and concentrated to near dryness.  
The resultant yellow oil (±64) was used directly in the next reaction without further 
purification. 
 
±64 was dissolved in dry hexanes (35 ml) followed by the addition of ground, activated 
4-Å molecular sieves (0.38 g) and lipase (Pseudomonas fluorescens, Amano Lipase AK, 
0.24 g).  To the well-stirred suspension was added vinyl acetate (3.4 mL, 36.2 mmol) 
over 3 minutes.  The suspension was stirred under an Ar atmosphere for 24 hours and 
then filtered through a pad of Celite and concentrated.  The resulting yellow oil was 
purified by silica gel flash chromatography (Hexanes – 25% EtOAc/hexanes) to give (S)-
64 (0.67 g, 44.1%, yellow oil) and (R)-65 (0.79 g, 41.6%, yellow oil). 
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Data for ±64:  Rf = 0.235 (15% EtOAc/hexanes); 
1H NMR (500 MHz, CHLOROFORM-
d)  5.88 (m, 1H), 5.57 - 5.64 (m, 1H), 4.80 (d, J = 6.11 Hz, 1H), 2.11 (br. s., 1H), 1.73 
(m, 3H), 0.15 - 0.21 (s, 9H); 13C NMR (125 MHz, CHLOROFORM-d)  129.9, 128.9, 
104.8, 90.5, 63.2, 17.5, -0.2; IR (ATR) 3341, 2962, 2173, 1250, 842 cm-1. 
 
Data for (S)-64:  Rf = 0.235 (15% EtOAc/hexanes); [α]D
17 = +56.6° (c = 2.1, CHCl3); 1H 
NMR (500 MHz, CHLOROFORM-d)  5.85 - 5.94 (m, 1H), 5.61 (ddd, J = 1.59, 6.24, 
15.16 Hz, 1H), 4.81 (d, J = 6.11 Hz, 1H), 1.98 (br. s., 1H), 1.74 (d, J = 6.60 Hz, 3H), 0.16 
- 0.22 (s, 9H); 13C NMR (125 MHz, CHLOROFORM-d)  129.9, 129.0, 104.8, 90.5, 
63.3, 17.5, -0.2; IR (ATR) 3662, 3346, 2965, 2901, 2173, 1250, 839 cm-1. 
 
Data for (R)-65: Rf = 0.510 (15% EtOAc/hexanes); [α]D
17 = -9.0° (c = 2.0, CHCl3); 
1H 
NMR (500 MHz, CHLOROFORM-d)  5.95 - 6.04 (m, 1H), 5.84 (d, J = 6.60 Hz, 1H), 
5.50 - 5.58 (m, 1H), 2.08 (s, 3H), 1.74 (d, J = 6.60 Hz, 3H), 0.16 - 0.21 (s, 9H); 13C NMR 
(125 MHz, CHLOROFORM-d)  169.6, 131.7, 126.0, 100.8, 91.6, 64.5, 21.2, 17.6, -0.3; 
IR (ATR) 3661, 2966, 2180, 1746, 1224, 841 cm-1. 
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4-153 
(S,E)-1-bromohex-4-en-1-yn-3-ol (S)-66 
To a solution of (S)-64 (0.60 g, 3.5 mmol) in acetone (11 mL) was added N-
bromosuccinimide (0.97 g, 5.5 mmol) followed by AgNO3 (0.14 g, 0.80 mmol).  The 
reaction was stirred for 3 hours at ambient temperature under Ar atmosphere.  Reaction 
was then chilled to 0°C, quenched with H20, extracted with Et2O, washed with water and 
brine, and concentrated under reduced pressure at 0°C.  The resulting yellow oil was 
purified by silica gel flash chromatography (Hexanes-15% EtOAc/hexanes) to give (S)-
66 (0.59 g, 95.6%, light yellow oil).  TLC Rf = 0.212 (15% EtOAc/hexanes); [α]D
17 = 
+54.5° (c = 1.4, CHCl3); 
1H NMR (500 MHz, CHLOROFORM-d)  5.86 - 5.96 (m, 1H), 
5.61 (qdd, J = 1.66, 6.22, 15.21 Hz, 1H), 4.84 (d, J = 6.11 Hz, 1H), 2.01 (br.s.,1H), 1.75 
(qd, J = 0.82, 6.60 Hz, 3H); 13C NMR (125 MHz, CHLOROFORM-d)  129.5, 129.5, 
79.4, 63.8, 46.4, 17.5; IR (ATR) 3292, 2972, 2212, 1444, 951 cm-1. 
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(S)-1-phenyl-3-(trimethylsilyl)prop-2-yn-1-ol (S)-67; (R)-1-phenyl-3-
(trimethylsilyl)prop-2-yn-1-yl acetate (R)-68 
To a solution of (trimethylsilyl)acetylene (1.5 mL, 10.7 mmol) in dry Et2O (12 mL) at -78 
°C was added dropwise a solution of n-butyllithium (2.3 M in hexanes, 4.2 mL, 9.7 
mmol) over 10 minutes under an Ar atmosphere.  The reaction mixture was then stirred 
for 30 minutes before a solution of benzaldehyde (0.91 mL, 9.0 mmol) in Et2O (2 mL) 
was added dropwise over 10 minutes.  The resulting mixture was allowed to gradually 
warm to ambient temperature.  After stirring for 22.5 hours, the mixture was quenched by 
slow addition of saturated NH4Cl followed by H2O.  The mixture was extracted with 
Et2O, washed with H20 and brine, dried over Na2SO4, and concentrated to near dryness.  
The resultant yellow oil (±67) was used directly in the next reaction without further 
purification. 
 
±67 was dissolved in dry hexanes (35 ml) followed by the addition of ground, activated 
4-Å molecular sieves (0.46 g) and lipase (Pseudomonas fluorescens, Amano Lipase AK, 
0.28 g).  To the well-stirred suspension was added vinyl acetate (3.3 mL, 35.8 mmol) 
over 3 minutes.  The suspension was stirred under an Ar atmosphere for 24 hours and 
then filtered through a pad of Celite and concentrated.  The resulting yellow oil was 
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purified by silica gel flash chromatography (Hexanes – 25% EtOAc/hexanes) to give (S)-
67 (0.89 g, 48.8%, clear oil) and (R)-68 (0.98 g, 44.6%, clear oil). 
 
Data for ±67:  Rf = 0.295 (15% EtOAc/hexanes); 
1H NMR (500 MHz, CHLOROFORM-
d)  7.54 - 7.59 (m, 2H), 7.38 - 7.43 (m, 2H), 7.33 - 7.37 (m, 1H), 5.47 (d, J = 4.65 Hz, 
1H), 2.27 (d, J = 5.62 Hz, 1H), 0.22 (s, 9H); 13C NMR (125 MHz, CHLOROFORM-d)  
140.2, 128.6, 128.4, 126.7, 104.8, 91.6, 65.0, -0.2; IR (ATR) 3377, 2962, 2174, 1251, 
1040, 843 cm-1. 
 
Data for (S)-67:  Rf = 0.295 (15% EtOAc/hexanes); [α]D
22 = -19.4° (c = 2.6, CHCl3); 
1H 
NMR (500 MHz, CHLOROFORM-d)  7.54 - 7.58 (m, 2H), 7.38 - 7.43 (m, 2H), 7.32 - 
7.37 (m, 1H), 5.47 (s, 1H), 2.34 (br. s., 1H), 0.22 (s, 9H); 13C NMR (125 MHz, 
CHLOROFORM-d)  140.2, 128.6, 128.4, 126.7, 104.9, 91.6, 65.0, -0.2; IR (ATR) 3394, 
2963, 2174, 1250, 1041, 840 cm-1. 
 
Data for (R)-68: Rf = 0.429 (15% EtOAc/hexanes); [α]D
21 = +32.7° (c = 2.8, CHCl3); 
1H 
NMR (500 MHz, CHLOROFORM-d)  7.54 (dd, J = 1.47, 7.83 Hz, 2H), 7.34 - 7.43 (m, 
3H), 6.51 (s, 1H), 2.11 (s, 3H), 0.21 (s, 9H); 13C NMR (125 MHz, CHLOROFORM-d)  
169.7, 136.9, 128.9, 128.6, 127.8, 101.2, 92.4, 65.8, 21.1, -0.3; IR (ATR) 3666, 2963, 
2182, 1742, 1222, 841 cm-1. 
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 (S)-3-bromo-1-phenylprop-2-yn-1-ol (S)-69 
To a solution of (S)-67 (0.83 g, 4.1 mmol) in acetone (12 mL) was added N-
bromosuccinimide (1.13 g, 6.4 mmol) followed by AgNO3 (0.14 g, 0.80 mmol).  The 
reaction was stirred for 3 hours at ambient temperature under Ar atmosphere.  Reaction 
was then chilled to 0°C, quenched with H20, extracted with Et2O, washed with water and 
brine, and concentrated under reduced pressure at 0°C.  The resulting yellow oil was 
purified by silica gel flash chromatography (Hexanes-10% EtOAc/hexanes) to give (S)-
69 (0.64 g, 73.7%, light yellow oil); Rf = 0.143 (15% EtOAc/hexanes); [α]D
17 = -5.6° (c = 
1.0, CHCl3); 
1H NMR (500 MHz, CHLOROFORM-d)  7.53 (m, 2H), 7.33 - 7.44 (m, 
3H), 5.50 (s, 1H), 2.28 (br. s., 1H); 13C NMR (125 MHz, CHLOROFORM-d)  139.8, 
128.7, 128.6, 126.6, 79.7, 65.5, 47.4; IR (ATR) 3395, 2974, 2901, 2212, 2181, 1029 cm-1. 
 
 
(S)-1-(4-ethoxyphenyl)-3-(trimethylsilyl)prop-2-yn-1-ol (S)-70; (R)-1-(4-
ethoxyphenyl)-3-(trimethylsilyl)prop-2-yn-1-yl acetate (R)-71 
To a solution of (trimethylsilyl)acetylene (1.5 mL, 10.7 mmol) in dry Et2O (12 mL) at -78 
°C was added dropwise a solution of n-butyllithium (2.3 M in hexanes, 4.2 mL, 9.7 
mmol) over 10 minutes under an Ar atmosphere.  The reaction mixture was then stirred 
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for 30 minutes before a solution of 4-ethoxybenzaldehyde (1.24 mL, 8.9 mmol) in Et2O 
(2 mL) was added dropwise over 10 minutes.  The resulting mixture was allowed to 
gradually warm to ambient temperature.  After stirring for 24 hours, the mixture was 
quenched by slow addition of saturated NH4Cl followed by H2O.  The mixture was 
extracted with Et2O, washed with H20 and brine, dried over Na2SO4, and concentrated to 
near dryness.  The resultant yellow oil (±70) was used directly in the next reaction 
without further purification. 
 
±70 was dissolved in dry hexanes (35 ml) followed by the addition of ground, activated 
4-Å molecular sieves (0.57 g) and lipase (Pseudomonas fluorescens, Amano Lipase AK, 
0.33 g).  To the well-stirred suspension was added vinyl acetate (3.3 mL, 35.8 mmol) 
over 3 minutes.  The suspension was stirred under an Ar atmosphere for 24 hours and 
then filtered through a pad of Celite and concentrated.  The resulting yellow oil was 
purified by silica gel flash chromatography (Hexanes – 25% EtOAc/hexanes) to give (S)-
70 (0.99 g, 44.8%, light yellow oil) and (R)-71 (0.93 g, 35.9%, clear oil). 
 
Data for ±70:  TLC Rf = 0. (15% EtOAc/hexanes); 
1H NMR (500 MHz, 
CHLOROFORM-d)  7.44 - 7.48 (m, 2H), 6.88 - 6.92 (m, 2H), 5.40 (s, 1H), 4.04 (q, J = 
7.09 Hz, 2H), 2.31 (br. s., 1H), 1.42 (t, J = 7.09 Hz, 3H), 0.18 - 0.25 (s, 9H); 13C NMR 
(125 MHz, CHLOROFORM-d)  159.0, 132.4, 128.1, 114.4, 105.2, 91.2, 64.5, 63.4, 
14.8, -0.2; IR (ATR) 3410, 2961, 2173, 1511, 1248, 840 cm-1. 
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Data for (S)-70: TLC Rf = 0.185 (15% EtOAc/hexanes); [α]D
17 = -18.0° (c = 2.5, CHCl3); 
1H NMR (500 MHz, CHLOROFORM-d)  7.43 - 7.49 (m, 2H), 6.87 - 6.93 (m, 2H), 5.41 
(s, 1H), 4.05 (q, J = 6.93 Hz, 2H), 2.22 (br. s., 1H), 1.42 (t, J = 6.97 Hz, 3H), 0.18 - 0.25 
(s, 9H); 13C NMR (125 MHz, CHLOROFORM-d)  159.0, 132.4, 128.1, 114.4, 105.1, 
91.2, 64.6, 63.4, 14.8, -0.2; IR (ATR) 3463, 2980, 2174, 1511, 1249, 841 cm-1. 
 
Data for (R)-71: TLC Rf = 0.377 (15% EtOAc/hexanes); [α]D
17 = +5.6° (c = 1.8, CHCl3); 
1H NMR (500 MHz, CHLOROFORM-d)  7.43 - 7.49 (m, 2H), 6.87 - 6.92 (m, 2H), 6.45 
(s, 1H), 4.05 (q, J = 6.93 Hz, 2H), 2.09 (s, 3H), 1.42 (t, J = 6.97 Hz, 3H), 0.17 - 0.27 (s, 
9H); 13C NMR (126 MHz, CHLOROFORM-d)  169.8, 159.4, 129.4, 129.0, 114.4, 
101.6, 92.0, 65.6, 63.5, 21.2, 14.8, -0.3; IR (ATR) 2963, 2181, 1743, 1513, 1223, 842 cm-
1. 
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(S)-3-bromo-1-(4-ethoxyphenyl)prop-2-yn-1-ol (S)-72 
To a solution of (S)-70 (0.93 g, 3.8 mmol) in acetone (11 mL) was added N-
bromosuccinimide (1.02 g, 5.6 mmol) followed by AgNO3 (0.13 g, 0.75 mmol).  The 
reaction was stirred for 2.5 hours at ambient temperature under Ar atmosphere.  Reaction 
was then chilled to 0°C, quenched with H20, extracted with Et2O, washed with water and 
brine, and concentrated under reduced pressure.  The resulting yellow oil was purified by 
silica gel flash chromatography (Hexanes-15% EtOAc/hexanes) to give (S)-72 (0.68 g, 
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70.9%, yellow oil); Rf = 0.186 (15% EtOAc/hexanes); [α]D
22 = -9.4° (c = 3.2, CHCl3); 
1H 
NMR (500 MHz, CHLOROFORM-d)  7.40 - 7.45 (d, J = 8.56 Hz, 2H), 6.88 - 6.92 (d, J 
= 8.56 Hz, 2H), 5.42 (s, 1H), 4.04 (q, J = 7.01 Hz, 2H), 2.41 (br. s., 1H), 1.43 (t, J = 6.97 
Hz, 3H); 13C NMR (125 MHz, CHLOROFORM-d)  159.1, 132.0, 128.0, 114.5, 79.9, 
65.0, 63.5, 47.0, 14.7; IR (ATR) 3374, 2980, 2212, 1611, 1510, 1241 cm-1. 
 
 
 
(S)-1-(trimethylsilyl)hex-1-yn-3-ol (S)-73; (R)-1-(trimethylsilyl)hex-1-yn-3-yl acetate 
(R)-74 
 
To a solution of (trimethylsilyl)acetylene (0.78 g, 1.1 mL, 8.0 mmol) in dry Et2O (8 mL) 
at -78 °C was added dropwise a solution of n-butyllithium (2.25 M in hexanes, 3.3 mL, 
7.3 mmol) over five minutes under an Ar atmosphere.  The reaction mixture was then 
stirred for 30 minutes before a solution of butyraldehyde (0.48 g, 0.6 mL, 6.7 mmol) in 
Et2O (2.5 mL) was added dropwise over five minutes.  The resulting mixture was allowed 
to gradually warm to ambient temperature.  After stirring for 1.5 hours, the mixture was 
quenched by slow addition of saturated NH4Cl.  The mixture was extracted with Et2O, 
washed with H20 and brine, dried over Na2SO4, and concentrated to near dryness.  The 
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resultant yellow oil (±73) was used directly in the next reaction without further 
purification. 
 
The yellow oil (±73) was dissolved in dry hexanes (26 ml) followed by the addition of 
ground, activated 4-Å molecular sieves (0.28 g) and lipase (Pseudomonas fluorescens, 
Amano Lipase AK, 0.17 g).  To the well-stirred suspension was added vinyl acetate (2.5 
mL, 27.1 mmol) over 3 minutes.  The suspension was stirred under an Ar atmosphere for 
25.5 hours and then filtered through a pad of Celite and concentrated.  The resulting 
yellow oil was purified by silica gel chromatography (hexanes-15% EtOAc/hexanes) to 
give (S)-73 (0.52 g, 45.6%, light yellow oil) and (R)-74 (0.70 g, 49.7%, clear oil). 
 
Data for ±73 racemic: TLC Rf = 0.370 (15% EtOAc/hexanes); 
1H NMR (500 MHz, 
CHLOROFORM-d)  4.36 (t, J = 6.60 Hz, 1H), 2.03 (br. s., 1H), 1.60 - 1.73 (m, 2H), 
1.41 - 1.52 (m, 2H), 0.92 - 0.98 (t, J = 7.34 Hz, 3H), 0.14 - 0.20 (s, 9H); 13C NMR (125 
MHz, CHLOROFORM-d)  106.9, 89.2, 62.6, 39.7, 18.4, 13.7, -0.1; IR (ATR) 3330, 
2961, 2874, 2174, 1250, 839 cm-1; HRMS (ESI-TOF) [M + H]+ calcd. for C9H19OSi 
171.1205, found 171.1195. 
 
Data for (S)-73: TLC Rf = 0.370 (15% EtOAc/hexanes); [α]D
18 = -7.1° (c = 2.4, CHCl3); 
1H NMR (500 MHz, CHLOROFORM-d)  4.33 - 4.40 (q, J = 6.03 Hz, 1H), 1.97 (d, J = 
5.14 Hz, 1H), 1.61 - 1.74 (m, 2H), 1.41 - 1.52 (m, 2H), 0.95 (t, J = 7.34 Hz, 3H), 0.14 - 
0.19 (s, 9H); 13C NMR (125 MHz, CHLOROFORM-d)  106.9, 89.2, 62.6, 39.7, 18.4, 
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13.7, -0.1; IR (ATR) 3340, 2960, 2875, 2172, 1250, 839 cm-1; HRMS (ESI-TOF) [M + 
H]+ calcd. for C9H19OSi 171.1205, found 171.1196.  
 
Data for (R)-74: TLC Rf = 0.556 (15% EtOAc/hexanes); [α]D
22 = +105.7° (c = 3.5, 
CHCl3); 
1H NMR (500 MHz, CHLOROFORM-d)  5.38 (t, J = 6.72 Hz, 1H), 2.04 - 2.12 
(s, 3H), 1.64 - 1.78 (m, 2H), 1.38 - 1.50 (m, 2H), 0.93 (t, J = 7.34 Hz, 3H), 0.10 - 0.20 (s, 
9H); 13C NMR (125 MHz, CHLOROFORM-d)  169.8, 102.7, 90.1, 64.1, 36.8, 21.1, 
18.3, 13.6, -0.2; IR (ATR) 2962, 2876, 2179, 1747, 1229, 842 cm-1. 
 
 
 
 
 
(S)-1-(trimethylsilyl)octadec-1-yn-3-ol (S)-76; (R)-1-(trimethylsilyl)octadec-1-yn-3-yl 
acetate (R)-77 
To a solution of (trimethylsilyl)acetylene (0.36 mL, 2.6 mmol) in dry Et2O (3.3 mL) at -4 
°C (brine/ice bath) was added dropwise a solution of n-butyllithium (2.25 M in hexanes, 
1 mL, 2.25 mmol) over 30 minutes under an Ar atmosphere.  The reaction mixture was 
then stirred for 30 minutes before a solution of palmitaldehyde (0.51 g, 2.1 mmol) Et2O 
(1 mL) was added dropwise over five minutes.  After stirring for 1 hour 5 minutes, the 
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mixture was quenched by slow addition saturated NH4Cl.  The mixture was extracted 
with Et2O, washed with H20 and brine, dried over Na2SO4, and concentrated under 
reduced pressure to afford ±76 (0.79 g, 98.4%, yellow oil).  The resultant yellow oil 
(±76) was used directly in the next reaction without further purification. 
 
The yellow oil ±76 (0.64 g, 1.9 mmol) was dissolved in dry hexanes (7.4 ml) followed by 
the addition of ground, activated 4-Å molecular sieves (0.16 g) and lipase (Pseudomonas 
fluorescens, Amano Lipase AK, 0.10 g).  To the well-stirred suspension was added vinyl 
acetate (0.7 mL, 7.6 mmol) over two minutes.  The suspension was stirred under an Ar 
atmosphere for 16.5 hours and then filtered through a pad of Celite and concentrated.  
The resulting yellow oil was purified by silica gel chromatography (Hexanes-2% 
EtOAc/hexanes) to give (S)-76 (0.27 g, 43.1%, clear oil) and (R)-77 (0.18 g, 25.3%, 
yellow oil). 
 
Data for ±76: Rf = 0.407 (15% EtOAc/hexanes) 
 
Data for (S)-76: TLC Rf = 0.407 (15% EtOAc/hexanes); [α]D
17 = +0.4° (c = 1.2, CHCl3); 
1H NMR (500 MHz, CHLOROFORM-d)  4.35 (t, J = 6.48 Hz, 1H), 1.88 (br. s., 1H), 
1.63-1.75 (m, 2H), 1.39 - 1.50 (m, 2H), 1.22 - 1.36 (m, 24H), 0.85 - 0.92 (t, J = 6.97 Hz, 
3H), 0.15 - 0.20 (s, 9H); 13C NMR (125 MHz, CHLOROFORM-d)  106.9, 89.2, 62.9, 
37.7, 31.9, 29.7, 29.7, 29.5, 29.5, 29.4, 29.2, 25.1, 22.7, 14.1, -0.1; IR (ATR) 3457, 2923, 
2853, 2175, 1250, 841 cm-1. 
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Data for (R)-77: TLC Rf = 0.625 (15% EtOAc/hexanes); [α]D
23 = +51.7° (c = 1.2, CHCl3); 
1H NMR (500 MHz, CHLOROFORM-d)  5.38 (t, J = 6.72 Hz, 1H), 2.09 (s, 3H), 1.70 - 
1.78 (m, 2H), 1.42 (m, 2H), 1.24 - 1.33 (m, 24H), 0.86 - 0.91 (t, , J = 6.97 Hz, 3H), 0.16 - 
0.19 (s, 9H); 13C NMR (125 MHz, CHLOROFORM-d)  169.9, 102.8, 90.2, 64.4, 34.8, 
31.9, 29.7, 29.7, 29.7, 29.7, 29.6, 29.5, 29.4, 29.4, 29.0, 24.9, 22.7, 21.1, 14.1, -0.2; IR 
(ATR) 2923, 2853, 2180, 1747, 1230, 842 cm-1. 
 
 
 (R)-2-(1-(trimethylsilyl)dodec-1-yn-3-yl)isoindoline-1,3-dione (R)-79 
 
To a solution of (S)-7 (3.5 g, 13.8 mmol) in THF (105 mL) was added phthalimide (3.0 g, 
20.2 mmol) followed by triphenylphosphine (5.3 g, 20.1 mmol).  The reaction mixture 
was then chilled to 0°C followed by the dropwise addition of DIAD (5.2 mL, 24.8 mmol) 
and stirred at 0°C under Ar atmosphere.  After 1.5 hours, reaction mixture was 
concentrated under reduced pressure, diluted with Et2O, and chilled to 0°C.  Precipitate 
was filtered off through Celite and the filtrate was concentrated under reduced pressure.  
The resultant yellow oil was purified by silica gel chromatography (Hexanes – 5% 
EtOAc/Hexanes) to afford (R)-79 (5.3 g, 100.0%, yellow solid).  TLC Rf = 0.278 (10% 
EtOAc/hexanes); [α]D
23 = -3.7° (c =5.4, CHCl3); 
1H NMR (500 MHz, CHLOROFORM-
d)  7.84 - 7.88 (m, 2H), 7.70 - 7.75 (m, 2H), 5.02 (t, J = 8.07 Hz 1H), 1.98-2.14 (m, 2H), 
1.44 (m, 2H), 1.20 - 1.36 (m, 12H), 0.84 - 0.90 (t, 6.97 Hz, 3H), 0.12 - 0.18 (s, 9H); 13C 
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NMR (125 MHz, CHLOROFORM-d)  167.0, 134.0, 131.9, 123.4, 101.9, 88.2, 42.4, 
33.4, 31.8, 29.4, 29.4, 29.2, 28.8, 26.3, 22.6, 14.1, -0.1; IR (ATR) 3473, 2922, 2851, 
2173, 1776, 1709, 1385, 1249 cm-1; HRMS (ESI-TOF) [M + H]+ calcd. for C23H34NO2Si 
384.2359, found 384.2349. 
 
 
 (S)-80  Mosher Ester of ±4 
Methoxy protons ratio 3.00:3.67 
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 (S,S)-80  Mosher Ester of (S)-4 
Methoxy protons ratio 3.00:0.05; (S)-4 ee = 96.8 
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 (R,S)-80  Mosher Ester of (R)-4 to determine ee of (R)-5 
Methoxy protons ratio 0.06:3.00; (R)-5 ee = 96.0 
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 (S)-81  Mosher Ester of ±7 
Methine proton ratio 1.00:0.98 
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 (S,S)-81  Mosher Ester of (S)-7 
Methine proton ratio 1.00:0.03; (S)-7 ee = 94.2 
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 (R,S)-81  Mosher Ester of (R)-7 to determine ee of (R)-8 
Methine proton ratio 0.00:1.00; (R)-8 ee = 100.0 
 
 
 
 (S,S)-82  Mosher Ester of (S)-17 
Methoxy protons ratio 3.00:0.19 ; (S)-17 ee = 88.0  
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 (R,S)-82  Mosher Ester of (R)-17 
Methoxy protons ratio 0.00:3.00 ; (R)-17 ee = 100.0  
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 (R,R)-83  Mosher Ester of (R)-18 
Terminal alkyne proton ratio 1.00:0.00; (R)-18 ee = 100.0  
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 (S,R)-83  Mosher Ester of (S)-18 
Terminal alkyne proton ratio 0.10:1.00; (S)-18 ee = 81.8  
 
 
 
 
 
 
 
 
 
 
 
018 S Mosher.esp
2.60 2.55 2.50 2.45
Chemical Shift (ppm)
0
0.005
0.010
0.015
0.020
0.025
0.030
0.035
0.040
0.045
0.050
0.055
0.060
0.065
0.070
N
o
rm
a
li
z
e
d
 I
n
te
n
s
it
y
1.000.10
2
.5
0
2
.5
0
2
.5
4
2
.5
5
 239 
 
 
 
 
 
 
 
 
 
Appendix A:  Selected NMR spectra from synthesized compounds  
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(3S,8R)-8-hydroxyheptadeca-1-en-4,6-diyn-3-yl acetate 
1H NMR: 
 
13C NMR: 
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(3R,8S)-8-hydroxyheptadeca-1-en-4,6-diyn-3-yl acetate 
1H NMR: 
 
13C NMR: 
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(3S,8S)-8-hydroxyheptadeca-1-en-4,6-diyn-3-yl acetate 
1H NMR: 
 
13C NMR: 
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(3R,8R)-8-hydroxyheptadeca-1-en-4,6-diyn-3-yl acetate 
1H NMR: 
 
13C NMR: 
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(3S,8R)-8-hydroxyundeca-1-en-4,6-diyn-3-yl acetate 
1H NMR: 
 
13C NMR: 
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(3S,8R)-8-hydroxytricosa-1-en-4,6-diyn-3-yl acetate 
1H NMR: 
 
13C NMR: 
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(3S,8R)-8-aminoheptadeca-1-en-4,6-diyn-3-yl acetate 
1H NMR: 
 
13C NMR: 
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(3S,8R)-8-(methylsulfonamido)heptadeca-1-en-4,6-diyn-3-yl acetate 
1H NMR: 
 
13C NMR: 
 
 
 
 248 
 
(3S,8R)-8-benzamidoheptadeca-1-en-4,6-diyn-3-yl acetate 
1H NMR: 
 
13C NMR: 
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(3S,8R)-8-(butylamino)heptadeca-1-en-4,6-diyn-3-yl acetate 
1H NMR: 
 
13C NMR: 
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(3S,8R)-8-((methylsulfonyl)oxy)heptadeca-1-en-4,6-diyn-3-yl acetate 
1H NMR: 
 
13C NMR: 
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(3S,8R)-heptadeca-1-en-4,6-diyne-3,8-diol 
1H NMR: 
 
13C NMR: 
 
 
 252 
 
N-((3S,8R)-3-hydroxyheptadeca-1-en-4,6-diyn-8-yl)benzamide 
1H NMR: 
 
13C NMR: 
 
 
 
 253 
 
(3S,8R)-8-(butylamino)heptadeca-1-en-4,6-diyn-3-ol 
1H NMR: 
 
13C NMR: 
 
 
 254 
 
(3S,8R)-8-(4-chlorobenzamido)heptadeca-1-en-4,6-diyn-3-yl acetate 
1H NMR: 
 
13C NMR: 
 
 255 
 
(3S,8R)-8-(3,4-dichlorobenzamido)heptadeca-1-en-4,6-diyn-3-yl acetate 
1H NMR: 
 
13C NMR: 
 
 256 
 
(3S,8R)-8-(4-methylbenzamido)heptadeca-1-en-4,6-diyn-3-yl acetate 
1H NMR: 
 
13C NMR: 
 
 257 
 
(3S,8R)-8-(4-methoxybenzamido)heptadeca-1-en-4,6-diyn-3-yl acetate 
1H NMR: 
 
13C NMR: 
 
 
 
 258 
 
(3S,8R)-8-benzamido-11-cyclohexylundeca-1-en-4,6-diyn-3-yl acetate 
1H NMR: 
 
13C NMR: 
 
 
 259 
 
(3S,8R)-8-(3-bromobenzamido)heptadeca-1-en-4,6-diyn-3-yl acetate 
1H NMR: 
 
13C NMR: 
 
 260 
 
(3S,8R)-8-(3-methylbenzamido)heptadeca-1-en-4,6-diyn-3-yl acetate 
1H NMR: 
 
13C NMR: 
 
 261 
 
(3S,8R)-8-(3-(trifluoromethyl)benzamido)heptadeca-1-en-4,6-diyn-3-yl acetate 
1H NMR: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 262 
 
(3S,8R)-8-(3,5-dichlorobenzamido)heptadeca-1-en-4,6-diyn-3-yl acetate 
1H NMR: 
 
13C NMR: 
 
 263 
 
(3S,8R)-8-(5-methylisoxazole-3-carboxamido)heptadeca-1-en-4,6-diyn-3-yl acetate 
1H NMR: 
 
13C NMR: 
 
 264 
 
(3S,8R)-8-(picolinamido)heptadeca-1-en-4,6-diyn-3-yl acetate 
1H NMR: 
 
13C NMR: 
 
 265 
 
(3S,8R)-8-(pyrazine-2-carboxamido)heptadeca-1-en-4,6-diyn-3-yl acetate 
1H NMR: 
 
13C NMR: 
 
 
 266 
 
(3S,8R)-8-(furan-2-carboxamido)heptadeca-1-en-4,6-diyn-3-yl acetate 
1H NMR: 
 
13C NMR: 
 
 267 
 
(3S,8R)-8-(2-chlorobenzamido)heptadeca-1-en-4,6-diyn-3-yl acetate 
1H NMR: 
 
13C NMR: 
 
 
 268 
 
(3S,8R)-8-(4-fluorobenzamido)heptadeca-1-en-4,6-diyn-3-yl acetate 
1H NMR: 
 
13C NMR: 
 
 
 269 
 
(3S,8R)-8-(4-(benzyloxy)butanamido)heptadeca-1-en-4,6-diyn-3-yl acetate 
1H NMR: 
 
13C NMR: 
 
 270 
 
(3S,8R)-8-isothiocyanatoheptadeca-1-en-4,6-diyn-3-yl acetate 
1H NMR: 
 
13C NMR: 
 
 271 
 
ethyl ((3S,8R)-3-hydroxyheptadeca-1-en-4,6-diyn-8-yl)carbamate 
1H NMR: 
 
13C NMR: 
 
 272 
 
N-((3S,8R)-3-hydroxyheptadeca-1-en-4,6-diyn-8-yl)acetamide 
1H NMR: 
 
13C NMR: 
 
 273 
 
(3S,8R)-8-(ethylamino)heptadeca-1-en-4,6-diyn-3-ol 
1H NMR: 
 
13C NMR: 
 
 
 274 
 
(3S,8R)-8-methoxyheptadeca-1-en-4,6-diyn-3-ol 
1H NMR: 
 
13C NMR: 
 
 275 
 
(1S,6R)-6-(butylamino)-1-cyclopropylpentadeca-2,4-diyn-1-ol 
1H NMR: 
 
13C NMR: 
 
 276 
 
(4S,9R,E)-9-(butylamino)octadeca-2-en-5,7-diyn-4-ol 
1H NMR: 
 
13C NMR: 
 
 
 277 
 
(1S,6R)-6-(butylamino)-1-phenylpentadeca-2,4-diyn-1-ol 
1H NMR: 
 
13C NMR: 
 
 278 
 
(1S,6R)-6-(butylamino)-1-(4-ethoxyphenyl)pentadeca-2,4-diyn-1-ol 
1H NMR: 
 
13C NMR: 
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Appendix B:  National Cancer Institute One Dose Screening Results  
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